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Abstract 
The Biological Impact of High Throughput Continuous Bioprocessing 
David John Sewell, Churchill College 
Micro scale, high throughput perfusion technology is under-developed and not widely utilised in 
academic or industrial settings for the development of CHO based mAb bioprocesses.  Work within 
this thesis highlights the design and characterisation of a sedimentation method of cell retention 
and its application in a fed batch designed ambr® micro scale bioreactor system.   
The work identifies periods of up to one hour required to perform the necessary sedimentation and 
media exchanges.  In comparison, bench scale equivalent culture reaches comparable cell densities 
as their microscale counterparts, highlighting suitability for screening development activities in this 
high throughput system that was previously unattainable with the high media demands of a 
perfusion process. 
The comparison of scales highlighted a lag in growth between the two perfusion methods that was 
thought to be a combination of periods of uncontrolled parameters at microscale (while cells were 
undergoing sedimentation) and small but frequent removal of cells from the microscale cultures, 
as retention efficiency was below 100%. 
In addition to this, the execution of the perfusion method highlighted CHO cell insensitivity to high 
levels of pH and DO variation that would normally elicit a severe decline in culture performance.  
Potential control strategies that focused on cellular sensitivity at inoculation were investigated and 
their application highlighted.  Whilst applicable to fed batch cultures, it is in perfusion (or other 
continuous methods) where a significant benefit will be realised as they can attain high performance 
through tight control during inoculation and allowing flexibility during extended periods of 
cultivation. 
Combining the functionality and capacity offered by the sedimentation method in the ambr® 
system with the highlighted potential control strategy for perfusion equips the bioprocessing 
industry to explore the benefits of perfusion culture to meet increasing global demand for mAbs. 
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Motivation and Thesis Structure 
Motivation 
Continuous cell culture was popularised by the development of the chemostat in 1950 (Monod, 
1950; Novick & Szilard, 1950).  The chemostat method involves diluting a culture with fresh 
medium at a rate matched to the removal of cells and spent medium from the culture.  The 
culture reaches a ‘steady-state’ cell concentration, that is representative of the limiting nutrient 
defined by the dilution rate, and physiochemical conditions applied (Pirt, 1975).  Researchers 
have utilised continuous culturing to investigate the growth kinetics of a cell line through 
systematic interrogation of the physiochemical parameters (Hoskisson & Hobbs, 2005).   
The reproducibility and robustness achieved by continuous cultures have allowed detailed 
systematic metabolic flux analysis to be conducted in both microbial and mammalian systems 
(Follstad, Balcarcel, Stephanopoulos, & Wang, 1999; Varma & Palsson, 1994).  Additionally, 
complex multi-institution investigations that require extensive parallel quantitative analysis of 
a cell line is possible with an established continuous system.  This is due to the system’s ability 
to maintain an extended steady-state condition.(Canelas et al., 2010). 
The operation of continuous cultures over batch, or fed-batch, provides advantages in the 
production of commercial products.  Firstly, the low residence time possible in continuous 
culture has been shown to improve the product quality attributes of unstable molecules.  This 
improved product quality sequentially results in an improved yield of the intact molecule (Lee 
et al., 2004; Rodriguez et al., 2010).  Furthermore, the operational cost of goods (COGs) 
analysis for continuous systems has highlighted a reduction when compared to equivalent fed-
batch production (Pollock, Ho, & Farid, 2013).  This lower COGs is partially due to a reduction 
in required fermenter sizes at commercial scale, which in turn also simplifies the scale-up from 
development. 
Despite these advantages, the commercial production of therapeutic proteins has relied heavily 
on the fed-batch mode of operation over the past 40 years.  Contributing factors include the 
simplicity of operation, the ability to conduct analytical testing at the end of each fermentation, 
and the confirmation of cell line stability over shorter ‘manufacturing windows’.   The 
increased use of fed-batch has been combined with a preference for mAb production in 
mammalian systems (namely Chinese Hamster Ovary (CHO) cells).  This is due to the ability 
of mammalian cell lines to process complex post-translational modifications (namely human 
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glycosylation patterns) to achieve desired product quality characteristics and avoid 
immunogenic responses (Birch & Racher, 2006). 
The popularity of this method has promoted the invention of numerous high-throughput scale 
down technologies to enable optimisation campaigns in a low resource setting (Bareither & 
Pollard, 2011; Rameez, Mostafa, Miller, & Shukla, 2014).   These systems provide the ability 
to satisfy the regulatory Quality by Design (QbD) directives (Guideline, 2009; Hakemeyer et 
al., 2016).  As no equivalent systems exist for continuous commercial bioprocess development, 
there is an inherent lower utilisation of this advantageous method of production.  This lower 
utilisation is coupled with lower prior knowledge and the ability to simplify the mode of 
operation. 
The primary motivation for this thesis is to identify cellular and or, biochemical characteristics 
specific to continuous bioprocess systems.  This identification will enable advance control 
strategies to be developed for commercial scale continuous bioprocess systems to add to prior 
knowledge on the continuous environment.  This primary motivation is linked to a secondary 
motivation, to understand the scale dependent and independent variables of scale down 
continuous bioprocess technologies, present specifically in a high throughput setting. 
Thesis Structure 
Chapter 1 - Introduction 
The first chapter provides a detailed context and comprehension for the investigations outlined 
in this thesis.  Specifically, a review is offered on the topic of upstream bioprocessing, tools, 
and methods, enabling the production of monoclonal antibodies to meet growing global 
demand.  
Chapter 2 - Materials and Methods 
The second chapter details the organisation of experiments and the specific materials and 
methods utilised when conducting them. 
Chapter 3 - The Design, Execution and Evaluation of a High-Throughput Continuous 
Microscale Environment  
The third chapter presents the repurposing of an advance fed-batch microscale system to 
operate continuous cultivations, specifically as a perfusion system.  This investigation entails 
the development of a cell retention methodology based on gravity cell settling.   
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Understanding the impact of the methodology on the continuous culture of mammalian cells 
highlights its suitability to identify cellular and or biochemical characteristics specific to 
continuous bioprocess systems.  Comparison to bench scale perfusion system is offered by the 
parallel operation of a 7L STR vessel functionalised with an ATF perfusion setup. 
Chapter 4 - The Evaluation of Micro and Bench Scales Perfusion Cultures as Tools for 
Production Culture Inoculum Expansion 
The fourth chapter presents two key evaluations.  Firstly, the characterisation of the microscale 
methodology from Chapter 3 is expanded to highlight the scale dependent differences in the 
cellular characteristics of the cultures.  Secondly, the cellular impact of reducing the culture 
dilution rate is evaluated to decouple any inherent sensitivity of the cell line to scale and method 
related observations. 
These evaluations are performed by progressing cells from the exponential growth phase of  
the respective perfusion cultures, into comparatively high physiochemical stress fed-batch 
cultures.  By elucidating the differences in performance that may be attributed to the proceeding 
perfusion culture it is possible to evaluate scale and method dependent cellular characteristics 
of perfusion cultures. 
Chapter 5 - The Evaluation of Fed-Batch Culture Performance in Response to Targeted 
Parameter Deviation Before and After Controlled Inoculation    
The fifth chapter utilise fed batch operation to focus investigations on cell line sensitivity 
present in the exponential growth phase.  Additionally, it highlights the need for contextual 
control strategies in the investigation of process limits.  Understanding the culture 
characteristics during this phase will provide novel control strategies not previously 
investigated for continuous culture operation.  
Chapter 6 - Conclusions and Future Work 
The sixth chapter presents the overarching conclusions from the experimental.  The logical 
next steps and directions for future work are presented. 
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Chapter 1 Introduction 
1.1 Antibodies 
As a function of the acquired immune response in mammals, antibodies (Abs) are produced by 
activated B-cells in response to antigen detection. The repeated exposure of the immune system 
to antigens generates clonal populations and the proliferation of activated B-cells.  This results 
in an increase in the levels of Abs secreted as an immune response (Delves & Roitt, 2000).   
Antibodies contain specialised structures that equip the molecules with the ability to 
simultaneously bind with antigens and recruit an immune response against the antigen. 
Utilising the IgG class of antibodies as an example, the basic Ab structure consists of two 
identical heavy chains combined with two light chains, with each chain consisting of variable 
and constant regions (Vidarsson, Dekkers, & Rispens, 2014) (Figure 1).   
 
Figure 1 Diagrammatic representation of the constitutional components of an IgG class antibody 
Highlighted by dashed braces are the functional structures within the antibody, antigen-binding site, Fab and 
Fc subdomains, respectively.  Light (grey) and heavy (white) chains are represented with their constitutional 
variable (V) and constant (C) regions. Association of chains is performed by di-sulphide bonds (-s-s-). 
 
Billions of combinations within the structures of the variable (V) domains of the heavy and 
light chains (Complementarity determining regions, or CDRs), enable comprehensive antigen 
recognition.  The combination of these variable domains with constant domains forms the Fab 
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region of the Ab.  Linkage of chains by di-sulphide bonds provides the Fab region with essential 
flexibility for interaction with the antigen-binding sites (Amzel & Poljak, 1979). 
The continuation of the heavy chain constant regions beyond di-sulphide bonds forms the Fc 
region of the Ab.  The Fc region provides the Ab with the ability to interact with the host system 
immune system (Unkeless, Scigliano, & Freedman, 1988). 
Recent advancements in antibody design have focused on the therapeutic application of bi-
specific antibodies.   These molecules have the ability to recognise two unique antigens, and 
conceptually have an advantage in combating diseases that have evaded traditional bivalent 
antibodies (Labrijn, Janmaat, Reichert, & Parren, 2019).  The manufacture of these molecules 
can be challenging.  A popular approach, coined ‘knob in hole’, is used to promote 
heterodimerisation of two unique heavy chains.  This involves engineering complementary 
mutations in the Fc region of the two desired heavy chains.  This result in complementary 
binding, and the formation of an intact Ab (H. Liu, Saxena, Sidhu, & Wu, 2017; Ridgway, 
Presta, & Carter, 1996). 
1.2 Therapeutic Application and Commercialisation of Antibodies (Abs)  
Mature B cells (plasma cells) are specialised in the production and excretion of Abs.  Their 
maturation, specifically the cleavage of the CD40 ligand, causes them to be terminally 
differentiated (Arpin et al., 1995).  This presented a challenge to in vivo research into Abs.  
Researchers couldn't determine which antigen marker the polyclonal population of B cells was 
expressing Abs against.   
The In vitro investigation of B cells required the culturing and expansion of monoclonal 
populations.  This was facilitated by scientists at the University of Cambridge who developed 
hybridoma technology.  This advancement involved combining normal B cells from the spleen 
of an immunised mouse with mouse myeloma cells.  The resulting culture of cells proliferated 
indefinitely and produced a high, detectable expression of Abs.  This discovery in 1975  was 
the first reported instance of the production of a monoclonal antibody (mAb).  Its significance 
was later recognised with the award of the Nobel Prize for Medicine in 1984 (Alkan, 2004). 
The Food and Drug Administration (FDA) approved the first recombinant therapeutic protein 
as a thrombolysis treatment 11 years later (Allen, 1987; Baruah, Dash, Chaudhari, & Kadam, 
2006).  Therapeutic protein product approvals have been greater than 10 per year (with mAbs 
consisting of >20%) since 1995.  In addition, over the past five years, product approval has 
increased to ~22 per year, with mAbs representing around 53% of these (Walsh, 2018).  This 
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popularity and continued development of mAbs is due to the wide scope of their utility in 
therapeutic areas (Pavlou & Belsey, 2005).   
The research and development activities have been facilitated by the development of genetic 
engineering techniques.  This has been focused in the fields of molecular cloning and delivery 
of plasmid DNAs (Al-Moslih & Dubes, 1973; Cohen, Chang, Boyer, & Helling, 1973; Graham 
& van der Eb, 1973; Svoboda et al., 1973).   The publication of the complete human genome 
(Venter et al., 2001) and continued work on the human proteome (M.-S. Kim et al., 2014) has 
accelerated molecular understanding of disease. This advancement has allowed researchers to 
design specific nucleotide sequences to target the disease antigen-binding sites (Filpula, 2007).  
Commercially, this specificity to target indications with high populations has enabled the 
market to evolve into a multi-billion dollar per year prospect (J. K. Liu, 2014). 
1.3 Host Cell Lines, Expression Systems and Stable Cell Line Generation 
The first therapeutic mAbs produced experienced human anti-mouse immune side effects.  This 
was due to the large size of the molecules combined with the host cell lines inability to 
effectively translate the respective genetic sequence (F. Li, Vijayasankaran, Shen, Kiss, & 
Amanullah, 2010).  Investigations identified glycosylation patterns native to the host cell 
system on translated antibody products as a cause for this immunogenic response (Q. Zhou & 
Qiu, 2019).  Therefore, it was vital to select host cell lines for their ability to accurately translate 
humanised glycan structures onto the secreted mAbs (Birch & Racher, 2006).  The E.coli host 
cell line is an example of an alternative option to mammalian hosts.  It possesses an advanced 
gene editing toolbox and shorter manufacturing windows (Rosano & Ceccarelli, 2014).  
However, these benefits are not commonly exploited for mAb production due to the inferior 
expression of humanised product attributes when compared to mammalian hosts (Spadiut, 
Capone, Krainer, Glieder, & Herwig, 2014).  
The Chinese Hamster Ovary (CHO) cell hosts have been studied and utilised extensively for 
therapeutic mAb expression since the 1980s (Birch & Racher, 2006).  Alternative mammalian 
host cell systems such as the non-secreting murine myeloma (NS0), Human PER.C6 and 
Human embryonic kidney (HEK) cell lines are used commercially, and their adoption or 
continued usage by an organisation is typically based on historic procedures and knowhow 
(Kunert & Reinhart, 2016).  The CHO host cell lines make up >70% of the cell lines used 
commercial expressed mAbs (Jayapal, Wlaschin, Hu, & Yap, 2007) and this ubiquitous use 
has led to continued improvements into the bioprocesses they define (Goh & Ng, 2018).  This 
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is highlighted by the reported productivity improvements over the decades, with fed batch 
process titres of 1g/L, 5g/L and more recently 10g/L achieved and exceeded (F. M. Wurm, 
2004). 
The improvements in productivity have been realised by combining the host cell lines with a 
complementary expression system.  A popular choice of a host cell line is CHO variants that 
lack the essential dihydrofolate reductase (DHFR) enzyme.  These host cell lines are 
transfected with a plasmid containing DNA for both the DHFR enzyme and therapeutic protein 
of interest.  The application of selective pressure, through an inhibitor such as methotrexate 
(MTX) and a thymidine lacking medium, forces the cell to co-express the acquired DHFR gene 
alongside the therapeutic protein of interest simultaneously to survive (Kaufman & Sharp, 
1982).   
Comparable selective expression pressure is generated by the CHOK1 variant of the CHO host 
(developed by Lonza Biologics, Switzerland).  This is achieved when the host is used in 
combination with the complimentary GS (glutamine synthase) Gene Expression System®, 
exploiting the cell lines essential requirement for glutamine.  The GS  Gene Expression System 
takes advantage of the host cell lines essential requirement for glutamine.  The endogenous 
glutamine synthase enzymatic reaction is blocked through the addition of a GS inhibitor such 
as methionine sulphoximine (MSX).  The co-expression of a transfected plasmid containing 
DNA for both the GS enzyme and therapeutic protein of interest ensures sufficient GS is 
available for cell survival (L. Fan et al., 2012).   
These two expression systems, DHFR and GS, inherently link cellular mAb productivity to 
cellular survival. This provides a failsafe method of cell line selection as only appropriately 
transfected cell lines will be able to grow (Dhara, Naik, Majewska, & Betenbaugh, 2018). 
Stable transfection is typically performed with the assistance of a viral promoter. An example 
of such a promoter is the retrovirus murine leukaemia virus (MLV).  This promotor enables the 
integration by transfection of DNA sequences into the host cell genome (T. K. Kim & 
Eberwine, 2010; Ye et al., 2010).  This process of transfection results in the random placement 
of the plasmid into the host cells' genome (T. K. Kim & Eberwine, 2010).   
This random integration generates variability in the performance of clones within each pool.  
Overtime (through natural selection) those with high survival characteristics will generate large 
subpopulations within the transfected pools.  These survival characteristics may not translate 
to desired expressed Ab quality or productivity characteristics.  To accurately characterise a 
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bioprocess and reproduce the performance in a commercial manufacturing setting, this 
variability in expression characteristics must be removed.   
Ensuring cell line monoclonality is a critical step in ensuring the robustness of the 
manufacturing process.  Several methods have been adopted to confirm culture clonality 
(Browne & Al-Rubeai, 2007).  Traditionally a labour-intensive method of limited dilution was 
widely adopted for CHO cells due to its application to cultures grown in suspension rather than 
on agar plates (Puck & Marcus, 1955).  More recently, high investment into commercial cell 
line construction has introduced flow cytometry, and other single cell sorting, techniques into 
clone selection (Borth, Zeyda, & Katinger, 2000; Grilo & Mantalaris, 2019; Yim & Shaw, 
2018).   
Ultimately, vast quantities of monoclonal cell lines will be generated with unique expression 
and stability characteristics.  Extensive screening procedures are conducted to determine the 
ranking of performance.  Statistically, the larger number of cell lines evaluated will result in a 
higher chance of discovering one with appropriate criteria.  Ranking criteria can consist of a 
combination of (but is not limited to), cell growth characteristics, cell specific productivity, 
titre, product quality and stability of these attributes as cell age increases (Birch & Racher, 
2006).   
1.4 Cell Line Response to Bioprocess Control, Development and Optimisation 
The evaluation of cell line performance is in relation to specific sensitivities and interactions 
present in the manufacturing physiochemical environment.  Due to the extensive utilisation of 
CHO hosts, many characteristics have been studied and successfully exploited through tight 
process control, in the commercial production of mAbs.  However, the variety of therapeutic 
mAb products generated gives rise to increasingly complex cell lines displaying unique 
characteristics to be investigated in development (De Jesus & Wurm, 2011). 
1.4.1 Hydrodynamic Stress 
Mammalian cell cultures are isolated from immobile vascularised tissue with very low 
hydrodynamic stresses.  Cells grown in suspension cultures are exposed to shear forces as they 
are mixed and sparged. Cell line sensitivity to shear has been a focus of researchers when 
culturing mammalian cells (Godoy‐Silva, Chalmers, et al., 2009; Walls et al., 2017).  
Hydrodynamic stress has historically been investigated in these two formats: the dissipation of 
energy from the mechanical agitation of the impeller; and the rupture forces of bursting bubbles 
originating from the sparging of gases (W. Hu, Berdugo, & Chalmers, 2011). As mammalian 
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cell cultures are intensified in the quest for higher productivities, agitation rates and gas 
sparging are set to increase to meet the nutrient demand of the cultures, focusing the need to 
characterise cell line sensitivity to hydrodynamic stress. 
For mechanical agitation, early studies investigating microcarrier/adherent cell suspension 
cultures shaped an adopted opinion that mammalian cells in suspension displayed a sensitivity 
at elevated agitation.  Increasing the agitation rate resulted in detachment of the mammalian 
hosts from the microcarriers (Clark, Hirstenstein, & Gebb, 1980; Croughan, Hamel, & Wang, 
2000; Venkat, Stock, & Chalmers, 1996).  
In review of hydrodynamic stress on mammalian cultures (W. Hu et al., 2011), evaluations of 
bench scale (G. Zhou & Kresta, 1996) and manufacturing scale (Wernersson & Trägårdh, 
1999) vessels are conducted.  The hydrodynamic stress experienced and investigated was at 
substantially lower levels than those shown to be detrimental to CHO host growth and 
productivity performance (Godoy‐Silva, Mollet, & Chalmers, 2009; Ma, Koelling, & 
Chalmers, 2002; Mollet, Godoy‐Silva, Berdugo, & Chalmers, 2007).  This comparative 
analysis provides operational flexibility to increase the agitation rates as the culture densities 
increase and the culture physiochemical environment requires it. 
Sparging gasses into the culture results in bubble formation that becomes a local focus of 
hydrodynamic stress when rupture occurs.  These bubbles will ultimately undergo a detachment 
process at liquid-air surfaces (MacIntyre, 1972).  This sudden release of air from the bubble 
has been shown to release high localised hydrodynamic forces that are inversely proportional 
to bubble size (Chisti, 2000), and equivalent to those generated in manufacturing scale STRs 
mechanical agitation (Wernersson & Trägårdh, 1999). 
The addition of a non-ionic surfactant (such as Pluronic F-68 (Polyoxyethylene-
polyoxypropylene)) has provided a multi-faceted improvement in reducing the hydrodynamic 
impact on cells from bubbles (Tharmalingam, Ghebeh, Wuerz, & Butler, 2008).  Firstly, the 
surfactant associates with the cell-surface lipid bilayer to increase the physical robustness of 
the membrane.   Secondly, the association with the cell membrane generates an increased 
hydrophobicity of the cell.  This enables the cell to more readily disassociate from the bubble 
surface, before any detachment or bursting event.  The increase in the distance reduces the 
exposure of the cells to peak hydrodynamic forces during rupture events (Walls et al., 2017).   
The potential sensitivities of CHO host cell lines to shear forces requires process control to 
adopt a conservative strategy to allow successful process operation.  Firstly, given its apparent 
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protective qualities, the medium formulation is regularly supplemented with Pluronic F68.  
Secondly, to maintain the culture dissolved oxygen (DO) level as required, gas flow rates are 
restricted to an upper limit and agitation only increased incrementally when the current gas 
transfer rates do not meet the set DO level.  The hydrodynamic forces are thus minimised whilst 
providing sufficient mixing and maintaining the physiochemical environment.  
1.4.2 pH Control 
Mammalian cultures rely on the exchange of hydrogen ions for the function of their enzymatic 
processes. The sub-optimal pH of a culture will impact these interactions and, in turn, can 
decrease the culture performance.  The growth performance of CHO cells can be sensitive to 
as little deviation as 0.1 from the optimal pH (F. Li et al., 2010). 
A sodium bicarbonate (NaHCO3) buffering component is often included in the medium 
formulations and the carbonic acid readily produced by the metabolically produced carbon 
dioxide (CO2) serve as an acid/base pair.  The pH is then maintained at an optimised value 
through controlled addition of gaseous CO2 and shot additions of NaHCO3, as required.   
Incorporated into cultures is an online pH probe that provides data to a proportional-integral 
(PI) control loop.  The PI controller first determines the distance from setpoint (Proportional 
term) and then sums the duration it has been there (accumulated Integral term).  Outputs from 
the PI controller will be converted into calculated flow rates of either CO2 or NaHCO3 to bring 
the pH back within the dead-band. 
The exposure to varied pH setpoints has been observed to contribute, at least in part, to variable 
process performance.  Specifically, this has been recognised where a decrease in pH displays 
a decline in growth and productivity parameters (Brunner, Fricke, Kroll, & Herwig, 2017). In 
addition, undesirable mAb product quality attributes have been shown to correlate with 
suboptimal control of culture pH (Goldrick et al., 2017).  The impact of pH on culture 
performance is not universal for all CHO host derived cell lines, and each may present a unique 
response to pH control (Trummer et al., 2006). 
1.4.3 Temperature Control 
Temperature, like pH, has a universal impact on enzymatic activity within living organisms.  
Mammalian culture systems work optimally within a physiological range, between 36 and 
38°C.  Temperature is maintained within cultures to a predetermined setpoint within this range.  
This control is performed with the combination of an online temperature probe and heating 
elements (typically a heated element positioned around the perimeter of the vessels). 
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The effects of temperature on the performance of mammalian culture systems have been 
extensively studied.  The majority of the focus has been on the impact of hypothermic (<35°C) 
conditions on culture performance (Fogolı́n, Wagner, Etcheverrigaray, & Kratje, 2004).  A 
reduction in the growth rates, maximal culture concentrations and culture metabolism has been 
observed when culture temperature is reduced (Borth, Heider, Assadian, & Katinger, 1992; 
Furukawa & Ohsuye, 1998; Reuveny, Velez, Macmillan, & Miller, 1986; Sureshkumar & 
Mutharasan, 1991; Weidemann, Ludwig, & Kretzmer, 1994). 
In addition, there are specific benefits to operating in a hypothermic range that translates to 
therapeutic mAb production.  A lower temperature has been shown to decrease the percentage 
of cultures in the S phase of the cell cycle, enabling cells to accumulate in G1 (Moore et al., 
1997).  This increased instance of G1 phase results in a delayed onset of culture apoptosis and 
therefore a prolonged culture duration.  Additionally, the temperature mediated reduction in 
cell metabolism prevents the build-up of potentially toxic waste metabolites (Xu et al., 2019).  
The observation of this delayed onset of apoptosis has been shown to increase productivity 
(Moore et al., 1997) and will be of particular benefit for cell lines that display an increased 
mAb production in G phase (Dutton, Scharer, & Moo-Young, 2006).  However, given that cell 
specific productivity is typically assumed to be higher in S phase (Lloyd, Holmes, Jackson, 
Emery, & Al-Rubeai, 2000), the benefits associated with extending batch or fed-batch culture 
duration are not always realised and are likely cell line specific (Bloemkolk, Gray, Merchant, 
& Mosmann, 1992). 
An increase in temperature above the physiological range evokes stress responses in 
mammalian cultures.  Studies at the transcriptional level indicate the overexpression of heat 
shock proteins (HSPs) at temperatures maintained above the physiological range (Kregel, 
2002).  These HSPs provide a protective environment to reduce the amount of protein 
aggregation that occurs during periods of high temperature stress.  However, this protection is 
not sufficient to counteract the conformational changes and a high rate of protein degradation 
that occurs at high culture temperatures (Parag, Raboy, & Kulka, 1987).  Furthermore, 
suppressed growth was observed in cultivations at temperatures as high as 42°C  (Sureshkumar 
& Mutharasan, 1991).  Recently, studies involving mild hyperthermic exposures have indicated 
a “eustress” response that acts in the absence of HSPs.  This has been observed to result in 
acquired thermotolerance presenting through maintaining membrane homeostasis, activating 
lipid remodelling, and redistributing chaperone proteins (Peksel et al., 2017). 
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This cumulative response to increased culture temperature emphasises the importance of 
maintenance within physiological ranges when operating production cultures.  Potential 
benefits have been investigated when operating a shift in temperature from physiological to 
hypothermic at the end of exponential growth (Hendrick et al., 2001; Kaufmann, Mazur, 
Fussenegger, & Bailey, 1999).  In addition, investigations have displayed a doubling of 
productivity utilising a hypothermic temperature shift, and have also presented beneficial 
mRNA stabilising effect of the hypothermic condition (Oguchi, Saito, Tsukahara, & Tsumura, 
2006). 
1.4.4 Dissolved Oxygen and Carbon Dioxide Saturation 
The saturation levels of dissolved oxygen (DO) and CO2 within a culture are critical elements 
of the physiochemical environment.  Dissolved oxygen maintenance is coupled to the culture 
agitation, sparging of oxygen, vessel geometry and minimisation of foam formation (as 
mentioned above, Section 1.4.1 Hydrodynamic Stress).  Levels of DO within cultures are 
maintained by altering a single, or combination, of these contributing factors (Amer, Feng, & 
Ramsey, 2019; Hanson et al., 2007). 
Observations have determined mammalian cells display an impact on cellular metabolism at or 
below five percent culture saturation, with a critical level observed at one percent saturation 
(Heidemann, Lütkemeyer, Büntemeyer, & Lehmann, 1998).  Additionally, hyperoxia 
conditions (approx. 200% saturation) have been shown to reduce the culture growth rate.  
Finally, operation outside a range of 10 to 100% saturation can result in undesirable product 
quality attributes (Restelli et al., 2006), and have a negative impact on culture productivity 
(Handlogten, Zhu, & Ahuja, 2018). 
During culture operation, to mitigate the risk of operating at a saturation below 5%, a set point 
of around 50% is typically maintained.  This provides a contingency for the process control 
systems (adjustment of agitation rates and volume of sparged oxygen) to respond if oxygen 
demand of the culture changes. Increases may occur when the culture progressing through 
exponential growth or when a surfactant such as antifoam is added that alters the gas transfer 
rates (Pappenreiter, Sissolak, Sommeregger, Striedner, & biotechnology, 2019). 
Increases of carbon dioxide (CO2) saturation within mammalian cell cultures is provided for 
the maintenance of culture pH (Section 1.4.2 pH Control).  Additional CO2 is generated as a 
metabolic by-product of respiration.  Mammalian cells can tolerate CO2 build-up, but do 
experience inhibitory thresholds where adverse effects are encountered.  Levels increasing 
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from 50 to 140-150 mmHg has been reported to impact growth and productivity (deZengotita, 
Schmelzer, & Miller, 2002; Zhu et al., 2005), with values greater than 111 mmHg reported to 
impact product quality (Xing, Li, Chow, & Lee, 2008).   
These inhibitory thresholds are of particular interest as they represent the levels experienced in 
the large volume culture vessels, due to the longer bubble residence time and decreased mixing 
velocities in larger, taller vessels (Sieblist et al., 2011).   
Investigations can be conducted in laboratory scale cultures, such as increased CO2 sparging, 
to determine the sensitivity of a particular culture or cell line.  However, solutions are typically 
identified in the large manufacturing scale cultures, specifically in bioreactor design (altering 
vessel geometry to increase gas transfer rates) and pH control strategies (Mostafa & Gu, 2003; 
Xing, Lewis, Borys, & Li, 2017). 
1.4.6 Nutrient Availability and Waste Accumulation 
The appropriate maintenance of available nutrients is a vital component of culture control and 
optimal culture operation. This control involves the exacting supply of carbohydrates, amino 
acids, lipids, nucleic acid precursors and rare metal ions, throughout stages of culture operation.  
Iterative improvements in medium and feed development over the past 30 years have resulted 
in multi g/L processes achieved (F. M. Wurm, 2004). 
Whilst the correct medium formulation provides the potential for culture success, incorrect 
formulations can be equally impactful.  In addition to the growth and productivity performance 
measures (Rodrigues, Costa, Henriques, Azeredo, & Oliveira, 2012; Simpson, Singh, Perani, 
Goldenzon, & Al-Rubeai, 1998), product quality variation is observed by incorrect control of 
culture nutrient supply (Costa et al., 2013; Hossler, Khattak, & Li, 2009). 
Fetal bovine serum (FBS) has been a widely used mammalian culture supplement in academic 
and commercial applications.  However, due to ethical and safety concerns, and lot-to-lot 
variation, fully chemically defined medium and supplement formulations have been developed 
and are an accepted standard in the commercial manufacture of mAbs (Gstraunthaler, 2003).  
These chemically defined medium can vary widely in their constitutive components but must 
facilitate the glyco-glutaminolysis activity that characterises mammalian cell culture (Pan, 
Streefland, Dalm, Wijffels, & Martens, 2017; Quek, Dietmair, Krömer, & Nielsen, 2010).   
Glyco-glutaminolysis is the cellular uptake and processing of glucose and glutamine, combined 
with the secretion of ‘waste’ metabolites, such as lactate and non-essential amino acids.  The 
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toxic build-up of waste metabolites and bi-products can result in premature culture termination.  
Specifically, lactate has been observed to accumulate through the stationary phases of culture 
growth.  This accumulation presents pressures on pH maintenance control that can result in a 
loss of control, stress to the culture and negative performance (Quek et al., 2010; Zagari, 
Jordan, Stettler, Broly, & Wurm, 2013).   
High aerobic glycolysis within cells can generate a redox potential that contributes to these 
elevated lactate concentrations (Halestrap & Wilson, 2012), this process is known as the 
Warburg effect (Warburg, Wind, & Negelein, 1927).  Many carbon feeding strategies have 
been explored to mitigate this accumulation (Claudia Altamirano, Illanes, Becerra, Cairó, & 
Gòdia, 2006; C. Altamirano, Paredes, Illanes, Cairó, & Gòdia, 2004; J. Li, Wong, 
Vijayasankaran, Hudson, & Amanullah, 2012).  However, due to the culture supply demands 
of glucose and glutamine for high product quality (Y. Fan et al., 2015; Hayter et al., 1992; 
Nyberg, Balcarcel, Follstad, Stephanopoulos, & Wang, 1999; Reinhart, Damjanovic, 
Kaisermayer, & Kunert, 2015), and the inherent complexity and crosstalk of the metabolic 
network (Grüning, Lehrach, & Ralser, 2010), no universal control strategy has been developed.  
It has been shown that by reducing this Warburg effect, cultures display improved growth and 
productivity (Buchsteiner, Quek, Gray, & Nielsen, 2018).  A review of the literature indicating 
mechanisms driving the consumption and production of lactate has indicated that control of the 
cytosolic redox potential may be key to controlling cellular lactate concentrations (Hartley, 
Walker, Chung, & Morten, 2018). 
Finally, it is critical to carefully monitor culture viability when controlling waste accumulation 
in the culture.  At the onset of culture apoptosis, there will be an increase in intercellular host 
cell proteins that may impact the product quality characteristics of the expressed mAb 
(Hogwood, Bracewell, & Smales, 2014; Park et al., 2017).  Therefore, strict culture harvest 
criteria are set, and the utilisation of low shear primary recovery devices are designated (Y. 
Fan, Ley, & Andersen, 2018) to ensure consistent product quality is achieved if cellular 
apoptosis cascades are initiated (Tait, Hogwood, Smales, & Bracewell, 2012). 
1.5 Modes of Operation 
Culture operation is managed through strategic control of the aforementioned nutrient demands 
and management of cellular waste.  The below subsections present the variety of cultivation 
modes employed, each offering advantages and drawbacks in the production of mAbs. 
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1.5.1 Batch 
The batch growth of cultures can be a robust mode of cultivation due to the simplicity of its 
operation.  Cells are inoculated into a nutrient rich medium and the culture expands, utilising 
available resources until they are depleted.  As a critical culture component becomes limiting, 
the culture will transition from exponential growth into a decline phase.  Nutrient limited 
cultures will quickly reach harvest criteria and the production mode terminated as viability 
decreases. 
 
Figure 2 Example of batch culture operation setup 
The diagrammatic example contains required components for operation of a batch culture including impeller, 
probes (e.g. pH and DO) shown in red, gas sparging line shown in black and jacket around the vessel to control 
temperature. 
 
The simplicity of batch culture enables its use as a low resource method of screening cell line 
performance.  The translation of this performance to other cultivation methods relies on the 
assumption that cell specific productivity (grams of protein produced/cell/day) is retained and 
any percentage change in productivity is accounted for by changes in culture duration and or 
density (Longobardi, 1994). 
1.5.2 Fed-Batch 
As the name suggests, fed-batch cultivation involves strategic feeding of key nutrients to batch 
cultures.  Fed-batch (FB) methods have proven the most popular method for therapeutic mAb 
production over the past 30 years, and continued refinement has contributed to 100-fold 
Probes/Sparging
Page 34 of 204 
 
improvements in overall bioprocess productivity (Chu & Robinson, 2001).  These 
improvements have been realised by increasing the duration a culture spends in each phase of 
growth to maximise productivity and maintain product quality. 
 
Figure 3 Example of fed batch culture operation setup 
The diagrammatic example contains required components for operation of a fed batch culture including 
impeller, probes (e.g. pH and DO) shown in red, gas sparging line shown in black, jacket around the vessel to 
control temperature and the nutrient feed bottle in yellow. 
 
Early investigations within cell culture identified the phases of culture progression that are the 
focus in fed-batch culture, in the present day (Monod, 1949).  These phases include inoculation, 
exponential growth, stationary and decline/death phases, and are presented in Figure 4, below. 
Nutrient Feed
Probes/Sparging
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Figure 4 Example presentation of a typical growth profile over a batch or fed-batch bioprocess 
operation. 
Example growth profile plots viable cell concentration over increasing process duration, with intersecting 
dashed lines designating specific phases of culture progression. (A) Inoculation/Lag following inoculation. 
(B) Exponential growth. (C) Stationary. (D) Decline/death 
 
Metabolic flux analysis of cultures operated in batch and fed-batch has defined characteristics 
of these 4 stages of culture progression and identified the complexity involved at each stage 
(Ahn & Antoniewicz, 2012; Dorka, Fischer, Budman, & Scharer, 2009; Gao, Gorenflo, 
Scharer, & Budman, 2007; Provost & Bastin, 2004; Templeton, Dean, Reddy, & Young, 2013). 
The duration of the exponential growth phase, and the resulting culture cell density, is 
dependent on the abundant supply of nutrients.  Metabolite analysis of medium removed during 
exponential growth can identify the key nutrients that are required to prolong the exponential 
growth (Butler & Jenkins, 1989).  Ultimately, the exponential growth will become limited by 
a depleted nutrient and the cultures will display a decline in growth rate and transition into a 
stationary phase. 
Page 36 of 204 
 
The determination of the exponential growth phase can be performed by plotting the log 
transformation of the viable cell concentration against the process duration.  During 
exponential growth this will result in a linear relationship between the log(Y) and X, enabling 
consideration of the phase of growth the culture is exhibiting during the process.  An example 
plot is provided in Figure 5, displaying this relationship with linear regression through the 
points considered in exponential growth. 
 
Figure 5 Example presentation of a log(Y) growth profile during bioprocess operation. 
Example Log(Y) profile plots Log(Y) over increasing process duration, with the timepoints considered to be 
in exponential growth highlighted by  
 
As illustrated in Figure 5, the linear relationship will not be represented as the culture 
progresses into the stationary phase.  This estimation of the end of exponential growth and the 
beginning of the stationary phase are clearly defined in this example presentation.  The practical 
determination of this phase boundary is challenging and can be influenced by factors such as 
sampling frequency, culture heterogeneity, and analytical variation.  True exponential growth 
can only be considered in the centre of the defined exponential growth phase as the influence 
of the initial lag and onset of the stationary phase will be minimally impacting the culture. 
Characteristics of the stationary phase include a physical increase in cellular size that has been 
coupled with an increase in cell specific productivity (Pan, Dalm, Wijffels, & Martens, 2017).  
In addition, this phase is characterised by an accumulation in lactate concentration as its 
consumption declines, and glucose is continued to be consumed (Martinez et al., 2013).  
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Ultimately, the environment is a heterogeneous mixture of cells in exponential growth, and 
those that have committed themselves to apoptosis.  To prolong the duration of the stationary 
phase, this complex and reactive physiochemical environment must be maintained. 
The final stage in a batch or fed batch culture is the decline/death phase, where culture viability 
is observed to decline.  Strategies such as the use of temperature (Moore et al., 1997), and the 
close monitoring of available metabolites, aim to prolong the duration of the culture and 
maximise productivity (Singh, Al.-Rubeai, Gregory, & Emery, 1994).  As the cultures progress 
into this decline phase, non-viable cells begin to rupture, and undesirable cell debris enters the 
cell culture supernatant.  This debris may impact the efficiency of the harvest and quality of 
the expressed product.  A limit is set for viability that defines when the culture is to be 
harvested. 
1.5.3 Continuous Culture – Non Cell Retention 
In contrast to the multiple growth phases experienced in batch and fed-batch culture, 
continuous culture is considerably simpler.  The chemostat is a popular method for continuous 
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culturing and was defined by researchers in 1950 (Monod, 1950; Novick & Szilard, 1950).
 
Figure 6 Example of chemostat culture operation setup 
The diagrammatic example contains required components for operation of a chemostat culture including 
impeller, probes (e.g. pH and DO) shown in red, gas sparging line shown in black, jacket around the vessel to 
control temperature, the fresh media in yellow and removed culture in blue. 
 
 
Following inoculation, chemostat cultures are grown in batch operation for a nominal time with 
the goal to establish exponential growth.  The continuous exchange of fresh medium and 
removal of culture (cells plus conditioned medium and expressed protein) is then initiated.   
This continuous exchange maintains the physiochemical environment and a cellular ‘steady 
state’ is reached where the growth rate matches the death rate for a given dilution rate.  These 
defined growth/death rates at a dilution rate will be realised by the culture because of a limiting 
nutrient within the medium formulation.  Changing the medium formulation will result in a 
new steady state to be established to reflect changes in the rate limiting nutrient.  This control 
of the physiochemical environment enables high experimental reproducibility and makes 
chemostat culturing a popular choice for researchers investigating a variety of cellular 
characteristics (Hoskisson & Hobbs, 2005). 
Fresh Media Removed Culture
Probes/Sparging
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In addition to chemostat culture, is the turbidostat culture method of operation.  This method 
aims to operate at, or as close to the culture maximum specific growth rate as possible, without 
experiencing culture ‘wash-out’.  This is achieved by closely monitoring the culture density, 
and adjusting the dilution rate respectively to increases or decreases in cellular concentration 
(Watson, 1972).   
Differences between the two methods are highlighted by the resulting selective pressure placed 
on polyclonal populations.  The chemostat method will select those cells with the highest 
efficiency for the limiting nutrient for the given dilution rate.  Turbidostat method will select 
those cells with the highest maximum specific growth rate (Flegr, 1997). 
1.5.4 Continuous Culture – Cell Retention 
The operation of a chemostat or turbidostat results in the continuous removal of cells and 
expressed product from the culture.  This restricts the culture cell density from reaching its 
potential maximum.  Opportunities exist in cell culture systems, where cell specific 
productivity is retained over time, to generate a highly productive process by retaining cells 
within the culture as they expand exponentially. 
This method of cell culture is generally defined as perfusion.  Perfusion methods of continuous 
culture operation have been developed that take advantage of the medium exchange of 
continuous culture, whilst retaining cells (and product if desired) within the culture. 
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Figure 7 Example of a perfusion culture operation setup 
The diagrammatic example contains required components for operation of a perfusion culture including 
impeller, probes (e.g. pH and DO) shown in red, gas sparging line shown in black, jacket around the vessel to 
control temperature, the fresh media in yellow, removed culture in blue and the cell retention device. 
 
Commercially applied examples of continuous bioprocessing methods can exist in perfusion 
production or the utility of a rolling inoculum.  Whilst not as popular as fed batch, the principles 
of perfusion offer highly productive bioprocesses with the ability to produce the wide variety 
of unstable, ‘difficult to express’ (DTE) molecules emerging from commercial research 
pipelines (Alves & Dobrowsky, 2017; Bonham-Carter & Shevitz, 2011).   
It is this ability of perfusion to remove volatile protein products from the culture environment 
that is coveted when a perfusion bioprocess is conceptualised over fed batch best practices.  
This has been demonstrated in the production of haemoglobin Factor VIII substitute for 
haemophilia A patients (Pollock et al., 2013).   
The operation of a cell retention device adds resource and complexity to the culture operation.  
The complexity translates into increased risk of failure that is considered when selecting 
perfusion as a method of cultivation over other methods.  Additionally, if perfusion is selected, 
there is a variety of cell retention methods that must be considered, each with their respective 
advantages and disadvantages. 
Fresh Media Cell‐Free PerfusateCell Retention Device
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1.5.4.1 Cell Retention Devices 
For a cell retention device to be considered appropriate, it must retain cells whilst not negatively 
impacting the culture viability or productivity.  In addition, the performance of the device 
should not deteriorate over time.  This deterioration may occur through the build-up of culture 
by-products, such as cellular particles generated through apoptosis.  In achieving efficient cell 
retention, devices exploit the physical properties of cells.  This is conducted through techniques 
based on one of two main methods, filtration or sedimentation (Voisard, Meuwly, Ruffieux, 
Baer, & Kadouri, 2003; Woodside, Bowen, & Piret, 1998).   
Filtration devices, such as spin filters and hollow fibre columns, must be carefully selected.  
Selection criteria are based on filter pore size, considering the cellular size to enable cell 
retention (upper limit) whilst not risking filter fouling (lower limit).  Additionally, any 
requirement to retain the expressed product within the culture must be considered in the filter 
sizing and increases the risks to filter fouling. 
Cultures are exposed to different growth environments depending on the cell retention method.  
In filtration methods, a cell free perfusate stream is drawn through a filter.  This generates 
hydrodynamic forces on the cells that will increase as the culture density increases or as the 
filter begins to foul. This may cause undesirable shear forces leading to cellular lysis (S. Wang 
et al., 2017). 
Early filtration devices were based on the spin filter technology, whereby the filter device was 
situated axially in the stir tank reactor (STR) (Avgerinos et al., 1990).  The popularity of this 
device was restricted by the inability to replace the filter in the event of filter fouling.  
Additionally, there is high complexity in scaling up the spin filter technology into commercial 
scale bioreactors (Bonham-Carter & Shevitz, 2011).  
In contrast, sedimentation devices, such as incline and vertical settlers, aim to exploit the 
difference in density of the cell and medium components of the culture.  This method generates 
a cell-free perfusate without the risk of filter fouling.   
In sedimentation methods, the culture is influenced firstly through the selective removal of 
lower density cells (typically non-viable or immature (Searles, Todd, & Kompala, 1994)), and 
secondly through the heterogeneous environments generated during settling.   
In addition to incline and vertical settlers, methods exist that utilise centrifugation and acoustic 
wave separation to achieve sedimentation.  Whilst relative success had been achieved with 
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these methods, technological challenges and investment to operate the systems at larger scales 
have prevented further investigation (Woodside et al., 1998). 
The lower economic and technological investment needed for cell settlers has provided an entry 
to explore perfusion for researchers and industry alike.  This exploration has expanded into 
characterisation and industrial processes taking advantages of the simplicity of operation and 
scalability of the method (Choo et al., 2007; Hülscher, Scheibler, & Onken, 1992; Searles et 
al., 1994; Z. Wang & Belovich, 2010). 
More recent investment and advancements into cell retention devices have focused on filtration 
based methods.  Specifically, hollow fibre filters external to the STR have been coupled with 
a recirculating pump to provide tangential flow across the filter surface.  Pumping the culture 
ensures a holdup volume is not experienced within the hollow fibre filter and homogenous 
culture is achieved.  In addition, existing externally from the reactor allows the option to replace 
the filter in the event of failure. 
A popular commercial system is the ATF system manufactured by Repligen (USA).  This is 
operated with a pressurised diaphragm inside a bulb structure.  An alternating tangential flow 
(ATF) is generated by the contracting and relaxing diaphragm.  This flow is directed from the 
culture, across a prefabricated hollow fibre column to enable the removal of cell free perfusate.   
Aiding its popularity is the fact the ATF system generates very low shear forces in comparison 
to peristaltic inline pumps (S. Wang et al., 2017), enabling scalability from a 1L STR model 
up to 500L STRs (Bonham-Carter & Shevitz, 2011).  This scalability is critical in enabling the 
bioprocess development work conducted at bench scale to be quickly translated to larger 
manufacturing scales. 
1.6 Scales of Operation 
In the commercial production of mAbs and other therapeutic protein products, manufacturers 
are bound by strict regulatory guidelines.  These guidelines are published by the International 
Council for Harmonisation (ICH) and adopted by each regional regulatory entity.   
Within the regulatory guidelines, the exploration of the culture operational space is promoted.  
This is to understand the robustness of the system, specifically the impact of culture control 
variation (‘Critical Process Parameters’ (CPPs)) on culture outputs (‘Critical Quality 
Attributes’ (CQAs)).  This investigation is known as ‘Quality by Design’ (QbD) and to provide 
the required detail, will entail high experimental resources.  To economically complete the 
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necessary experiments, varying degrees of scale down systems have been adopted that have 
been characterised to inform commercial manufacturing scale cultures.  The scales represented 
in the following sections are depicted for reference of physical dimensions in Figure 8, below. 
 
Figure 8 Example volumes and dimensions for bioreactors at different scales 
The reported heights and visual depiction of the scales is provided for reference and variation can occur 
between different manufacturers and vessel geometries.  The height of the commercial scale vessel is not fully 
represented as its height is more than three times that of the pilot scale.  
 
The development of commercial manufacture of fed batch processes utilises operating volumes 
from 200µl up to 20,000L.  Justification and rationale for the operation of these scales are 
provided in Sections 1.6.1 to 1.6.4, below. 
To operate a commercial scale bioreactor with a fed batch process developed at microscale 
requires careful consideration and balance of scale dependant variables (mixing, shear force 
and gas transfer rates).  The first reported instance of a 20,000L bioreactor by Lonza Biologics 
in 2005 (Birch & Racher, 2006) reaffirmed that mammalian cells can be grown in suspension 
at larger scales and that they did not display such high sensitivity to shear as was once feared 
due to the lack of a cell wall (Nienow, 2006) 
Therefore, the process would look to match scale independent variables (such as Nutrient Conc, 
DO & CO2, pH, and Temperature) in the scale up operation.  Unfortunately, scale dependent 
variables can negatively impact the scale independent variables if not balanced appropriately.  
The exacting balance of mixing, shear, and gas transfer rates is not always possible when 
scaling up, and optimisations at each scale may be required.  Recently, advancements in micro 
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and bench scale bioreactor operation have enabled a more efficient transition to commercial 
scale vessels with process characterisation aligning for growth and product quality attributes 
across scales (Manahan et al., 2019).  
The increase in gas sparging rates in 20,000L vessels is an example of the compromise used to 
make this balance.  This is performed to minimise the increased mixing speed to achieve the 
required gas transfer rate, therefore minimising the shear forces exerted on the culture (Xing, 
Kenty, Li, & Lee, 2009).  Unfortunately, there is no uniform bioreactor or impeller design and 
GMP manufacturing facilities are unlikely to switch away from established systems due to the 
need for requalification and approval processes.  This required process engineers to balance 
the scale-up of a process for the specific vessel identified (Sieblist, Jenzsch, & Pohlscheidt, 
2016). 
1.6.1 Commercial Manufacturing (Commercial Scale) 
The success of mAbs and other therapeutic proteins during the 1990s resulted in high demand.   
In order to meet this demand, facilities were constructed to operate multiple vessels that 
reached operational volumes of up to 20,000 litres.  These vessels are now accepted as the 
norm for a manufacturing facility and process design in development is now carried out to meet 
this production scale (Gronemeyer, Ditz, & Strube, 2014; Kelley, 2009). 
The operation of a commercial manufacturing scale vessel presents the opportunity to produce 
vast quantities of product.   Therefore, operational time in a facility is a valuable commodity 
and is meticulously planned to maximise outputs.   
The time required for the operation of a vessel includes the culture duration and activities that 
support it, such as facility downtime for cleaning and sterilisation in-between runs and the 
preparation of medium and inoculum cultures.  Strategies have been adopted to minimise these 
associated activities.  These include the use of pre sterilised, single use systems (Eibl, 
Löffelholz, & Eibl, 2014; Shukla & Gottschalk, 2013).   
The expansion of inoculum cultures is not an activity that can be accelerated as it relies on the 
growth rate of the cells.  Each production vessel is initiated from a single 1-2mL cryogenically 
stored vial, and substantial efforts are directed into growing cells as per process operating 
criteria to ensure batch to batch reproducibility.  For a production vessel of 10,000L in size, 
this will include the operation of multiple large scale vessels of increasing volume and 
complexity (Kloth, Maclsaac, Ghebremariam, & Arunakumari, 2010). 
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1.6.2 Clinical Supply (Pilot Scale) 
The development pathway of any new drug involves progression through clinical trials to 
assess the toxicological and pharmacological characteristics in support of approval and 
commercialisation.  The success rate for new drugs to reach commercial release is low.  
Therefore, scale must be considered when supplying material for clinical trials and avoid 
excessive wastage if a new drug is unsuccessful. 
Pilot scale vessels are operated at volumes between 10 and 50% of the designated commercial 
scale.  In addition to material supply, the data generated is critical in translating the 
understanding generated at smaller scale into the successful operation of commercial scale 
cultures.   
The focus of this understanding has been in culture responses to vessel dynamics, 
hydrodynamic forces and maintaining consistency in process monitoring systems (Marks, 
2003; Nienow, 2006). 
Process optimisations have been successful in recent years and industrial mAb producers are 
focusing at larger pilot scale vessels for commercial production in exchange for the typical 
20,000 litre scale vessels.  This trend in smaller vessel size is reinforced by the popularity of 
single use disposable bioreactor systems.  These are now reaching 2,000L scale and present 
significant manufacturing facility flexibility and reduction in setup costs (De Jesus & Wurm, 
2011). 
1.6.3 Process Development (Bench Scale) 
Process development and characterisation activities have typically been performed in bench 
scale vessels, with working volumes between 1 and 20 litres. This scale, therefore, represents 
a critical step in the development of bioprocess as experiments required cannot feasibly be 
performed at larger scales (F. Li et al., 2006).  
However, the operation at bench scale may not provide the capacity to conduct the experiments 
required by the QbD paradigm.  The experimental resource desired has been further increased 
through the popularity of the ‘design of experiments’ (DoE) concepts and Plackett Burman 
statistical design to screen process parameters (González-Leal et al., 2011). 
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1.6.4 Process Development (Micro Scale) 
In the fulfilment of the experimental demand, microscale systems (generally defined as up to 
50mL operating volume) have been adopted.  The translation of scale down technologies is far 
more challenging below bench scale, as the previous commonality between monitoring and 
sampling systems is no longer appropriate.  A variety of microscale systems exists with varying 
degrees of complexity, operational throughput, automation, and robustness (Betts & Baganz, 
2006; B. J. Kim, Diao, & Shuler, 2012). 
Microtitre plate based systems, originally designated for cellular based assays, have been used 
to rapidly accelerate bioprocess development screening in a low cost setting (Barrett, Wu, 
Zhang, Levy, & Lye, 2010).   
Whilst conceptually they are an extension of flask based models with their reliance on 
humidified, shaking incubators for process conditions control, microtiter plates provide 
additional function through their high throughput nature.  Agitation is provided to the cultures 
through orbital shaking platforms, to ensure culture homogenisation.  The cultures are then 
maintained within a climate controlled incubator (temperature, humidity, and gas 
composition), enabling critical temperature, pH, and DO maintenance to be achieved.  This 
application has been furthered by the successful adoption of a bespoke automation system to 
handle the majority of plate interaction steps (Markert & Joeris, 2017).  
This process parameter control is crude as there is no associated online monitoring or 
maintenance.  This limits the complexity of screening possible within the systems.  In addition, 
requirements to have cultures exposed to the incubator generates scenarios of evaporation and 
critically, culture contamination risk. 
Nevertheless, comparable evaluations of growth and productivity in microtitre plate systems 
to shake flask counterparts have been performed.  These justify the utility for microtitre plate 
systems to improve the early bioprocess development screening, where manually operated 
flask based systems are extensively used (Barrett et al., 2010; Bos et al., 2015; Girard, 
Meissner, Jordan, Tsao, & Wurm, 2002).    
The Duetz Microflask system was developed by Applikon Biotechnology as a commercially 
available microtitre plate based system.  It incorporated a membrane cover combination to the 
24 well plates.  This generated semi-closed systems that enable sufficient gas transfer with a 
lower risk of evaporation or contamination.  Evaluations have confirmed that, given its 
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throughput and low resource, this is a vital tool in the early screening of bioprocessing activities 
(Warr, Patel, Ho, & Newell, 2011; Warr, White, Chim, Patel, & Bosteels, 2011). 
Online monitoring and advanced control over a culture's respective CPPs is critical in 
generating a robust, scalable process.  Newly developed microscale systems utilise non-
invasive, pre sterilised and calibrated fluorometric spot sensors for the monitoring of pH and 
DO.  Commercialised by PreSens Precision Sensing GmbH (Germany), these sensors are 
integrated into the flask, plate or vessel wall.  The sensors are read non-invasively at pre-set 
intervals through the excitation of reference dyes in the sensor.  The functionality of the sensors 
uses the Dual Lifetime Referenced (DLR) method (Boniello, Mayr, Bolivar, & Nidetzky, 
2012). 
One system to adopt these pH and DO sensors is the Biolector® (M2P Labs, Germany) system 
and Micro24 system (Applikon), providing online pH and DO monitoring in existing, familiar 
microtitre plate environment (Warr, Betts, Ahmad, Newell, & Finka, 2013; Wewetzer et al., 
2015).  This monitoring ability is paired with an automated sparging and or microfluidic 
manifold to enable highly desirable automated control of pH and the provision of metabolic 
substrates to operate a fed-batch methodology (Funke et al., 2010; Warr, 2014). 
Whilst showing promise in their capacity and reproducibility for bioprocessing screening 
applications, the investment into microtitre plate based systems has been limited.  This can be 
partially accredited to their need to be operated as open systems, to facilitate sufficient gas 
transfer, and their risk of spilling when agitation is increased in line with gas transfer demands 
(Betts & Baganz, 2006). 
Ultimately, the comparison of functionality of these enhanced microtitre plate based systems 
is contrasted with advanced microscale STR systems.  The microscale STR systems aim to 
provide linearity in performance, from microscale systems to the STR bench, pilot, and 
commercial manufacturing scale systems. 
One such system, invented by The Automation Partnership (Royston, UK), now part of the 
Sartorius Group, is the Advanced Microscale BioReactor (ambr®15) system.  The system 
utilises single use disposable sparged miniature STRs, prefabricated with fluorometric spot 
sensors for pH and DO, and pre-irradiated for sterility. These miniature STRs are paired with 
the bespoke control system that offers the vessels parallel automated control of pH, DO, 
temperature, and feeding regimes through a liquid handling robotic arm.  Each vessel is 
operated as a closed system, with only the pipetting interactions exposing the vessel through a 
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sampling port.  To ensure sterility, the entire fabricated bioreactor system must be placed inside 
a laminar flow cabinet. 
The ambr®15 system comprises of either 24 or 48 vessels (depending on the variant) with 
vessels arranged into culture stations (CSs) of 12 vessel blocks.  In each CS, the temperature 
and agitation are controlled universally, facilitated by the sharing of the head plate and agitation 
plate for each CS.  Other process conditions can be set specifically for each vessel 
independently.  The automated sampling and liquid addition combined with the automated 
control systems presents a very powerful tool for bioprocess development activities such as 
DoE, cell line or medium screening (Sandner, Pybus, McCreath, & Glassey, 2018). 
The ambr®15 system has been validated through extensive characterisation, which renders the 
system comparable to large scale STR vessels (Nienow et al., 2013).  This investigation has 
been further extended to the evaluation of bench scale and ambr®15 vessels in commercial 
bioprocesses (Hsu, Aulakh, Traul, & Yuk, 2012; Lewis, 2010; Moses, Manahan, Ambrogelly, 
& Ling, 2012; Rameez et al., 2014).  Due to the success of these evaluations, ambr®15 has 
been widely adopted in industrial settings.  The systems fine control of CPPs, and the inherent 
high experimental capacity, has enabled it to be utilised to address problems that required 
comprehensive and exhaustive experimental designs to determine suitable operating ranges 
(Goldrick et al., 2017; Janakiraman, Kwiatkowski, Kshirsagar, Ryll, & Huang, 2015).   
1.6.5 Continuous Process Development Scales 
The scales of operation detailed above must be replicated for continuous cultures to facilitate 
a commercial manufacturing process.  For perfusion cultures, this is readily achieved through 
the association of ATF systems with existing STR vessels from commercial manufacture to 
process development.   
However, the ATF system is limited to operate at bench scale for process development.  The 
lack of a robust micro scale, high throughput technology for perfusion process development is 
an obstruction for the wider evaluation of perfusion culture (e.g. for new cell lines or process 
optimisations).  
Additionally, without a micro scale technology, the vast medium requirements of all 
continuous culture result in limited scope development activities.  Furthermore, the lack of high 
throughput systems prevents the parallel observation of steady states during optimisation and 
screening evaluations.   
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Options for conducting microscale evaluations for perfusion bioprocesses are limited and 
primitive when compared to the bespoke technology designed for fed batch.  Adaptation of 
existing fed-batch microscale cell culture systems to continuous cell culturing applications is 
an option for achieving a microscale continuous process development tool.  
Due to the highly engineered nature of microscale systems, it is difficult to repurpose them for 
perfusion by retrofitting a cell retention device. Microtitre plate-based systems such as 
SimCell™ platform (Seahorse) (Legmann et al., 2009) and BioLector® (Blesken, Olfers, 
Grimm, & Frische, 2016) offer high experimental capacity, however, these systems would 
require significant operator interaction to mimic perfusion through an adapted cell retention 
methodology.   
Additional industrial investigations (Du et al., 2015; C. J. Huang, Lin, & Yang, 2015) have 
looked at small scale perfusion models for medium development.  These evaluations cannot 
dynamically measure and control process parameters (such as pH) in real time, such that 
extensive bioprocess development activities can be conducted. 
More recently, microscale systems have been developed that were specifically designed to 
operate in perfusion mode (Mozdzierz et al., 2015) but they have not yet been evaluated with 
mammalian expression systems and, as novel applications, inherently will require significant 
economic and technical investment to fully characterise the system as a scale down model. 
The ambr®15 system has a high prevalence in FB bioprocess development due to its advanced 
ability at process control and automation.  If a method for cell retention was refined for this 
system, its high throughput nature and small (10-15mL) working volumes presents an 
interesting proposition for investigating the ambr®15 system as a microscale option for 
perfusion development. 
One cell retention strategy that has been proposed for the ambr®15 system is gravity cell 
settling within the culture vessel, this would allow perfusion operation without the requirement 
to retrofit a cell retention device. Early studies conducted using traditional gravity settling 
devices (Searles et al., 1994) can successfully be adopted in the design of a microscale cell 
settling method. An early application using this strategy (Goletz, Stahn, & KREYE, 2016) and 
several industrial investigations (Conference abstracts presented with supplementary files 
(BioMarin Pharmaceutical, 2017; MilliporeSigma, 2017)) highlighted interest in the method 
adoption, although no specific reports exist on a thorough comparative evaluation of this 
adapted system. 
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1.7 Research Aims and Objectives 
This thesis aims to present the development and characterisation of a novel methodology for 
microscale perfusion cell culture.  Through the characterisation of the method, its functionality 
as a bioprocess development tool will be highlighted.   
This development and characterisation will be achieved by operating the automated micro-
bioreactor (ambr®) system in perfusion cultivation by utilising sedimentation to retain cells 
within the culture.  Interrogating the perfusion operating parameters at microscale, and 
conducting equivalent bench and microscale evaluations will highlight nuances of continuous 
perfusion culture operation within the system. 
Additionally, this thesis aims to investigate the suitability of control and operation strategies 
for continuous cultures.  As a primary motivation, novel control strategies that are sympathetic 
to the characteristics of continuous cultures will be investigated.   
This aim will be achieved by analysing the performance of perfusion culture and identifying 
characteristics that do not align with typical control strategies developed for fed-batch 
manufacturing.  Characteristic identification includes focusing on the exponential growth 
phase of cultures, common of both fed batch and continuous perfusion systems, respectively.  
The prolonged period that the perfusion culture exists in exponential growth increases the level 
of consideration needed in control strategies for continuous operation and increases the focus 
of culture characteristics present during this phase.  Therefore, leading to insight into novel 
control strategies, appropriate for continuous bioprocessing. 
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Chapter 2 Materials and Methods 
For comprehension and concise formation of results chapters, the following information is 
presented.  Alterations to materials and methods are explicitly outlined at the instance where 
the change is made. 
2.1 Experimental numbering system 
The given chapter numbering enables a coherent decimal-based experimental numbering 
system.  For example, the first experiment in Chapter 3 is numbered Experiment 3.1, and the 
second Experiment 3.2, and so forth.  A further division within an experiment is donated by an 
alphabetical suffix and stated explicitly at the first occurrence.  The experiments conducted 
within this thesis and their respective details are summarised in Table 1. 
Table 1 Summary of experiments contained within this thesis. 
 
Experiment  Scale Outline 
3.1 
a micro Evaluation of micro scale perfusion methodology (30min cell settling, 
1.0VVD dilution rate). 
b bench Biological replicate of 3.1a, operated at bench scale, with ATF hollow 
fibre cell retention system (1.0VVD dilution rate). 
3.2 
a micro Technical replicate of 3.1a, with 33.5min cell settling (1.0VVD 
dilution rate). 
b micro Technical replicate of 3.1a, with 37min cell settling (1.0VVD dilution 
rate). 
4.1 
a micro Fed batch cultures operated with cells derived from micro scale 
perfusion cultures (1.0VVD dilution rate). 
b bench Fed batch cultures operated with cells derived from bench scale 
perfusion cultures (1.0VVD dilution rate). 
4.2 - bench Fed batch cultures operated with cells derived from bench scale perfusion cultures at decreasing dilution rates (1.0, 0.75 and 0.5 VVD)
5.1 
a micro Fed batch evaluation of the impact of cell aging in continuous systems, 
compared to ongoing subculture. 
b micro Fed batch evaluation of cell line sensitivity to pH at and post 
inoculation. 
5.2 - micro Fed batch evaluation of multi-parameter cell line sensitivity post inoculation. 
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Plotting of data and generation of figures from these experiments were performed using the 
commercial scientific 2D graphing and statistics software, Prism (GraphPad Software Inc, 
USA).  Error bars are provided as ± SD, where the error bars are physically smaller than the 
donated symbol, no error bar is presented. 
2.2 Cell line, Medium and Bioreactor systems 
A proprietary, Chinese hamster ovary (CHO) cell line expressing a low concentration of novel 
bispecific monoclonal antibody (Cell line 1) was employed throughout all chapters. 
Two animal component free proprietary medium compositions were used; a proprietary 
medium developed specifically for passaging cultures and fed-batch operation (basal), and 
another proprietary medium developed for supporting high cell concentrations associated with 
perfusion systems (enriched).  The glucose concentrations in the basal and enriched medium 
was 5 and 15 g/L, respectively. 
Cell line and medium were provided with permission, and thanks, by MedImmune, Cambridge. 
The cell line was developed within the environment of the basal medium.  Optimal setpoints 
for pH and temperature were provided as pH 7.2±0.1 and 36.5°C, respectively. 
Where a fed-batch culturing method was applied either within the production phase operation 
in perfusion evaluation of Chapter 4, or within traditional fed-batch in Chapters 5 and 6, the 
basal medium was complemented with propriety concentrated nutrient feeds.  These feeds were 
added to cultures as bolus additions, as detailed in the respective chapter’s experimental design.  
Glucose concentrations in perfusion experiments (Chapters 3 and 4) was maintained through 
the perfusion of enriched medium.  For fed-batch processes (Chapters 4 and 5) glucose was fed 
back on demand as detailed in associated experimental design sections, utilising a 500g/L stock 
solution. 
Each experiment was initiated with cells revived from vials of a common frozen cell stocks.  A 
common frozen cell stock was utilised (referred to as Development Cell Bank 1 (DCB1)) for 
Cell Line 1.  Detailed in Chapter 5 is the expansion of DCB1 to generate the cell banks DCB2, 
DCB3, and DCB4. 
Before inoculation the revived cells were sub-cultured twice per week, in basal medium, in 
vented shake flasks (Corning, USA) in a humidified orbital shaker incubator maintained at 
36.5°C and 5% CO2. 
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All reference to microscale experiments within this thesis refers to work conducted in the 
ambr®15 bioreactor system (Sartorious Stedim, UK).  The 24 and 48 variants were used 
interchangeably depending on the capacity required and availability.   
All reference to bench scale experiments within this thesis refers to work conducted in glass 
7L bioreactors (Applikon, UK), with working volumes ranging between 3 and 6L.  For 
operation in perfusion at bench scale integrated bioreactor controllers (DasGip, DE) were 
combined with additional pump units (Electrolab Biotech, UK).  This combination maintained 
culture volume by pumping fresh medium back to the vessel on demand, as it was removed at 
a constant rate by the bioreactor controller. 
Online oxygen and pH measurements were made with fluorescent spot sensors (Presens, DE) 
and traditional probes (Mettler Toledo, UK), for micro and bench scale experiments, 
respectively. 
The dissolved oxygen saturation was controlled to 50% through the sparging of O2 on demand, 
along with an increase in agitation, as required. 
The 2-way control of pH to set point ± dead band was performed through automated integrated 
PI or PID loops for micro or bench scale systems, respectively.  Feedback was actioned by the 
addition of liquid base addition or sparging CO2 gas on demand.  Perfusion experiments or 
periods of perfusion through hybrid processes utilised 1-way control of pH through sparging 
of CO2, relying on the buffering capacity of the perfused medium to control acidic conditions. 
Temperature was controlled to 36.5°C through the combination of an integrated temperature 
probe and a heated head plate or heated jacket for micro and bench scale, respectively (Sartorius 
and DasGip, respectively) 
Material was harvested from experiments for at-line and offline analysis through aseptic 
removal from bioreactor vessel, centrifugation, and where appropriate, analysed immediately, 
or stored at -80°c for later processing.  
2.3 At-line and Offline Sample Analysis 
The execution of sample analysis throughout this thesis is designated as ‘at-line’ in instances 
where the data produced is used directly in the observations and operations of the process.  
Sample analysis conducted ‘offline’ includes those where data is utilised for assessing 
performance but due to the time delay associated with the acquisition of results, cannot be used 
directly in the observations and operations of the process. 
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Instruments conducting ‘at-line’ analysis include;  
ViCell XR cell counter (Beckman Coulter, USA) for the cellular analysis of samples from all 
experiments, via the trypan blue exclusion method.  
From microscale experiments where there are low sample volumes present, the YSI 2900 
(Xylem Analytics, UK) was used for the biochemical analysis of Glucose and Lactate 
concentration.  Similarly, in microscale experiments, the ABL90 FLEX Analyser (Radiometer, 
UK) was used for pH sensor calibration and offset adjustment. 
From bench scale experiments where larger sample volumes exist, the Nova FLEX (Nova 
Biomedical, USA) was used for comparative glucose, lactate, and pH measurements.  As a 
benefit of the modular Nova FLEX system, samples analysed here also generated osmolality 
measurements by freezing point method. 
Instruments conducting ‘off-line’ analysis include; 
For experiments conducted in Chapter 3, to provide additional comparative data, time course 
samples were submitted for full amino acid analysis.  For amino acid profile analysis, cell free 
perfusate was run on AccQTag Ultra C18 column (ACQUITY UPLC system, Waters).  Amino 
acid peaks were integrated against commercial standards (Waters) and all values were scaled 
to respect commercial confidentiality of cell line and medium.  This sample analysis was 
generously offered and performed by the BioProcess Analytics team, at Medimmune, 
Cambridge. 
The mAb concentration was determined using Protein A ’dip-and-read’ Biosensors on the 
Octet System (Pall ForteBio).  A serial dilution of the purified mAb product was performed 
and run in parallel with inter assay controls to determine the titre and control run variation. 
The mAb aggregation was determined by SEC-UPLC for both pre and post purification. 
Unpurified, clarified cell culture supernatant and Protein A purified material was filtered 
through a 0.22µm AcroPrep™ plate filter (Pall) prior to loading the supernatant to the 
automated injection by UPLC (Waters) on SEC column (Acquity UPLC® Protein BEH SEC 
200Å, Waters), peak detections were made at wavelengths 220nm and 280nm. 
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2.4 Rate Calculations 
Integral viable cell concentration, specific glucose consumption, and specific net lactate change 
is calculated by equations reported by others (Adams, Korke, & Hu, 2007; Villiger-Oberbek, 
Yang, Zhou, & Yang, 2015).   
The integral viable cell concentration (IVCC) for each culture is calculated by: 
𝐼𝑉𝐶𝐶௡ ൌ  𝐼𝑉𝐶𝐶௡ିଵ ൅ ቆ൬𝑉𝐶𝐶௡ ൅ 𝑉𝐶𝐶௡ିଵ2 ൰ ൈ ሺ𝑡௡ െ  𝑡௡ିଵሻቇ 
Whereby the integral viable cell concentration (IVCC) and viable cell concentration (VCC) for 
time (t), tn and tn-1, are represented by IVCCn, IVCCn-1, VCCn and VCCn-1, respectively.   
For Fed Batch 
Utilising IVCCn, the specific glucose consumption (qc,n) is calculated by: 
𝑞௖,௡ ൌ
ቀ൫𝑐𝑝௫,௡ିଵ െ 𝑐𝑝௫,௡൯ ൅ 𝑐𝑎௫,௡ିଵቁ
∆𝐼𝑉𝐶𝐶௡  ൈ 𝑉௡  
Where cpx, cax and V are the glucose present (g), glucose added (g) and volume (L), 
respectively. 
The specific lactate net change (ql,n) is calculated by: 
𝑞௟,௡ ൌ ሺ𝑙𝑝௫,௡ െ 𝑙𝑝௫,௡ିଵሻ∆𝐼𝑉𝐶𝐶௡  ൈ 𝑉௡  
Where lpx and V are the lactate present (g) and volume (L), respectively. 
The specific production rate qp,n is calculated by: 
𝑞௣,௡ ൌ 𝑝௫,௡∆𝐼𝑉𝐶𝐶௡  ൈ  𝑉௡  
Whereby px and V are the product present (g) and volume (L), respectively. 
For Perfusion 
Utilising IVCCn, and the specific glucose consumption (qc,n) is calculated by: 
𝑞௖,௡ ൌ
ቀ𝑐௫,௡ିଵ ൈ ሺ1 െ 𝐷௡ሻ ൅ ሺ𝑚௫ ൈ 𝐷௡ሻቁ െ 𝑐௫,௡
∆𝐼𝑉𝐶𝐶௡  ൈ 𝑉௡  
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Where D, mx and cx are the daily dilution rate (VVD), measured glucose in fresh medium added 
per day (g) and measured glucose in culture (g), respectively. 
Similarly, where measured lactate in culture (g) is px, the specific lactate net change (ql,n) is 
calculated by: 
𝑞௟,௡ ൌ 𝑝௫,௡ െ ሺ𝑝௫,௡ିଵ ൈ ሺ1 െ 𝐷௡ሻሻ∆𝐼𝑉𝐶𝐶௡  ൈ  𝑉௡  
 
No product retention occurred and thus cell specific productivity (qp,n) was calculated by:  
𝑞௣,௡ ൌ 𝑝௫,௡∆𝐼𝑉𝐶𝐶௡ ൈ  𝑉௡ ൈ 𝐷௡ 
 
 
  
Page 57 of 204 
 
Chapter 3 The Design, Execution, and Evaluation of a High-
Throughput Continuous Microscale Environment  
3.1 Introduction 
In the production of therapeutic proteins, mammalian cell lines are selected for their ability to 
accurately express the desired product.  Whilst popular for their accurate expression, 
mammalian cell lines have comparatively slow growth rates (22-24 hours doubling) to other 
organisms, for example, bacterial cells (approximately 20-120 minutes doubling). Therefore, 
investigating the performance of a mammalian cell line requires supporting prolonged culture 
durations.   
This time investment is compounded when investigating continuous cultures.  Traditional 
steady state evaluation requires the culture to be maintained at steady state for three to seven 
residence times to confirm the steady state is not a transient stage of the culture (this results in 
up to two weeks for each condition) (Pirt, 1975).  Extended continuous cultures require large 
medium volumes to support the dilution rate operated.  These large medium volumes are 
physically restrictive and not economically viable when compared to the cost of fed-batch 
culture investigation.   
High throughput experimental environments allow for a comprehensive and exhaustive 
investigation of biological systems.  Specifically, this high throughput environment is of 
interest to mammalian systems as it enables the experiments to be conducted in parallel.  If this 
is combined with a microscale system, it presents a low medium resource environment that has 
application in the investigation of continuous culturing. 
A popular system for high throughput microscale investigation of fed-batch culturing is the 
ambr®15 system.  Several adjustments must be made to exploit the capabilities of the ambr®15 
system for the operation of continuous culturing.  To facilitate perfusion operation within the 
ambr®15 system (as a commercially relevant mode of continuous culturing), an efficient cell 
retention device must be employed. 
The ambr®15 system has been designed with highly sophisticated control systems and 
automation functionality.  The system operation requires vessels to be permanently fixed within 
the robotics during operation, with frequent interaction occurring with the sample port located 
on top of each vessel.  Therefore, the operation of an externally located, retrofitted cell retention 
device would be extremely challenging and seemingly unfeasible.   
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Gravity cell settling, as previously presented for its potential for refunctioning the ambr®15 
system (1.6.5 Continuous Process Development ), allows the vessels to remain in their 
designated positions whilst employing a sedimentation method of cell retention.  Gravity cell 
settling is achieved in situ by stopping gassing and agitation of vessels, allowing cells to settle 
in preparation for liquid exchange.  This operation presents a potential impact on cell viability 
or productivity, and operator priority must be the swift return to process control following the 
cell settling procedure. 
In addition, and in relation to settling time, the volume to be exchanged post cell settling was 
a considered design parameter for this method development.  As semi-continuous medium 
exchange is performed, to best mimic the operation at larger scales an approach must be sought 
that minimises the volume exchanged per cell settling, whilst not sacrificing the ability to 
conduct higher order dilution rates through inefficient use of the system capacity. 
This chapter presents the development and evaluation of a sedimentation based method of cell 
retention utilised within the ambr®15 system.   
To understand the magnitude and holistic impact of these frequent interruptions to normal 
operating conditions, evaluations are conducted extending the cell settling time incrementally 
beyond what is required from a cell retention efficiency perspective. This experimentation 
highlights critical operating ranges and identifies the extent of cell line sensitivity when these 
periods of settling are exceeded.   
Understanding the robustness of the methodology will highlight its suitability to identify 
cellular and or biochemical characteristics specific to continuous bioprocess systems.  This 
robustness will be compared with a highly developed, commercially adopted technology in the 
form of the ATF system.  
The method of gravity cell settling within the vessel generates a universal, culture wide 
exposure to an uncontrolled environment at each cell settling event.  The ATF system aims to 
eradicate any heterogeneous locations or events within the process through continuous 
recirculation of culture from the vessel to the retention device.  Therefore, sampling from each 
system will represent the heterogeneous impact of the respective mode of cell retention. 
3.2 Method Development 
In the ambr®15 system, automated interaction with the installed vessels is conducted by a 
robotic liquid handling arm equipped with either a 1mL or 5mL pipette tip (working volumes 
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of 0.9 and 4mL, respectively).  In addition to the inherent differences in volume capacity 
between the two tips, the diameter of the 5mL tip prevents it from being submerged into the 
vessel through the access port (depicted below in Figure 9).  In developing a perfusion 
methodology, this difference presented a reliance of the ambr®15 system on the 1mL pipette 
size in achieving cell free medium removal, following a period of gravity sedimentation.   
 
Figure 9 Diagrammatic depiction of the ambr®15 vessel geometry and highlighted operational 
components 
Highlighted components include the access port for 1mL tip insertion, the impeller, sparger, location of optical 
sensors for pH and DO monitoring, and the simplified three-dimensional geometry measurements (mm). 
 
Optimal operation of the cell retention methodology required accurate incremental removal of 
the uppermost fraction of culture as it became ‘cell free’.  This step was repeated to achieve 
the required dilution rate.  Therefore, precise control of the robotic liquid handling arm was of 
interest.  Achievement of minimal immersion prevented impacting the cell settling process and 
enabled perfusate removal at the earliest possible time point post initiation of cell settling. 
The system functionality inherently facilitates fine control over the height at which the pipette 
travels into the vessel (to the precision of 0.01mm).  Unfortunately, this fine control is not 
contextualised by the manufacture, as no correlation is provided for the relationship between 
the pipette height (mm) and vessel fill volume (mL).  To enable this functionality, the 
relationship was explored.  
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Figure 10 The relationship between, volume in vessel (mL) versus height of tip (mm) 
The linear relationship between the two variables is presented by the slope of the fitted line, 0.3899 
(R2=0.9987). 
 
The relationships presented above (Figure 10) were acquired experimentally through the 
controlled deployment of the 1mL pipette tip into the vessels to predetermined heights above 
the system platform, on which the vessels reside.  Repeated aspiration was conducted at each 
height until the pipette returned dry and the remaining volume in the vessel was weighed.  An 
understanding of the linear relationship between the two variables allowed the deployment of 
the pipette tip to heights that represented top fractions at any culture operational volume. 
The next step in method development was to calculate feasible volumes to attempt to exchange 
in a single cell settling step whilst achieving relevant dilution rates for cultures.  This was 
achieved through considering the geometry of the microscale vessel (Nienow et al., 2013), 
applying the relationship between height and culture volume (Figure 10) and considering the 
theoretical settling velocity of 1.4 cm/h for CHO cells  (Searles et al., 1994).  This theoretical 
velocity combined with spatial measurements suggested the top 2.7 mL of the culture would 
be ‘cell free’ after 30 minutes.  Volumes of this magnitude would enable three sequential 
medium removal interactions (operating at 90% capacity of the 1mL tip) to be performed at a 
single cell settling step.   
Experimental testing of the theoretical cell settling efficiency in situ enables the confirmation 
of assumptions made with regards to the cell settling velocity and any delay of transitioning 
from turbulent to gravity driven laminar flow in producing a reliable and reproducible cell 
settling methodology for further characterisation. 
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This testing was conducted through filling twenty-six ambr®15 vessels from a common culture 
of known cell concentration and installing them into the microscale system, with the control 
systems activated (Agitation, temperature, and gas flow).  Vessels were then divided into four 
sets, and each set was designating incrementally increasing settling times for evaluation.  The 
settling times evaluated were 15, 20, 25, and 30 minutes, respectively.  
Following the respective settling times, sampling was performed from the top 2.7mL fraction, 
and analysed for its cellular concentration, in comparison to the starting cell concentration to 
provide a cell retention efficiency for the given fraction removed.   
 
Figure 11 Plotted histogram of cell removal from culture (%) at culture settling times (mins) 
Percentage cell loss from microscale reactor vessel following cell retention by incrementally increasing the 
gravity settling time from 15 minutes to 30 minutes, with a starting concentration of 6.08x106cells/mL across 
replicates. Data shows mean ± SD, n=6 
 
The percentage of cells removed was observed to decrease as the culture settling time increases 
(Figure 11). The values decrease with (4.3±1.3), (2.2±0.4), (1.0±0.5) and (0.6±0.3) percent, 
representing 15, 20, 25, and 30 minutes, respectively.  This performance displayed at 30 
minutes cell settling, indicated a >99% cell retention.  To preserve the concept of perfusion 
mimic when applying this cell settling methodology, settling times <30 minutes were not 
evaluated further to avoid a resulting ‘chemostat like’ environment, due to their lower cell 
retention percentage. 
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Many factors contribute to the capacity at which the ambr®15 system can operate perfusion. 
This capacity is ultimately defined by the time required to perform the culture exchange steps 
combined with the number of steps to be performed per day. 
To provide an example, at 1.0 VVD and one third of the culture volume exchanged at each 
step, a CS operating at 50% capacity (six vessels out of a possible 12) required additional 30 
minutes to handle the robotic liquid exchange. Operating four CSs (in the 48 vessel ambr®15 
variant) at 50% capacity required settling or sampling to be scheduled for 12 hours per day and 
at-line measurements such as automated cell counting carried out required an additional four 
hours.  This time requirement remained safely below the maximum capacity to allow downtime 
for system maintenance that typically must be performed for around 30 minutes daily when the 
robotic liquid handling arm is idle. This setup allowed the operation of 24 vessels 
simultaneously in the 48-vessel variant of the ambr® microscale system, which yields a 
sufficiently large number to make Design of Experiments (DoE) studies of continuous systems 
possible.   
The existing setup and capacity could allow operation of the system running at a higher volume 
exchange rate than 1.0 VVD. Increasing the fraction of the vessel exchanged per step would 
limit the physical space that the cells were expected to settle into, thus the number of iterations 
of liquid exchange steps per day would ideally be increased. The current setup allowed 
experiments to be conducted at as high a volume exchange rate as 1.5 VVD, corresponding to 
a specific growth rate (µ) of 0.062h-1.  Since this exceeded the maximum specific growth rate 
(µmax = 0.05 h-1) reported for CHO cells (López-Meza et al., 2016), the present setup was 
suitable for the range of all reported specific growth rates that CHO cells could operate under. 
3.3 Experimental Design 
This chapter consists of two independent revivals of frozen cell stocks and thus two 
independent experiments, Experiments 3.1 and 3.2, respectively.  In Experiment 3.1, two 7L 
stirred-tank reactors (STR) ‘bench scale’ vessels and an ambr®15 ‘microscale’ system were 
inoculated from the same source culture.  The cells were cultured in basal medium, with a 
starting volume for bench and micro scale of 3.5L and 15mL, respectively.  
Upon initiation of perfusion the working volumes are adjusted to 3L and 10.7mL for bench 
scale and microscale vessels, respectively. All vessels were operated at 1.0 vessel volume 
exchanges per day (VVD).   
Page 63 of 204 
 
In Experiment 3.2, an additional ambr®15 micro scale system was inoculated with cells in 
basal medium for parallel operation and from the same source culture. These were also 
operated, as detailed above, at 1.0 VVD dilution rate. 
The micro scale reactors were operated at 1.0 VVD with the developed gravity settling 
methodology detailed above (Section 3.2 Method Development).  These cultures were allowed 
three partial medium exchange steps per day, conducted at eight hour intervals to equal the 
target VVD.   
All cultivations were perfused with enriched medium starting from the initiation of perfusion 
mode, approximately 96 hours post inoculation. The bench scale vessels were operated in 
perfusion mode using an alternating tangential flow (ATF2) device (Repligen, USA) in 
combination with 0.22µm hollow fibre filter for cell retention, and continuous perfusion rate 
of 1.0 VVD. 
In Experiment 3.1 a direct comparison is made between the culture performance within the 
developed microscale cell settling perfusion methodology and a bench scale ATF system.    
In Experiment 3.2 the microscale perfusion methodology was challenged beyond 30 minutes 
settling time.  The initial settling time of the CSs was increased to 33.5 and 37 minutes.  This 
experiment was conducted to comprehensively explore the effect of extended exposure of the 
cells to micro-aerated and nutrient-limited conditions on their viability.  These two conditions 
in Experiment 3.2 are highlighted as 3.2a and 3.2b for 33.5 and 37 minutes, respectively.  
3.3.1 Data Analysis 
Where replicates are reported, means and standard deviations (SDs) are provided in the format 
mean ± SD. The number of replicates from a single culture station in Experiment 3.1, 
Experiment 3.2a, and Experiment 3.2b microscale setup were n = 6, n = 4, and n=6, 
respectively.  Paired or unpaired two tailed t-tests were used, where appropriate, to determine 
significance across conditions, and each specific application is referred to in the text.  
Comparison from microscale to bench scale (n = 2) was made using one way ANOVA.  Vessels 
within a single culture station were treated as replicates for reporting statistical significance 
except when the vessel position effect was investigated, where no replicates were present. 
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3.4 Results 
3.4.1 Resuspension of the Culture and Recovery to the Set Points 
The operation of gravity cell settling required turning off the gassing and agitation control for 
the cultures.  The measurements of pH and DO were observed to reproducibly decline during 
the settling period and return to the operating range following resuspension throughout the 
duration of the cultures (Figure 12).   
 
Figure 12 Sample traces of pH and dissolved oxygen in response to cell settling over a 1 day period 
Sample traces from one microscale vessel in Experiment 3.1; online DO (Blue) and pH (Red) measurements 
recorded during the process. Both parameters are plotted on their respective axes against the process duration 
(days). Variation in the acidity and oxygenation during one day of cultivation, which entails three exchange 
steps (1.0VVD volume exchange rate), displayed the recovery between liquid exchange steps back to control 
set points 
 
In the achievement of 1.0 VVD dilution rate, the tactic was employed to conduct three 
independent cell settling steps and exchange one third of the vessel volume in each instance 
with fresh enriched medium.  As presented in Figure 12, a period of stabilisation was required 
for pH and DO before they reached levels experienced prior to cell settling.  This period 
between cell settling steps allowed cultures to normalise before the initiation of the next cell 
settling.  
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Figure 13 Sample traces of pH and DO from a single cell settling step 
Sample traces from one microscale vessel in Experiment 3.1, displaying a single cell settling step; online DO 
(Blue), and pH (Red) measurements recorded during the process. Both parameters are plotted on their 
respective axes against the process duration (minutes). 
 
A closer interrogation of an individual cell settling step reveals the different responses in pH 
and DO over time, in the process of cell settling (Figure 13).  The pH observably dropped by 
approximately 0.8 units over 30 minutes and the decline in pH started immediately after the 
agitation was stopped (at approximately 60 minutes), slowing towards the end of the settling 
time. The DO immediately and very sharply declined from the set point (50%) down to below 
5% saturation within 10 minutes and readings plateaued between 2 and 5% saturation. pH and 
DO did not recover to the set points until resuspension (at approximately 110 minutes). 
3.4.2 Growth Performance 
Evaluation of the perfusion culture’s response to the cell retention methodology is presented in 
Experiment 3.1, as a comparison to bench scale ATF cultures, and in Experiment 3.2 as the 
extension of cell settling time at micro scale.  Deviations in culture performance were observed 
in the respective growth characteristics, and in the following figures replicates from all 
experiments are overlaid to highlight the differences experienced in each condition.  
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Figure 14 Viable cell density of perfusion cultures over process duration in response to cell retention 
method. 
Microscale reactors: (▲) Experiment 3.1, n=6 (30 minutes settling); (▼) Experiment 3.2a, n=4 (33.5 minutes 
settling); (■) Experiment 3.2b, n=6 (37 minutes settling); Bench scale reactors: (♦) Experiment 3.1, n=2. Data 
shows mean ± SD. Blue intersecting line indicates the start of perfusion. 
 
All cultures progressed through the initial batch growth and entered exponential growth 
following the initiation of perfusion on day four (indicated by the intersecting blue line, Figure 
14).  In the performance of culture from Experiment 3.1, microscale vessels (operating with a 
30 minute cell settling time) reached the maximum viable cell concentration of (7.20 ± 1.14) 
x107 cells/mL 20 days post inoculation.  Equivalent bench scale cultures (operated with an 
ATF, hollow fibre cell retention device) showed an improvement in the duration taken to reach 
maximum viable cell concentration (13 days post inoculation), and the maximum viable cell 
concentration was (8.32 ± 0.55) x107 cells/mL. The difference in the maximum viable cell 
concentrations of the cultures was not significant (p-value = 0.24).   
Experiment 3.2 looked to investigate the impact of increasing the cell settling on the cultures 
performance.  Increasing the settling time from 30 to 33.5 minutes did not yield a significant 
change (p-value = 0.91) in the maximum viable cell concentration, although the average 
maximum value attained was slightly lower, (6.88 ± 2.13) x107 cells/mL.  A further increase 
from 30 and 33.5 minutes to 37 minutes did not yield a significant change (p-value = 0.38 and 
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0.45, respectively) in maximum viable cell concentration either; the average was lower than 
that for 30 and 33.5 minutes (6.53 ± 1.40) x107 cells/mL.  
There was variation in the time taken to reach the maximum viable cell concentration in 
Experiment 3.2a. The average duration of (19.5±1.73) days was earlier than the uniform 20 
days post inoculation observed for all replicates in Experiment 3.1.  However, this difference 
was not significant (p-value = 0.49). Vessels across Experiment 3.2b did not reach this maximal 
cell concentration until later in the culture duration (Day 25), and this difference was highly 
significant (p-value < 0.001). 
 
Figure 15 Viability percentage of perfusion cultures over process duration in response to the cell 
retention method. 
Microscale reactors: (▲) Experiment 3.1, n=6 (30 minutes settling); (▼) Experiment 3.2a, n=4 (33.5 minutes 
settling); (■) Experiment 3.2b, n=6 (37 minutes settling); Bench scale reactors: (♦) Experiment 3.1, n=2. Data 
shows mean ± SD. Blue intersecting line indicates the start of perfusion. 
 
The culture viability remained high for bench scale cultures throughout their exponential 
growth (Figure 15).  On day 12 post inoculation the maximal viable cell concentration was 
reached and the growth rates plateaued.  After the point of maximal viable cell concentration, 
the viability began to decline, and by day 17 post inoculation it had declined to below 70%.    
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The microscale evaluation in Experiment 3.1 (30mins settling) also presented high viability 
(>90%) throughout the exponential expansion.  This was observed at (90.2±2.0) on the day of 
maximal viable cell density.   
A non-significant decrease (p-value = 0.15) was observed in viability on the day of the 
maximum viable cell concentration as the settling time was increased to 33.5 minutes 
(86.9±4.5) %. The decrease in cell viability was not significant either (p-value = 0.18) when 
the settling time was further increased from 33.5 minutes (86.9±4.5) % to 37 minutes 
(81.7±6.1) %. However, the total decrease in viability observed with increasing the settling 
time from 30 minutes to 37 minutes was statistically significant (p-value < 0.01), indicating 
that increasing the culture settling time had an adverse effect on culture viability.   
After culture settling, the microscale vessels were serviced sequentially by the robotic arm to 
replace the perfusate with fresh medium, and this introduced further lag on each vessel situated 
on positions 2-6 on each CS.  The evaluation of individual vessel cell settling times in the 
operation CSs designated times (e.g. 30, 33.5, and 37 minutes) provides additional granularity 
on the impact of settling time on culture performance.  Interrogation of this positional impact 
on settling time, and in turn growth performance is presented in Figure 16.  
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Figure 16 Position of the microscale vessels within their respective culture stations, and the actual 
settling times for each vessel observed prior to automated robotic liquid exchange 
(A) – (B) Microscale vessel location on each culture station in Experiments 3.1 and 3.2. Differences in the 
viable cell concentration of neighbouring vessels determined by paired t-test at a significance threshold of 
(P<0.05), denoted by *, where significant. (C) Actual settling times (minutes: seconds) for each vessels in their 
respective positions 1-6 on the CSs to the initiation of automated liquid exchange, caused by the robotic arm 
servicing one vessel at a time. ◊ Vessels 1 and 5 in experiment 3.2a were terminated on Day 10 due to hardware 
failure. 
 
The vessel positions with similar settling times in Experiment 3.1 and Experiment 3.2a were 
considered as biological replicates, whereas those in Experiment 3.2a and Experiment 3.2b 
were evaluated as technical replicates (Figure 16).  In Experiment 3.1 (30 minutes), a 
significant difference (P<0.05) is seen in the viable cell concentration profiles of vessels 2 & 3 
and 5 & 6, respectively.  In addition, Experiment 3.2a (33.5 minutes) displays this significant 
difference between vessels 3 & 4, and in Experiment 3.2b between vessels 1 & 2, and 3 & 4, 
4& 5 and 5 & 6, respectively. Although significant positional effects were observed in the 
viable cell concentrations between the neighbouring vessels in each CS, the biological and 
cultural replicates with similar settling times did not display significant differences 
consistently. However, the subsequently serviced vessels in Experiment 3.2b exhibited 
significant variability in the viable cell concentrations as the settling times increased.  
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3.4.3 Cellular Content of the Perfusate 
The cell content of the perfusate was analysed to investigate the retention performance of the 
microscale experiments as they progressed. 
 
Figure 17 Cell retained per liquid exchange step (%) for microscale vessels. 
Retention percentage determined as the ratio of the total cell content of perfusate to the total cell count for its 
respective culture suspended, plotted against process duration. (▲) Experiment 3.1, n=6 (30 minutes settling); 
(▼) Experiment 3.2a, n=4 (33.5 minutes settling); (■) Experiment 3.2b, n=6 (37 minutes settling). Data shows 
mean ± SD. 
 
The average cell retention percentage was retained above 95% for the majority of the cultures 
(Figure 17).  This retention was maintained throughout the fold increases in cellular 
concentration occurring between inoculation and maximum viable cell concentration.  On the 
day of maximum viable cell concentration, the average cell retention was (96.2 ± 0.5) %, (97.5 
± 0.5) %, and (97.0 ± 1.8) % for Experiments 3.1, 3.2a, and 3.2b, respectively.  
As cultures progressed into the late exponential growth phase (18 - 21 days post inoculation), 
Experiment 3.2 cultures with extended settling times displayed a statistically significant 
increase in average cell retention (%) (Experiment 3.1 vs 3.2a, and Experiment 3.1 vs 3.2b (p-
value < 0.05)).  No significant difference was observed between the two CSs in Experiment 
3.2. 
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The ViCell XR (Beckman Coulter, US) cell counter provided for average cell diameter data in 
addition to automated cell number and viability counting.  This average cell diameter value 
provides insight into the size of the cells present in the perfusate in comparison to those in the 
culture. 
 
Figure 18 Comparison of Average cell diameter (µm) plotted for microscale cultures and respective 
perfusate. 
Average cell diameter is plotted against process duration (days) for the cell samples in the microscale cultures 
(●) and in the perfusate (○). Plot represents the mean for all microscale samples (n=16) with SD shown when 
the variation was greater than 3.5% of the mean. 
 
A highly significant difference (p-value < 0.001) in the average diameter of the cells across all 
culture samples and perfusate samples was observed (Figure 18), (13.27 ± 0.95) and (9.50 ± 
0.50) µm, respectively.  This difference indicates that the individual cells analysed in the 
perfusate samples that are inherent of a lower density are also smaller in diameter.  
In addition, the viability measurements of the perfusate samples at maximum viable cell 
concentration (93.1 ± 4.8) % was consistently higher than that of the homogenous microscale 
cultures (86.2 ± 5.5) % (n=16) (p-value < 0.001).  
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3.4.4 Controlled Process Parameters 
Evaluation of the monitoring associated with the culture control parameters enables further 
characterisation and comparison of the culture performance within micro and bench scale 
perfusion methodologies, respectively. 
 
Figure 19 Culture response in online measured dissolved oxygen (%) plotted against process duration. 
Online microscale vessel readings have been averaged over their respective 24-hour periods to provide a 
representative value for the period.  Microscale reactors: (▲) Experiment 1, n=6 (30 minutes settling); (▼) 
Experiment 2, n=4 (33.5 minutes settling); (■) Experiment 2, n=6 (37 minutes settling); (♦) Bench scale 
reactors: Experiment 1, n=2. Data shows mean ± SD. Perfusion initiation is indicated with an intersecting blue 
line. 
 
The online readings for dissolved oxygen (%) from micro and bench scale vessels are displayed 
in Figure 19.  In order to provide representative readings, the microscale vessels in an 
environment fluctuated by periods of no control (during cell settling, see Figure 13) an average 
is reported for each 24 hour period.  Following inoculation, the oxygen demand in the cultures 
gradually increased, as the cell count increased, and the high starting DO percentage was 
gradually depleted towards the set point (50%).  The point at which oxygen sparging was 
needed to supplement the oxygen transfer provided by agitation alone was met by day two and 
day three post inoculation for bench and microscale vessels, respectively.  For the remainder 
of culture duration, dissolved oxygen was maintained at the set point throughout both the micro 
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and bench scale operations. The systems were both able to supply sufficient oxygen to support 
the culture growth at the high viable cell concentrations observed (Figure 14).  
 
Figure 20 Culture response in online measured pH plotted against process duration. 
Online microscale vessel readings have been averaged over their respective 24-hour periods to provide a 
representative value for the period.  Microscale reactors: (▲) Experiment 1, n=6 (30 minutes settling); (▼) 
Experiment 2, n=4 (33.5 minutes settling); (■) Experiment 2, n=6 (37 minutes settling); (♦) Bench scale 
reactors: Experiment 1, n=2. Data shows mean ± SD. Perfusion initiation is indicated with an intersecting blue 
line. 
 
The observed pH for micro and bench scale cultures is presented in Figure 20.  The pH of both 
microscale and bench scale cultures accumulated acidity but were observed within ±0.1 pH 
units of set points for seven to ten days post inoculation.  
At day 10 post inoculation the decreasing pH trend of the bench scale cultures was reversed 
and pH control was returned to the CO2 sparging on demand, in the upper range of pH 7.2 to 
7.3.  The culture pH for microscale vessels continued to become more acidic and consistently 
remained within the pH range of 7.0 to 6.9.   
This difference in pH profiles indicated a cellular adjustment occurring in the bench scale 
cultures, which was not observed in microscale cultures. Closer inspection of biochemical 
measurements conducted throughout the culture and retrospectively can highlight causation for 
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this difference in pH and offer insight into the level of impact it may have on process screening 
applicability. 
3.4.5 Biochemical Analysis 
The analysis of the cultures consumption of available carbon sources provides insight into the 
culture performance, highlighting potential areas for improvement when optimisation is 
sought.  Central to the metabolism of mammalian cultures is the utility of glucose as the 
primary carbon source. 
 
Figure 21 Culture response in at-line measured glucose (g/L) plotted against process duration. 
At-line microscale and benchscale vessel readings for glucose (g/L). Microscale reactors: (▲) Experiment 1, 
n=6 (30 minutes settling); (▼) Experiment 2, n=4 (33.5 minutes settling); (■) Experiment 2, n=6 (37 minutes 
settling); (♦) Bench scale reactors: Experiment 1, n=2. Data shows mean ± SD. Perfusion initiation is indicated 
with an intersecting blue line. 
 
The measured glucose that was observed in the vessels throughout the micro and bench scale 
evaluations is presented in Figure 21.  The fluctuations observed are a function of cellular 
consumption of residual glucose and the influx and removal of glucose through the perfusion 
cultures.  The starting glucose concentration, of approximately 5g/L, was gradually consumed 
in all cultures before perfusion being initiated on day four. Once perfusion was initiated, the 
influx of enriched medium increased culture glucose concentrations.  
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Excess glucose was available for the cultures in all bench and microscale vessels on the day of 
maximum viable cell concentration; (0.50±0.04), (2.22 ± 0.37), (3.07 ± 1.02) and (3.98 ± 1.33) 
g/L, for Experiments 3.1a, 3.1b, 3.2a, and 3.2b respectively.  The presentation of glucose 
concentration across scales does not align with reference to culture progression.  However, the 
time differences in reaching maximal cell concentrations enables a normalisation of the data 
and therefore a comprehensive comparison to be made.  This normalisation is presented in 
Figure 22 as cell specific glucose consumption rate (g/cell/day). 
 
Figure 22 Culture cell specific glucose consumption rate (mg/cell/day) in response to scale over process 
duration (days). 
Plotted cell specific glucose consumption rate over process duration, (○) combined microscale from 
Experiment 3.1 and 3.2, n=16; (♦) Bench scale reactors: Experiment 3.1, n=2. Data shows mean ± SD. 
Perfusion initiation is indicated with an intersecting blue line. 
 
Whilst variation does exist, cultures follow similar trends over the first seven days post 
inoculation, dropping slightly as perfusion is initiated (day four) and then peaking shortly 
thereafter (day five).  The variation observed appears to plateau by day eight post inoculation 
as all cultures are established in exponential growth, with (4.88±4.61) and (3.68±2.12) x10-7 
mg/cell/day for micro and bench scale vessels, respectively.  This comparability between scales 
continued through the day of maximal growth and as cultures began to decline in viability, up 
to harvest. 
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Alongside glucose consumption, lactate production and consumption must be considered to 
gain a more comprehensive understanding of the biochemical status of the cultures, starting to 
explain some of the variation observed in pH. 
 
Figure 23 Culture response in at-line measured lactate (g/L) plotted against process duration. 
At-line microscale and benchscale vessel readings for lactate (g/L). Microscale reactors: (▲) Experiment 1, 
n=6 (30 minutes settling); (▼) Experiment 2, n=4 (33.5 minutes settling); (■) Experiment 2, n=6 (37 minutes 
settling); (♦) Bench scale reactors: Experiment 1, n=2. Data shows mean ± SD. Perfusion initiation is indicated 
with an intersecting blue line. 
 
The concentration of lactate (g/L) was measured from micro and bench scale cultures in 
Experiments 3.1 and 3.2, and is plotted in Figure 23.  Starting at less than 0.5g/L, the lactate 
concentration accumulated in the cultures during the initial batch phase of the microscale 
cultures.  This accumulation resulted in lactate concentrations on day four post inoculation of 
(0.67 ± 0.05), (2.59 ± 0.48), and (3.12 ± 0.20) g/L for experiments 3.1, 3.2a, and 3.2b, 
respectively.  The lactate concentrations of microscale vessels aligned during perfusion 
operation and maintained at approximately 1g/L throughout the remainder of the perfusion 
phase.   
The lactate concentrations for bench scale cultures peaked along with the microscale cultures 
on day four post inoculation and remained elevated >1g/L until the ninth day post inoculation 
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when it deviated from the microscale cultures and began to decline.  This decline correlated 
with glucose availability in the culture, presented in Figure 21. 
The glucose concentration of bench scale cultures declined from a peak at the sixth day post 
inoculation (8.22 ± 0.25) g/L and was fully utilised starting from the tenth day post inoculation 
(0.29 ± 0.01) g/L.  A metabolic shift was observed as the cultures also metabolised the available 
lactate, dropping from (1.70 ± 0.23) g/L on the ninth day post inoculation, to (0.04 ± 0.06) g/L 
by the 11th day post inoculation.  
A correlation was also observed between this glucose and lactate consumption event and the 
increased culture pH, presented in Figure 20, whereby pH is shown to recover back to the initial 
set point in the bench scale cultures. This metabolic switch did not occur in any of the 
microscale vessels and consequently, the pH remained depressed (Section 3.4.4 Controlled 
Process Parameters). 
To further detail this metabolic variation, a retrospective analysis was conducted on retained 
samples from Experiments 3.1 and 3.2.  This looked to quantify the individual amino acid 
levels within the medium and this highlights the metabolic pathways preferences of the cultures 
in the events presented above. 
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Figure 24 Glucose (g/L) presented with Amino Acid (mg/L) concentrations highlighting the metabolic 
shift in bench scale cultures plotted over process duration (days) 
Microscale and bench scale vessel readings for (A) Glucose (g/L), (B) Scaled glutamine (mg/L), (C) Scaled 
alanine (mg/L) and (D) Scaled glycine (mg/L). Concentrations were scaled randomly in the interest of 
protecting the IP of the proprietary medium and are reported as “Scaled concentrations (mg/L)”.  Microscale 
reactors: (▲) Experiment 1, n=6 (30 minutes settling); (▼) Experiment 2, n=4 (33.5 minutes settling); (■) 
Experiment 2, n=6 (37 minutes settling); (♦) Bench scale reactors: Experiment 1, n=2. Data shows mean ± SD. 
 
To succinctly present the biochemical response present in the bench scale vessels in 
comparison to the microscale vessels, Figure 24 contains culture concentrations of glucose 
(g/L), glutamine (mg/L), alanine (mg/L) and glycine (mg/L) in positions A, B, C, and D, 
respectively. Figure 24A presents the measured glucose concentrations (g/L) to provide a 
corresponding time course for responses in amino acid abundances within the cultures. 
Presented in Figure 24B and C, a difference is observed in the concentrations of glutamine and 
alanine in the bench scale vessel compared to other cultures.  Observed on day 12 post 
inoculation the bench scale cultures simultaneously begin consuming additional glutamine and 
alanine.  Concurrently, a significant increase is observed in the concentration of glycine for 
bench scale cultures when compared to microscale (Figure 24D).  Statistically, a significant 
difference (p-value < 0.05) was observed in the glycine, alanine, and glutamine between the 
bench scale and microscale cultures starting from the 12th day post inoculation.  
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In conclusion of the amino acid analysis and in addition to the trends presented in Figure 24, 
both bench scale and microscale systems concentrations of asparagine, cysteine, and serine 
were shown to concurrently deplete over time.  The concentration of the remaining amino acids 
remained constant and not statistically different (p-value > 0.05) (Appendix Figure I).   
3.4.6 Productivity and Product Quality 
Culture productivity was measured throughout the exponential expansion of perfusion cultures.  
Alongside the productivity assessment, samples were tested for product quality by SEC for 
aggregation of the expressed mAb.  
 
Figure 25 Titre (mg/L) of micro and bench scale cultures plotted across process duration (days) 
Microscale reactors: (▲) Experiment 1, n=6 (30 minutes settling); (▼) Experiment 2, n=4 (33.5 minutes 
settling); (■) Experiment 2, n=6 (37 minutes settling); (♦) Bench scale reactors: Experiment 1, n=2. Data shows 
mean ± SD 
 
The measured mAb concentration within cultures is low over the first few days of culture 
(Figure 25), due to the low cell density over this period (Figure 14).  The average mAb 
concentration increased in line with the viable cell concentration across all cultures to the 
respective maximum viable cell concentration.  On the day of the maximum viable cell 
concentration, the product concentration was (189 ± 19), (267 ± 18), and (267 ± 13) mg/L for 
microscale Experiments 3.1, 3.2a and 3.2b, respectively. The differences observed between 
Experiments 3.1 and 3.2a, as well as between Experiments 3.1 and 3.2b were significant 
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(p-value < 0.001, for both). The mAb concentration in the bench scale vessels was (253 ± 9) 
mg/L at the point of maximum viable cell concentration and the difference between the 
microscale and the bench scale product concentration was not significant (p-value = 0.92). 
Due to observed differences in cell concentration (Section 3.4.2 Growth) between scales, and 
the inherent link between cell concentration and mAb titre, objective performance evaluation 
requires the calculated cell specific productivity. The cell specific productivity measurements 
for bench and microscale cultures were performed as detailed in Section 2.4 Rate Calculations.   
 
Figure 26 Cell specific productivity (mg/cell/day) of micro and bench scale cultures plotted across 
process duration (days) 
Microscale reactors: (▲) Experiment 1, n=6 (30 minutes settling); (▼) Experiment 2, n=4 (33.5 minutes 
settling); (■) Experiment 2, n=6 (37 minutes settling); (♦) Bench scale reactors: Experiment 1, n=2. Data shows 
mean ± SD 
 
The bench scale cultures displayed no marked improvement over microscale cultures in their 
cell specific productivity measurements (Figure 26).   Additionally, variation was observed in 
cell specific productivity across cultures during the first 10 days of culture.  This variation was 
observed to reduce as the cultures approached similar phases of operation, such as exponential 
growth in advance of the culture maximum cell density.  
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The average specific productivity (3.05 ± 1.1) on day eight post inoculation narrowed to 
(3.06±0.17) x10-6 mg/cell/day on day 19 post inoculation, displaying a non-significant 
difference between scales (p-value = 0.86).   
Table 2 Monomer percentages of micro and bench scale cultures taken pre and post protein A 
purification 
 
Experiment Pre-purification monomer (%) Post-purification monomer (%) 
3.1a 44.8±0.7 94.0 
3.1b 61.0±0.7 93.3 
3.2a 54.6±8.7 95.1 
3.2b 53.3±6.5 94.0 
 
Protein A purified perfusate was collected and evaluated for monomer purity for each 
microscale and the bench scale experiment.  Samples were taken from the vessels at maximal 
viable cell concentration (Table 2).  The product purity achieved by cultivation at microscale 
was  93.3%, 95.1%, and 94.0% for the microscale Experiments 3.1, 3.2a, and 3.2b, 
respectively, and that achieved at bench scale was 94.0%, indicating comparability across 
microscale and bench scale cultures.  
In addition to this, the average monomer content of the perfusate was measured pre Protein A 
purification, indicating the quality of the mAb product was (61.0 ± 0.7), (54.6 ± 8.7), and (53.3 
± 6.5) % for the microscale Experiments 3.1, 3.2a, and 3.2b, on the days 19, 19 and 24 post 
inoculation, respectively. The differences observed between Experiments 3.1 and 3.2a and 
between Experiments 3.2a and 3.2b were not statistically significant (p-values = 0.1 and 0.8, 
respectively). However, the product quality was significantly lower in Experiment 3.2b than in 
Experiment 3.1 (p-value < 0.05). The long settling times were observed to be associated with 
lower product quality that was nevertheless higher than the monomer content of the bench scale 
cultures at 14 days post inoculation ((44.8 ± 0.7) %).  This difference between the bench scale 
and microscale cultures was highly significant (p-value < 0.001, Experiment 3.1).  
3.5 Discussion 
The operation of perfusion cultures within the ambr®15 system required the sedimentation of 
the cultures in situ to allow the exchange of a cell free fraction of medium.  In retaining cells 
within vessels to perform liquid exchange steps, periods of uncontrolled bioprocess activity 
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were experienced.  Fortunately, these uncontrolled periods were not unmonitored, and they 
appeared reproducibly throughout the microscale perfusion bioprocess operation. 
These periods were highlighted by drops in DO and pH, likely to be caused by the metabolic 
activity of the cells consuming residual oxygen and producing CO2 and lactate. As oxygen 
became limited (approximately after 10 minutes of cell settling) the slowing down of the 
cellular metabolic activity through reduced oxidative phosphorylation at low (<5%) DO 
saturations (Heidemann et al., 1998) could consequently have slowed down the rate of pH drop, 
since CO2 production would slow down.   
The location of the optical sensors at the bottom of the vessel was thought to contribute to the 
magnitude of these observed changes. As cells settled down at the bottom of the vessel, the 
sensors only picked up the parameters associated with an oxygen depleted and by-product 
accumulated local environment. Thus, hypoxic stress was thought not to be as extreme across 
the entire culture.  
Efficient resuspension of the cultures was important to recover the system back to its control 
set points.  This allowed the culture to evade the adverse effects of the microenvironment such 
as hypoxia or toxicity.   Hydrodynamic investigation of the mixing time within microscale 
vessels indicate < 5 seconds is required for resuspension (Nienow et al., 2013).  Upon 
resuspension, this short resuspension time was realised as the immediate recovery of pH back 
towards set point was observed.   
The initially recovered values were higher than those measured prior to settling. The DO 
rapidly responded to the re-introduction of aeration and agitation, however, the values were 
observed to overshoot immediately after resuspension, only to recover to the set points within 
the first hour. Increased sparging of oxygen into the vessel to recover the DO back to 50% was 
thought to remove CO2 from the culture, resulting in the slight elevation of the pH, an issue 
commonly mitigated in scale up applications (Matsunaga, Kano, Maki, & Dobashi, 2009).  
Observations of the cell settling methodology in isolation can only present the recorded cellular 
environment experienced by the cultures.  Feasibility for its application to a perfusion process 
is hampered by the critical levels of DO attained, and drastic pH deviations, during the cell 
settling.   
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However, considering the holistic, process wide impact of the cell settling methodology and 
how these perturbations impact the growth, viability, and production of the cultures provides 
valuable insight into method performance. 
At microscale, the retention efficiency depended on settling cells from the surface of culture. 
A drop was observed in the percentage of culture retained during each liquid exchange step, 
this was from 99% initially tested, towards 95% as the cell concentration increased and culture 
progressed. The cell retention performance values (>95%) were higher than the values reported 
earlier (90% retention, (MilliporeSigma, 2017)) indicating improved performance in the 
present setup.  However, this small percentage loss was thought to be a small and frequent cell 
bleed that could contribute to depressed growth rates and lag time in reaching maximum cell 
concentration.   
Additional information was gained on the performance of the cell retention methodology by 
analysing the small subpopulation that was being removed at each perfusion step.  Although 
the viability of cells has been reported to affect their settling velocity (Searles et al., 1994), 
with non-viable cells moving 30 – 50% slower than viable cells (Z. Wang & Belovich, 2010), 
the cultures investigated here did not adhere to the earlier observations.  However, given the 
difference in physical size, the cells removed were more likely those which displayed lower 
specific productivity due to their stage in the cell cycle, as reported earlier (Lloyd et al., 2000). 
In the conduction of the cell settling methodology, vessels within each CS were serviced 
sequentially post settling period, such that incremental increases in the respective settling times 
were experienced.  This occurrence of variation in settling time enabled the closer investigation 
of the impact of the uncontrolled period on the perfusion bioprocess.  An increase in statistically 
significant variation was observed in line with settling time.  Thus, a combination of this 
interrogation combined with initial method development work presenting minimum settling 
times of above 30 minutes and suggesting an operational maximum settling time of this cell 
line to be kept shorter than 41 minutes.   
It is noted however, as cell size distributions will vary between individual cell lines and clones 
these figures should be investigated in each new application and the operating range 
investigated here provides a wide investigative space to find operational space for future cell 
lines, well within the operational limits or boundaries.  
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The growth performance of microscale perfusion cultures presented statistically comparable 
maximum cell concentration to bench scale operation.  The cultures were observed reaching 
high cell concentrations exceeding 7.0 x107 cell/mL in bench and microscale alike.   
However, differences were observed in the achievement of these maximal cell densities that 
the further characterise the microscale methodology.  An extended phase of exponential growth 
observed for the cultures growing at microscale and was thought to be at least partially related 
to the efficiency (very small, frequent cell bleeds) or periods of uncontrolled cultivation, 
experienced in gravity cell settling. In contrast, cells operated at bench scale were considered 
to be retained at 100% efficiency as the 0.2µm pore size within the hollow fibre filter was 
sufficiently small to prevent the passage of cells, without periods of uncontrolled cultivation. 
In addition to a lag period in reaching maximal cell concentration, microscale perfusion vessels 
also experienced differences in the pH environments generated when compared to bench scale 
cultures.  Following an initial growth period, bench and micro scale cultures began to see an 
accumulation of lactate and sequential drop in pH.  This was reversed in bench scale cultures 
as the improved growth characteristics enabled the cultures consumption of residual glucose 
and increased back metabolism of lactate.  This metabolic scenario was confirmed by further 
amino acid analysis. 
In the bench scale cultures, data suggest pyruvate was selectively converted into alpha-
ketoglutarate, which entered the TCA cycle, and excess pyruvate was be converted into 
glycine. The concurrent increase in the by-product alanine concentration provided further 
support for the activation of this pathway. Glutamine concentration was shown to decrease 
supporting that the glutamate pool was utilised in alpha ketoglutarate production, rather than 
glutamine. 
Despite these differences, in pH, the specific glucose consumption and lactate production of 
the microscale and bench scale systems were similar (Figure 22 and Figure 23, respectively). 
Earlier reports indicated that even a small variation such as 0.1 in pH could significantly impact 
culture growth and metabolism, in particular glucose consumption and lactate production (F. 
Li et al., 2010). The cell line employed in this study was very robust, withstanding a pH 
variation of 0.3 without demonstrating any observable differences in two major indicators of 
metabolic activity after the 10th day following inoculation; glucose utilisation and lactate 
production. However, the sensitivity of the cell line to variations in pH needs to be considered 
in designing the system, e.g. introducing two-point pH control in the system. 
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Comparison of the micro and bench scale systems is furthered with the evaluation of 
productivity and product quality assessments.  Cell specific productivity does not appear to be 
impacted by the method of cell retention, with comparability presented in cell specific 
productivity once cultures are established.  This supportive productivity data is paired with 
comparable product quality outcomes, where aggregation was consistently below 6% across 
micro and bench scale cultures post protein A purification.  In addition, monomer content 
achieved in microscale pre protein A was significantly higher than bench scale, suggesting that 
the unique microscale perfusion environment did not negatively impact product quality when 
compared to the characterised ATF bench scale perfusion environment (Kelly et al., 2014; 
Walther, McLarty, & Johnson). 
In conclusion, the microscale system supported statistically comparable maximum cell 
concentration to that displayed in bench scale operation specific for this experimental cell line, 
with cultures reaching very high cell concentrations exceeding 7.0 x107 cell/ml; the cultures 
were not limited by oxygen, and the pH of the system was maintained at a stable level. The 
differences in culture pH between the microscale and bench scale cultures did not yield 
differences in the CHO cell physiology, with the specific glucose consumption and net specific 
lactate production rates remaining similar.   
The present setup could utilise either the 48-vessel or the 24-vessel variants of the microscale 
system at 50% capacity with half of each culture station being utilised at a time. At a liquid 
exchange rate of 1 vessel volume per day, this setup allowed suitable maintenance downtime 
and a single operator intervention per day. This evaluation has shown the potential and 
applicability of this setup in conducting multifactorial DoE to effectively evaluate perfusion 
process set points, media optimisation, or as a cell line screening tool.   
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Chapter 4 The Evaluation of Micro and Bench Scales Perfusion 
Cultures as Tools for Production Culture Inoculum Expansion  
4.1 Introduction 
Perfusion culturing of Cell line 1 at microscale, as presented in Chapter 3, achieved a maximum 
density of (7.20 ± 1.14) x107 cells/mL.  Due to the continuous dilution of the cultures with 
fresh medium, this high cell density did not result in a highly concentrated mAb product.   
The observed high volume and low concentration harvest of perfusion is a contrast to the low 
volume, and high concentration typically observed in fed batch methods.  The low 
concentration prevents prevalent commercial production of mAbs through continuous 
culturing methods. 
However, the high cell density observed in continuous culture has a direct application to the 
supply of cells for inoculation in commercial scale vessels.  Each commercial scale inoculation 
is initiated by thawing cryopreserved cell stocks (from a single vial of a common source).  This 
culture is expanded in incrementally increasing culture volumes until sufficient cells are 
present to achieve the desired seeding density. This expansion is achieved by multiple 
subcultures per week followed by multiple pilot scale (or larger) vessels (Shukla & Thömmes, 
2010).  An example of this expansion process is presented in Figure 27, below. 
 
Figure 27 Diagrammatic representation of typical inoculum expansion 
Presented in this figure is the typical expansion process and volume requirements for a fed batch bioprocess 
inoculum, in order to operate high volume manufacturing scale vessels.  At each step cells are grown to 
between 2 and 10 x106cells/mL prior to inoculation of the next stage. 
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Perfusion cultures maintain exponential growth up to a maximum density (Clincke et al., 2013).  
This exponential growth can be maintained indefinitely as a pseudo-steady state with the 
application of regular culture ‘cell bleeds’, reducing cellular concentration below the critical 
density.  The cellular state present in perfusion exponential growth is thought to be similar to 
what would be targeted during the inoculum expansion subculture (Kloth et al., 2010).   
Therefore, high density perfusion cultures may streamline inoculum expansion by reducing the 
number of incrementally increasing scale-up vessels required (Figure 27).   
The use of perfusion cultures for inoculum expansion shifts the focus of evaluations from the 
quantity and quality of the expressed mAb to the health and viability of cells within the culture.  
The impact of the continuous expansion can be simultaneously experienced across multiple 
cellular processes, including the transcriptome (Fomina-Yadlin et al., 2015), metabolome 
(Sellick et al., 2011) and proteome (Nissom et al., 2006).  Simultaneous characterisation of the 
impact on these cellular frameworks within a perfusion culture is challenging for a single 
culture, and unfeasible in a high throughput setting.   
Therefore, experiments within this chapter aim to first characterise the cellular content present 
in micro and bench scale perfusion cultures.  This is conducted holistically by utilising the 
perfusion cultures as inoculum expansions, inoculating production cultures.  Observed 
differences in the subsequent production cultures will be expected to have origins in the 
perfusion methodology.  This dual mode strategy for investigation has been highlighted 
previously by conducting batch and fed-batch to alter the metabolism and progressing the 
cultures to a continuous system to evaluate the impact (Europa, Gambhir, Fu, & Hu, 2000). 
Variation observed in inoculum expansion is documented to impact culture performance in 
production cultures (Kallos & Behie, 1999).  Differences were highlighted in the growth rates 
of the respective micro and bench scale perfusion methods (Chapter 3).  Sub- populations that 
grow slower were thought to be promoted in the microscale perfusion cultures, as the fast 
growing populations were expected to ‘over-grow’ during the cycling of nutrient availability 
(Stephens & Lyberatos, 1987).   Therefore, utilising the microscale perfusion methodology for 
the generation of n-1 inoculation cultures presents the opportunity to further characterise the 
methodology and compare it to bench scale systems.  
Secondly, the cell line sensitivity to decreasing perfusion dilution rates was evaluated at bench 
scale.  This auxiliary investigation served to characterise and attribute any variation observed 
at micro scale with sensitivity to dilution rate. 
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4.2 Materials, Methods, and Experimental Design 
Materials and methods utilised for both perfusion and fed batch operation are as presented in 
Chapter 2 Materials and Methods.  The two investigations and their unique design 
characteristics are outlined below and in Table 3.   
Table 3 Experimental outline for evaluations contained in Chapter 4 
 
Experiment Scale Cell 
line 
Dilution rate (VVD) of 
perfusion phase 
Seeding density for 
production phase 
Fed-batch 
condition 
4.1a Micro 1 1.0 2.5, 5, 10, 15 1X, 2X 
4.1b Bench 1 1.0 2.5, 10 1X, 2X 
4.2 Bench 1 1.0, 0.75, 0.5 10 1X 
 
To aid the comprehension of the experimental design, a discussion is offered following each 
experimental subsection (e.g. Results for Experiment 4.1 are followed by Discussion for 
Experiment 4.1, then Results for Experiment 4.2 are followed by Discussion for Experiment 
4.2).    
The first of these investigations (Experiment 4.1a) followed the microscale methodology for 
gravity cell settling, presented in Chapter 3.  The microscale perfusion cultures were used to 
inoculate microscale fed-batch production cultures.  The operation of the production cultures 
was performed at multiple production conditions.  These conditions varied the seeding density 
and feeding regime to highlight the cellular characteristics of the proceeding perfusion cultures.   
Parallel evaluations in bench scale cultures were conducted (4.1b) to highlight scale dependent 
characteristics present in Experiment 4.1.  Due to the high throughput nature of the microscale 
system, additional conditions were conducted at microscale, compared to those evaluated at 
bench scale.   
The second investigation (Experiment 4.2) was conducted at bench scale.  The dilution rate of 
the inoculum perfusion vessels was varied, whilst the process conditions of the production 
phase are kept consistent.  This design highlighted cellular characteristics related to different 
dilution rates of the perfusion cultures.  
The bolus addition of the nutrient feed was conducted daily from day 1, in production cultures.  
This frequency was selected to ensure that the nutrient demands of the high cell density present 
at inoculation was supported.   
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Given the proprietary nature of the medium and feed compositions, only a simplified 
adjustment of feeding ratios, rather than informed medium optimisation investigations, were 
utilised.  Presented in this Chapter is the culture response, at different scales and seeding 
densities, to a platform 2-part feed volume (1x condition) and one that is volumetrically 
doubled (2x condition). Respective seeding densities for following production vessels and the 
feed conditions applied on each day are detailed in Table 3. 
Cultures were progressed through the production phase up to day 14 post inoculation or until 
viability declined below 60%, whichever came first. 
4.2.1 Transition of Cultures From Perfusion to Production 
The transition of cells into production cultures was initiated when perfusion vessels were within 
exponential growth.  An understanding of maximal cell density was gained from work 
conducted in Chapter 3.  Therefore, the target cell density for the transition was determined to 
be at 40 x106 cells/mL to ensure cells were established in exponential growth. 
The experiments detailed in Table 3 require the inoculation of the production cultures with 
cells originating from the respective perfusion cultures.  The incorrect operation of this 
inoculation step can result in extended periods of time where the physiochemical environment 
of inoculum cultures is uncontrolled.   Characteristics associated with high density culture, 
such as net high accumulation of waste and inherently high oxygen demand, have potential to 
negatively impact on the production vessel performance unless the transition is managed 
appropriately.    
4.2.1.1 Pooling Cultures – Production Phase Evaluation 
For Experiment 4.1, the screening of seeding density and feeding ratio in the production phase 
cultures required large quantities of high concentration inoculum to be generated.  To supply 
this, multiple perfusion vessels were operated for the micro and bench scale experiments, 
respectively.  Comparable replicate perfusion cultures (n=9 and n=2 for micro and bench scale, 
respectively) from within the same scale were pooled together in the transition step.  The 
pooling step highlighted specific scale-related challenges. 
At microscale, the combination of nine vessels from n-1 perfusion resulted in a total culture 
volume of approximately 90mL.  The pooling was performed utilising a vented shake flask 
(Corning®) and a humidified incubator to provide rudimentary temperature, CO2, and O2 
maintenance conditions while the inoculation was conducted. 
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At bench scale, two perfusion vessels were combined to provide approximately six litres of 
culture volume.  The main concern was to ensure agitation of the pooled inoculum whilst 
inoculation was conducted.  The cultures were extracted from the perfusion vessels into a 20L 
culture bag.  This bag was then placed on a rocking platform (WAVE25, GE) whilst transition 
was performed.  Agitation through the rocking action of the culture ensured homogenisation 
during inoculation and aided the culture to maintain viability.   
In order to conduct the transition without delay, it was important to have pre-prepared 
production vessels for inoculation.  Such preparations include ensuring the inoculation medium 
is within operating ranges for temperature and pH, alongside performing at-line sensor 
calibration checks and applying offsets.   
Experiment 4.2 evaluated different dilution rates in the perfusion cultures before inoculating 
the production cultures.  This required segregation of dilution rate conditions and alleviated the 
need for pooling material.  This experiment was conducted at bench scale to accurately control 
the designed dilution rate continuously rather that the incremental semi-continuous dilution 
rate offered in the microscale system. 
4.3 Results 
4.3.1 Experiment 4.1 The Cellular Characteristics of Micro and Bench Scale Perfusion 
Present in Production Cultures 
4.3.1.1 Growth Performance and Biochemical Characteristics of Perfusion Cultures 
The micro and bench scale perfusion cultures were inoculated at a target seeding density of 
0.8x106 cells/mL, respectively.  The measured viable cell concentrations from the operation of 
these vessels are presented in Figure 28, below. 
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Figure 28 Growth of perfusion vessels operated at micro and bench scale over process duration (days) 
Viable cell density (cells/mL x106) of perfusion vessels.  Viable cell density is plotted against process duration 
(days), (●) and (■) represent micro (n=9) and bench (n=2) scale vessels, respectively.  Perfusion initiation is 
indicated with an intersecting blue line. 
 
Following inoculation, cells were grown in batch for the first four days of culture.  The viable 
cell density during this period reached (6.17±1.03) and (6.13±0.21) x106 cells/mL for micro 
and bench scale vessels, respectively.  The initiation of perfusion systems on the fourth day 
post inoculation (indicated by the intersecting blue line) enabled the cultures to extend this 
period of exponential growth. A similar growth profile is experienced in the micro scale vessels 
when compared to bench scale.   
The two scales display no significant difference throughout the process duration, however, the 
level of significance decreases when values up to day seven are expanded to day ten (P-value 
= 0.23 and 0.10, respectively).  This decrease in significance is representative of the microscale 
vessels taking an additional two days to reach the target density (40x106cells/mL) set for 
transfer into the production vessels.  Cell densities at transfer were (45.71±5.34) and 
(39.27±1.40) x106cells/mL on days 12 and 10, for micro and bench scale vessels respectively. 
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Additional process monitoring displays comparability between bench and microscale perfusion 
vessels, up to their transition into production operation.  This is highlighted by the key process 
variables pH and dissolved oxygen, in addition to key metabolites glucose and lactate. 
 
Figure 29 Measured glucose of perfusion vessels operated at micro and bench scale over process 
duration (days) 
Glucose concentration (g/L) of perfusion vessels.  Glucose concentration is plotted against process duration 
(days), (●) and (■) represent micro (n=9) and bench (n=2) scale vessels, respectively.  Perfusion initiation is 
indicated with an intersecting blue line. 
 
The measured glucose (g/L) present within micro and bench scale cultures during the perfusion 
phase of operation is highlighted in Figure 29.  A decline in glucose concentration was 
observed over the first four days of batch culture.  The concentrations decreased from initial 
values of approximately 4g/L, to (0.01±0.01) and (1.12±0.45) g/L for micro and bench scale 
vessels, respectively.  Following the initiation of perfusion, and the influx of fresh medium, 
these glucose concentrations rapidly increased, reaching (10.2±0.2) and (9.8±0.3) g/L by day 
six for micro and bench scale, respectively.  No significant difference was observed between 
glucose concentrations over this period of time (p-value= 0.3).   
On day seven, a decline was observed in glucose concentration for bench scale vessels, to 
(7.3±0.2) g/L, where microscale vessel glucose concentration remained above 10g/L.  
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Increased culture glucose consumption aligned with viable cell concentration in Figure 28, 
whereby an increase was observed for bench scale cultures.  As cultures progressed towards 
transition criteria (40x106 cells/mL) the residual glucose concentration within the vessels 
continued to decline, but was never limiting, with measured values at transition at (3.9±0.6) 
and (2.6±0.2) g/L for micro and bench scale, respectively.  
In close relationship to measured glucose levels within the vessels, Figure 30 presents the 
measured lactate (g/L) that was present in the vessels through a function of the cells' 
production, consumption, and perfusion process dilution. 
 
Figure 30 Measured lactate of perfusion vessels operated at micro and bench scale over process duration 
(days) 
Lactate concentration (g/L) of perfusion vessels.  Lactate concentration is plotted against process duration 
(days), (●) and (■) represent micro (n=9) and bench (n=2) scale vessels, respectively.  Perfusion initiation is 
indicated with an intersecting blue line 
 
Observed lactate concentration within vessels begun at concentrations >0.3g/L for both micro 
and bench scale systems.  During the initial batch period, an inverse relationship was observed 
between glucose and lactate levels. The concentrations of glucose are observed gradually 
depleting from initial starting points of (4.19±0.04) and (4.59±0.15) g/L, respectively.   
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Lactate concentrations within the cultures are seen to increase to a maximum of (1.89±0.06) 
and (1.96±0.10) g/L, respectively.  Following this maximum, and the initiation of perfusion, 
lactate concentrations were observed to reduce, establishing homeostasis between 1 and 1.5 
g/L.  Measured lactate concentration at culture transition is (1.08±0.11) and (1.54±0.06) g/L 
for micro and bench scale vessels, respectively. 
The metabolic demand that drives these changes in measured glucose and lactate places 
pressure on control systems associated with maintaining process setpoints, namely dissolved 
oxygen percentage and pH. 
 
Figure 31 Dissolved oxygen (%) of perfusion vessels operated at micro and bench scale over process 
duration (days) 
Dissolved oxygen (%) of n-1 perfusion vessels in preparation of inoculum for hybrid process production 
vessels.  Dissolved oxygen is plotted against process duration (days), (●) and (■) represent micro (n=9) and 
bench (n=2) scale vessels, respectively.  Values for microscale vessels are averaged over 24 hour periods to 
provide representative values incorporating cell setting.  Perfusion initiation is indicated with an intersecting 
blue line. 
 
Following inoculation, where oxygen saturation is elevated within vessels, cellular demand for 
oxygen quickly brought saturation towards the controlled 50% threshold (as indicated by the 
dashed red line, Figure 31), by day 1 and 2 for bench and microscale respectively.   
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Dissolved oxygen was maintained above 43% saturation for all cultures throughout the 
perfusion step, with cellular demand never exceeding supply.  The cumulative impact of the 
micro scale cell settling retention protocol on average oxygen saturation is represented in 
Figure 31 with a consistently lower oxygen saturation observed for the micro scale cultures 
when compared to the bench scale cultures.  
 
Figure 32 The pH of perfusion vessels operated at micro and bench scale over process duration (days) 
pH is plotted against process duration (days), (●) and (■) represent micro (n=9) and bench (n=2) scale vessels, 
respectively.  Values for microscale vessels are averaged over 24 hour periods to provide representative values 
incorporating cell setting.  Perfusion initiation is indicated with an intersecting blue line. 
 
At inoculation, pH was accurately controlled to pH 7.2±0.1 with the utility of sparged CO2 
preventing elevation above 7.3.  This control strategy was maintained through to the point of 
perfusion initiation on day four. On day 4, a deviation in pH for micro and bench scale cultures 
was presented.   
In accordance with data presented in Figure 31, lower averaged pH measurements for 
microscale vessels were caused by the low culture pH experienced during the method of cell 
retention.   However, declines in pH were observed for both micro and bench scale cultures, as 
they progressed towards transition.   
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This was highlighted by a decrease in culture pH, presented between days five and 12 post 
inoculation in the micro scale vessels where monitored pH is seen to decrease from (7.24±0.01) 
to (6.86±0.02), respectively.  In bench scale it appeared that the culture impact on process 
control is suppressed and a pH decline is not experienced until nine days post inoculation, 
where a decline from (7.30±0.00) to (7.16±0.02) is initiated.  
4.3.1.2 Production Culture 
The perfusion cultures reached the target cell density (40 x106 cells/mL) on days 10 and 12 for 
bench and micro scale vessels, respectively.  Following this, the inoculation of production 
cultures was conducted (see, Section 4.2.1 Transition of Cultures From Perfusion to 
Production). 
The successful inoculation of the production vessels at micro scale was highlighted by the 
maintenance of high viability in the pooled cultures and post inoculation production culture 
cell counts. 
Measured viability of pooled cultures prior to microscale transition was (94.5±1.7) % and post 
inoculation the from cell counts on days 0, 1 and 2 post inoculation were (92.7±1.5), (91.1±1.9) 
and (91.2±2.2), respectively.  The breakdown of percentage viability for 1x and 2x feed 
conditions are provided in Figure 33 and Figure 41, respectively.  This maintenance of viability 
over the initial culture period represented a successful transition from perfusion to production 
vessels at micro scale. 
Viability of bench scale vessels prior to transition was (98.1±0.7) % and those post inoculation 
from cell counts on days 0, 1 and 2 were (97.2±0.7), (97.6±0.6) and (96.9±1.0), respectively.  
This maintained viability over the initial culture period also represented a successful transition 
from perfusion to production vessels for bench scale.  Analysis of viability progression 
throughout bench scale production cultures is provided in Figure 50.  
4.3.1.2.1 The 1x Feed Condition in Microscale Production Culture 
Viability measurements from microscale vessels operated in the 1x feed condition were stable 
up to day four for all seeding densities.  They are observed to maintain viability from (92.4±2.0) 
% at inoculation to (89.8±0.4) % on day four (Figure 33). 
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Figure 33 Viability (%) of production phase micro scale vessels operated at incremental seeding 
densities at the 1x feed condition (Experiment 4.1a) 
Viability is plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 
10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
From day five onwards, a decline in viability (86.1±0.4) was observed.  This decline in viability 
was consistent across all cultures.  Whilst all cultures were declining simultaneously towards 
harvest viability (60%), an inverse relationship was observed between the starting seeding 
density and the viability.  Viability at harvest highlighted this with seeding densities 2.5, 5, 10 
and 15 x106 cells/mL presenting viabilities of (57.9±0.5), (54.9±1.0), (50.6±0.8) and (47.1±2.3) 
%, respectively. 
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Figure 34 Viable cell density (cells/mL x 106) of production phase micro scale vessels operated at 
incremental seeding densities at the 1x feed condition (Experiment 4.1a) 
Viable cell density is plotted against process duration (days); symbols , ▲, ■ and ● represent seeding 
densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
Following the inoculation of production microscale vessels in the 1x feed condition, 
exponential growth was successfully established (Figure 34).  All cultures progressed towards 
a transition into a stationary phase between days four and seven.  This transition was 
highlighted by peak viable cell density, observed to correlate to the magnitude of seeding 
density.  The peak viable cell density was (10.37±0.80), (13.89±0.96), (18.99±0.36) and 
(24.03±2.13) x106cells/mL, for conditions 2.5, 5, 10 and 15 x106 cells/mL, respectively.   
Following the peak viable cell density, an accelerating decline in cell viability was observed.  
Cultures were observed to decline to harvest criteria (<60% viability) at day 10 post inoculation 
(Figure 33).  Analysis of the viable cell density profiles highlighted statistically significant 
increases in performance correlating to increases in seeding density (P-values<0.05 for each 
respective paired combination). 
Routine at-line monitoring of culture glucose and lactate concentrations are presented in Figure 
35 and Figure 36, respectively.  
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Figure 35 Glucose concentration (g/L) of production phase micro scale vessels operated at incremental 
seeding densities at the 1x feed condition (Experiment 4.1a) 
Glucose g/L plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 
10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
A concentrated glucose stock (500g/L) is fed back into the cultures on demand, the profile 
presented (Figure 35) reflects the accuracy of operation and ability of the control system to 
maintain the glucose concentration within the cultures. 
Glucose concentration was observed to be accurately controlled within the design parameters 
throughout the process with the following exceptions.  Glucose concentration slightly exceeded 
8g/L in the 2.5 x106cells/mL seed density culture on day one, the value recorded was (8.7±0.1) 
g/L.  Glucose concentration was observed to drop below 2g/L on day four for triplicate cultures 
in the 15 x106cells/mL seed density condition, leading to an average value of (2.4±1.3) g/L.  
These high and low glucose concentrations were examples of the highest and lowest culture 
glucose demands, correlating with viable cell density (Figure 34) and were consistent glucose 
consumption rates (Figure 37, below). 
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Figure 36 Lactate concentration (g/L) of production phase micro scale vessels operated at incremental 
seeding densities at the 1x feed condition (Experiment 4.1a) 
Lactate (g/L) plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 
10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
The trend of lactate concentration over the culture duration represented a sigmoidal fashion, 
whereby residual lactate levels increase slowly over the first six days of culture, from a starting 
concentration of (0.4±0.3) g/L at inoculation, to (2.1±0.5) g/L on day 6 post inoculation (Figure 
36). 
Lactate concentrations are then observed to triple, increasing to (6.0±0.4) g/L by day eight.  
Following this sharp increase in concentration, lactate levels plateau over the final days of 
culture, (6.5±0.02) and (6.4±0.02) g/L for days nine and ten, respectively.  These changes in 
lactate concentration can be indicative of the cellular processing of available glucose (presented 
earlier, Section 3.4.5 Biochemical Analysis).   
The calculation of cell specific consumption rates for glucose (Figure 37) and lactate (Figure 
38) within the cultures takes into account the glucose added to maintain the controlled process 
range, the measured concentration, and the viable cell density between daily measurements. 
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Figure 37 Cell specific glucose consumption rate (g/cell/day) of production phase micro scale vessels 
operated at incremental seeding densities at the 1x feed condition (Experiment 4.1a) 
Glucose consumption (g/cell/day) plotted against process duration (days); symbols , ▲, ■ and ● represent 
seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
On the first day of culture, the rates of glucose consumption reached peaks of (6.8±1.1), 
(5.4±0.7), (4.6±0.6) and (4.2±0.6) x10-10 g/cell/day for seeding densities 2.5, 5, 10 and 15 
x106cells/mL, respectively (Figure 37). 
Whilst fluctuations occurred in the consumption rates throughout the cultures, this elevated 
level was maintained up to day eight post inoculation, where an average of (4.4±1.2) x10-10 
g/cell/day was observed across all seeding densities.  Following day eight, consecutive declines 
in average glucose consumption rates in-line with a decrease in culture viability were observed 
(Figure 33).  The average glucose consumption rate on days nine and ten was (3.3±1.4) and 
(2.4±1.3) x10-10 g/cell/day, respectively. 
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Figure 38 Cell specific net lactate change (g/cell/day) of production phase micro scale vessels operated 
at incremental seeding densities at the 1x feed condition (Experiment 4.1a) 
Cell specific net lactate change (g/cell/day) is plotted against process duration (days); symbols , ▲, ■ and 
● represent seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
The cell specific net lactate change represents the simultaneous lactate production and 
consumption occurring in the microscale cultures (Figure 38).  There were two defined peaks 
presented in the positive net change in specific lactate rates, with the first occurring on day one. 
The calculated rates at the first peak are (1.5±0.1), (1.1±0.1), (0.6±0.1) and (0.5±0.1) x10-10 
g/cell/day for seeding densities 2.5, 5, 10 and 15 x106cells/mL, respectively.  Following the 
first peak, the cell specific net lactate change rates were observed to decrease.  The rates were 
observed to be low until day six of culture.  On day six, the rates for all cultures increased 
towards the second peak on day eight.   
The other culture biochemical monitoring and control was the pH and dissolved oxygen 
saturation.  No deviation from the control range (pH 7.2±0.1) was observed between seeding 
densities in the 1x feeding condition.  The residual lactate present in vessels (Figure 36) resulted 
in the pH trending towards the bottom of the control range for the duration of the culture.  This 
maintenance was achieved through the addition of sodium bicarbonate. 
Similarly, the agitation and O2 sparging on demand maintained the dissolved oxygen level at 
50% of the saturation point. 
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Figure 39 Titre (mg/L) representing the process performance of production phase micro scale vessels at 
1x feed condition (Experiment 4.1a) 
Titre plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 10, 5 and 
2.5 x106cells/mL, respectively (n=3 for each). 
 
Measurements for mAb concentration (Titre) increased over time in line with viable cell 
density (Figure 34), peaking at day 8 post inoculation (Figure 39).  Peak titre values were 
(230.0±10.2), (377.0±14.2), (552.0±74.5) and (651.3±111.7) for seeding densities 2.5, 5, 10 
and 15 x 106cells/mL, respectively. 
This stepwise increase in titre and correlation with viable cell density results in the maintenance 
of calculated cell specific productivity across seeding densities (Figure 40, below).   
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Figure 40 Cell specific productivity (g/cell/day) representing the process performance of production 
phase micro scale vessels at 1x feed condition (Experiment 4.1a) 
Cell specific productivity (g/cell/day) plotted against process duration (days); symbols , ▲, ■ and ● 
represent seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
The cell specific productivity experienced was consistent across seeding densities 5, 10, and 
15 x106 cells/mL.  Variation was observed in the cell specific productivity for the 2.5 x106 
cells/mL seeding condition.  This is highlighted by a suppressed rate present on day eight of 
culture.  The peak average cell specific productivity for all cultures was (3.1±0.3) x1011 
g/cell/day, on day 10.  
Table 4 Percentage monomer post Protein A purification of microscale cultures at 1x feed condition 
 
Seeding Density (x106 cells/ml) Monomer (%) 
2.5 (96.6±0.5) 
5 (97.0±0.1) 
10 (97.3±0.6) 
15 (97.1±0.2) 
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The product quality of the mAb expressed from Cell line 1 was not observed to be impacted 
by seeding density in the 1x feed condition.  Monomer percentage observed post Protein A 
purification was greater than 96% for all dilution rate cultures (Table 4) 
4.3.1.2.2 The 2x Feed Condition in Microscale Production Culture 
The 1x and 2x feed condition microscale cultures were inoculated simultaneously from the 
same high cell density pooled culture. 
 
Figure 41 Viability (%) representing the process performance of production phase micro scale vessels 
at 2x feed condition (Experiment 4.1a) 
Viability (%) plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 
10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
High culture viabilities were observed at inoculation, (92.1±0.7), (92.8±0.0), (93.3±0.5) and 
(94.4±0.6) reported for seeding densities 2.5, 5, 10 and 15 x106 cells/mL, respectively (Figure 
41).  This high viability was not maintained and a decrease in viability was observed on day 
one of culture.  The decline in culture viability was observed and continued in all seeding 
density conditions as cultures progressed.  Culture viability declined below the harvest criteria 
(<60%) on day seven in all cultures.  Therefore, the process duration for the 2x feed condition 
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was three days shorter than that experiences for the 1x feed condition, seven days and ten days, 
respectively. 
Viable cell concentrations indicated a deviation in performance from the 1x condition as early 
as day one of culture (Figure 42).  Cultures seeded at the lower seeding densities had lower 
viable cell concentrations on day one post inoculation than their counts at inoculation, 
(2.32±0.40) to (2.21±0.11), and (4.59±0.47) to (4.26±0.37), for 2.5 and 5 x106 cell/mL target 
seeding densities, respectively.   
 
Figure 42 Viable cell density representing the process performance of production phase micro scale 
vessels at 2x feed condition (Experiment 4.1a) 
Viable cell density plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 
15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each) 
 
Following this lag period of approximately two days, cultures appeared to return to growth.  
An exponential growth phase was not observed for any 2x feed condition cultures, and they 
entered a stationary phase where viable cell densities gradually peaked on day six.  The 
observed peak viable cell densities were (4.8±0.1), (7.9±0.03), (13.3±0.6) and (17.9±0.7) for 
seeding densities 2.5, 5, 10, and 15, respectively.   
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The difference in average growth profiles was observed to significantly increase (p-value < 
0.05) in line with seeding density, as was experienced in the 1x condition.  All cultures 
experienced a decrease in viable cell density on day seven and were harvested as the culture 
viability harvest criteria was achieved. 
Comparative viable cell density observed up to day seven of cultures represented statistically 
significant decreases (p-value < 0.05) across all 2x condition cultures when paired to equivalent 
seeding densities in the 1x feed condition. 
Throughout the production cultures, glucose concentrations were accurately controlled above 
2g/L and never dropped into a glucose-limited environment (Figure 43).   
 
Figure 43 Glucose concentration (g/L) representing the process performance of production phase micro 
scale vessels at 2x feed condition (Experiment 4.1a) 
Glucose concentration (g/L) is plotted against process duration (days); symbols , ▲, ■ and ● represent 
seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
The glucose monitoring standard deviations in the 2x condition were visibly lower at each data 
point than those observed in the 1x feed condition.  Cellular content of the 2x condition (Figure 
42) was lower for respective cultures in the 2x condition and resulted in a lower demand being 
placed on the feeding of glucose back into the system to reach maintenance concentrations.    
Page 108 of 204 
 
The measured glucose concentrations were representative of the highest and lowest culture 
glucose demands, correlating with an inverse relationship with cellular density (and seeding 
density, Figure 42) assuming constant cell specific glucose consumption rates. 
 
Figure 44 Lactate concentration (g/L) representing the process performance of production phase micro 
scale vessels at 2x feed condition (Experiment 4.1a) 
Lactate concentration (g/L) is plotted against process duration (days); symbols , ▲, ■ and ● represent 
seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
The lactate concentrations began at <1g/L for all seeding densities within the microscale 2x 
feed condition at inoculation.  During the first four days of culture, these levels slowly 
increased for all cultures, towards but remaining below 2g/L.  
 Between days four and seven, the concentrations of lactate within cultures increased.  The 
lactate concentrations for seeding densities 5, 10, and 15 x106cells/mL increased from <2g/L 
to >6g/L on days four and six, respectively.  Similarities are drawn between these profiles and 
those presented in the 1x feed condition with a peak concentration being reached at culture 
harvest, where viability is low. 
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An outlier was observed in the 2 x106 seeding density culture, whereby lactate concentrations 
reached (3.95±0.23) g/L at harvest.  The lower cell concentration and poor growth of this 
condition (Figure 42) were thought to partially contribute to this presentation. 
 
Figure 45 Cell specific glucose consumption rate (g/cell/day) 
Glucose consumption rate (g/cell/day) is plotted against process duration (days); symbols , ▲, ■ and ● 
represent seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
The cell specific glucose consumption rate is presented in Figure 45.  On the first day post 
inoculation the rates for seeding densities 2.5, 5, 10 and 15 x106cells/mL, were (8.6±0.8), 
(6.3±0.3), (4.7±0.2) and (3.9±0.2) x10-10 g/cell/day, respectively.  The order of highest to 
lowest cell specific glucose consumption rates was maintained from the first day post 
inoculation through to harvest.  Whilst variation existed in cell specific consumption rates, this 
decreased as cultures progressed and on day 5 post inoculation, the average across all seeding 
densities was (4.2±0.7) x10-10 g/cell/day. 
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Figure 46 Cell specific net lactate change (g/cell/day) representing the process performance of 
production phase micro scale vessels at 2x feed condition (Experiment 4.1a) 
Cell specific net lactate change (g/cell/day) is plotted against process duration (days); symbols , ▲, ■ and ● 
represent seeding densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
Whilst not possible to observe exact rates of production or consumption as they occur 
simultaneously within the culture, the net change is presented in the daily lactate measurements 
(Figure 44) 
An initial peak in cell specific net lactate change was calculated, with values of (2.0±0.2), 
(1.4±0.03), (0.8±0.06) and (0.5±0.03) x10-10 g/cell/day for seeding densities 2.5, 5, 10 and 15 
x106cells/mL, respectively (Figure 46).  This cell specific rate on day one decreased as the 
culture progressed and on day 3 the cell specific rate had declined to between (0.5±0.07) and 
(-0.1±0.03), for seeding densities 2.5 and 15 x106cells/mL, respectively. 
The lactate concentrations for all cultures peaked in the final few days of culture (Figure 44), 
this change was represented in the cell specific net lactate change, with values increasing up to 
day six post inoculation and becoming depressed on the final day of culture, as cellular activity 
began to decrease in line with falling viability (Figure 41). 
pH control, as previously outlined for the 1x feed condition, was maintained within the process 
limits of 7.2±0.1.  Given the high lactate concentration experienced in both the 1x and 2x 
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conditions, the pH was controlled along the bottom of this process limit through the addition 
of sodium bicarbonate, on demand. 
 
Figure 47 Dissolved oxygen (%) representing the process performance of production phase micro scale 
vessels at 2x feed condition (Experiment 4.1a) 
DO plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 10, 5 and 
2.5 x106cells/mL, respectively (n=3 for each). 
 
The observed dissolved oxygen saturation was well maintained at or above the 50% level 
throughout the 2x condition cultures (Figure 47).  These profiles were observed to increase 
towards the last days of culture, with values >70% experienced on day six for the 2.5 x106 
cells/mL seeding density culture.  This increase in the final days can be representative of the 
declining culture viability (Figure 41) and, in turn, lower oxygen demand. 
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Figure 48 Titre (mg/L) representing the process performance of production phase micro scale vessels at 
2x feed condition (Experiment 4.1a) 
Titre plotted against process duration (days); symbols , ▲, ■ and ● represent seeding densities 15, 10, 5 and 
2.5 x106cells/mL, respectively (n=3 for each). 
 
As experienced previously for the 1x feed condition, the measured mAb concentration was 
observed to increase as cultures progressed (Figure 48). A separation was observed in the titre 
measurements between seeding densities within the 2x feed condition.  An analysis of the 
average profiles displayed a significant difference between each respective seeding density.  
The highest peak within the 2x feed condition was achieved by the 15 x106 cell/mL seeding 
density, where concentration was observed to reach (442±18) mg/L on day five. 
A similar profile was observed in the 10 x106cell/mL seeding density, whereby a peak was also 
observed on day five, (344±26) mg/L.  In comparison, the cultures of 2.5 and 5 x106 cell/mL 
achieved significantly lower peak titres, with values less than 200 and 100mg/L for conditions 
5 and 2.5 x106 cells/mL, respectively. 
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Figure 49 Cell specific productivity (g/cell/day) representing the process performance of production 
phase micro scale vessels at 2x feed condition (Experiment 4.1a) 
Cell specific productivity plotted against process duration (days); symbols , ▲, ■ and ● represent seeding 
densities 15, 10, 5 and 2.5 x106cells/mL, respectively (n=3 for each). 
 
During the first few days of culture, comparable cell specific productivities were calculated for 
all cultures, with average productivity (0.9±0.04) and (1.4±0.07) x10-11g/cell/day for cultures 
on days one and two, respectively (Figure 49).  As the cultures progressed, lower specific 
productivity was observed with the lower seeding densities (2.5 and 5 x106 cells/mL, 
respectively), when compared to others operated in the 2x feed condition.  Average cell specific 
productivity at harvest was (2.6±0.3) x10-11g/cell/day. 
Table 5 Percentage monomer post Protein A purification of microscale cultures at 2x feed condition 
 
Seeding Density (x106 cells/ml) Monomer (%) 
2.5 (97.7±2.1) 
5 (87.7±13.6) 
10 (96.3±0.2) 
15 (96.4±0.0) 
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The observed monomer percentage was > 96.2 % for three of the four seeding densities 
evaluated for the 2x condition cultures.  The post protein A monomer percentage for the three 
cultures inoculated at 5 x106 cells/ml was 96.82, 95.34, and 71.99 %, respectively.   Statistical 
analysis of all triplicate values reveals no significant differences between any pairs of samples 
(p-value >0.05). 
4.3.1.2.3 Bench Scale Production Cultures 
Given the high throughput nature of microscale systems, it was not feasible to conduct an 
investigation at bench scale that contained the variety and replication of conditions selected in 
microscale.  The conditions conducted at bench scale included (n=2) of seeding densities 2.5 
and 10 x106 cells/ml, both operated at 1x and 2x feed conditions, respectively. 
Unfortunately, a replicate vessel was terminated shortly after inoculation due to equipment 
failure, and thus the 1x condition inoculated at 2.5 x106 cells/mL is reported as n=1. 
 
Figure 50 viability representing the process performance of production phase bench scale vessels at 1x 
and 2x feed condition (Experiment 4.1b) 
Viability plotted against process duration (days); symbols, ■,▲,  and ● represent seeding densities (feed 
condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
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The viabilities over the initial few days of the bench scale cultures were maintained above 95% 
across all conditions (Figure 50).  A decline in viability is first observed in the 2x feeding 
condition, seeding density 2.5 x 106cells/mL, where readings of (93.2±1.7) and (87.0±0.0) % 
were experienced for days four and five, respectively. 
This decline in viability was observed in the other 2x feed condition (seeding density 10 x106 
cells/mL) on day six, where viability of (87.4±3.4) % was recorded.  Following this, the 2x 
feed condition cultures displayed no difference in their rates of decline and reached harvest 
criteria on day nine. 
Cultures operated in the 1x feed condition displayed an improved culture viability profile 
throughout the experiment.  A decline in viability was observed on day seven in the 10 x 
106cells/mL seeding density condition.  The condition still reached harvest criteria on day nine.  
The performance of cultures seeded at 2.5 x106cells/mL, with the 1x feed condition displayed 
improvement over all other conditions evaluated at bench scale.  Not only was the decline in 
viability initiated later, day eight, but the rate of decline was slower, enabling the culture to 
remain above the harvest criteria until day 12. 
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Figure 51 Viable cell density representing the process performance of production phase bench scale 
vessels at 1x and 2x feed condition (Experiment 4.1b) 
VCD plotted against process duration (days); symbols, ■,▲,  and ● represent seeding densities (feed 
condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
 
From inoculation (day zero) to day one all cultures were observed to increase their viable cell 
density (Figure 51).  On day one, consistency is achieved in cell concentrations within 
respective seeding densities, with (12.4±0.04) and (3.59±0.09) reported for 10 and 2.5 
x106cells/mL, respectively.  Following this, deviation occurs based on the feeding regime, with 
improved performance originating from cultures operated in the 1x feeding regime.   
Peak viable cell densities were experienced on day four for the 2x feed condition, with values 
(8.1±0.4) and (25.2±0.3) x106 cells/mL for seeding densities 2.5 and 10 x106 cells/mL, 
respectively.  In the 1x feed condition peak viable cell density was experienced on days seven 
and five for seeding densities 2.5 and 10 x106 cells/mL, with (20.0±0.01) and (29.6±0.00) x106 
cells/mL, respectively.   
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Figure 52 Glucose concentration (g/L) representing the process performance of production phase bench 
scale vessels at 1x and 2x feed condition (Experiment 4.1b) 
Glucose plotted against process duration (days); symbols, ■,▲,  and ● represent seeding densities (feed 
condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
 
The availability of glucose was maintained throughout the duration of the culture, with the 
lowest recorded concentration (0.96g/L) occurring on day one of the cultures for the 10 
x106cell/mL seeding density culture, operated at 1x feed condition (Figure 52). 
Due to the high cellular concentration, and resulting culture glucose demand, both feeding 
conditions operated from the 10 x 106cells/mL seeding density regularly dropped below 2g/L.  
The glucose added following this measurement was sufficient on each day to provide the key 
metabolite over the subsequent 24 hour period. 
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Figure 53 Lactate representing the process performance of production phase bench scale vessels at 1x 
and 2x feed condition (Experiment 4.1b) 
Lactate plotted against process duration (days); symbols, ■,▲,  and ● represent seeding densities (feed 
condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
 
The concentration of lactate was observed to increase on the final days of culture for all 
conditions Figure 53.  The observed values for the 1x feed condition were (3.9±0.5) and 
(2.3±0.0) g/L for seeding densities 2.5 and 10 x106 cells/mL, respectively.  The 2x feed 
condition concentrations were (7.5±0.6) and (5.1±0.2) g/L for seeding densities 2.5 and 10 x106 
cells/mL, respectively.  
Lactate concentrations in bench scale cultures displayed two distinct trends that differ from 
those observed at microscale.  Firstly, the lower seeding density 2x feed condition presents an 
exponentially increasing lactate concentration.  This increase is observed throughout the 
culture duration up to day eight and plateaus on the final day of culture (day nine).  This trend 
is similar to that generated in the respective microscale culture (Figure 44), whereby lactate 
accumulation is persistent throughout the culture duration. 
The second trend observed begun with an initial accumulation of lactate within vessels.  This 
occurred over the first four days of culture, and the concentration increased up to approximately 
2g/L.  Following this initial accumulation, lactate concentration was then observed to decrease 
as the cultures grew exponentially.  On the final two days of each respective culture, a sharp 
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increase in lactate concentration was observed. This increase in concentration resulted in peak 
lactate concentration on the final day of culture. 
 
Figure 54 Online pH measurements representing the process performance of production phase bench 
scale vessels at 1x and 2x feed condition (Experiment 4.1b) 
pH plotted against process duration (days); symbols, ■,▲,  and ● represent seeding densities (feed 
condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
 
Throughout the culture duration, the control strategies successfully maintained pH and oxygen 
saturation to the respective setpoints (pH 7.2±0.1, DO 50%).  Fluctuations occurred within this 
culture biochemical environment that presented themselves as pH measurements moving 
between the top and bottom of the deadband (Figure 54). 
In a correlation to evolving lactate concentration within the culture (Figure 53), the pH started 
at the top of the deadband was observed to decline as lactate concentration increased.  This 
trend was observed to oscillate as lactate levels within cultures decreased and then peaked at 
the last days of culture.   
Cultures with low cellular growth, and in turn low oxygen demand, saw a rise in dissolved 
oxygen percentage in the final few days of culture as oxygen supply from agitation alone was 
in excess of demand. 
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Figure 55 Titre representing the process performance of production phase bench scale vessels at 1x and 
2x feed condition (Experiment 4.1b) 
Titre plotted against process duration (days); symbols, ■,▲,  and ● represent seeding densities (feed 
condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
 
Over the first four days of culture, there are two distinct titre profiles generated, separated with 
relation to their seeing density (Figure 55).  Cultures inoculated at 10 x106cell/mL displayed 
titre measurements of 365.3 (n=1) and (410.7±14.9) mg/L for 1x and 2x feed conditions, 
respectively.  These values are in contrast to the vessels inoculated at 2.5 x106cells/mL, where 
titre was achieved as (133.2±6.6) and (123.9±4.5) mg/L for conditions 1x and 2x, respectively. 
Following day four, cultures seeded at 2.5 x 106cells/mL were observed to deviate as the 
feeding condition applied impacted the titre measurement.  The vessels in the 1x feed condition 
continued onto a peak titre measurement of (754.3±20.9) mg/L on day 11, whereas the 2x feed 
condition only reached (276±10.3) mg/L, occurring on day seven. 
For the higher seeding density cultures, higher titre measurements observed on day four was 
continued throughout the remainder of the culture.  A high correlation was observed between 
titre profiles operated at different feed conditions, with both reaching peak titre on day eight, 
985.5, and (972.9±114.4) mg/L for 1x and 2x, respectively. 
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Figure 56 Specific productivity representing the process performance of production phase bench scale 
vessels at 1x and 2x feed condition (Experiment 4.1b) 
Specific productivity plotted against process duration (days); symbols, ■,▲,  and ● represent seeding 
densities (feed condition); 10 (2x), 10 (1x), 2.5 (2x) and 2.5 (1x) x106cells/mL, respectively. (n=2 for each) 
 
The cell specific productivity did not display excessive variation over the first four days, 
however following this point there were distinct trends in performance observed (Figure 56).  
These differences were highlighted by the performance in the 10 x106cell/mL seeding density 
conditions.  Improved specific productivity was observed in the 2x feed condition, with specific 
productivity measurements 5.0 and (6.3±0.4) x10-11 g/cell/day achieved on day nine for feeding 
conditions 1x and 2x, respectively. 
The 2x feed condition also promoted comparable cell specific productivity in the 2.5 x106 
cell/mL seeding density cultures up to day seven.  Specific productivity of (4.3±0.07) and 
(4.0±0.5) x10-11 g/cell/day was observed for the 10 and 2.5 x106cell/mL seeding density 
conditions, respectively.  Furthermore, the cell specific productivity for the 2.5 x106cell/mL 
seeding density condition plateaued as the culture progressed towards harvest, (3.9±0.1) x10-
11 g/cell/day was observed on the final day of culture. 
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Table 6 Percentage monomer post Protein A purification of bench scale cultures at 1x and 2x feed 
conditions 
 
Seeding density (x106 cells/ml) Feed condition Monomer (%) 
10 1x 96.3 (n=1) 
10 2x (95.8±0.3) 
2.5 1x (95.3±0.5) 
2.5 2x (94.6±0.6) 
 
The product quality of the mAb expressed from bench scale cultures was lower than that 
observed for microscale.  However, no significant difference was observed and the monomer 
percentage was > 95% post Protein A purification, indicating no impact on product quality. 
4.3.2 Interim Discussion (Experiment 4.1) 
The microscale perfusion methodology achieved comparable culture Key Performance 
Indicators (KPIs), e.g. maximum viable cell density and specific productivity, to equivalent 
bench scale cultures (Chapter 3).  Despite this comparability, differences existed in the growth 
of cultures in microscale perfusion that is in contrast to the accepted robustness and scalability 
of the ambr® 15 system (Lewis, 2010).  Therefore, experiments have been conducted to 
characterise the method-related impact on culture performance.  This information is critical 
when determining the scalability of process knowledge gained through perfusion operation at 
microscale. 
During Experiment 4.1, a lag in growth was observed between scales (Figure 28).  This lag 
was present in the microscale cultures and resulted in a two day delay in reaching the transition 
criteria (inoculation of production cultures).  These differences are characteristic artefacts of 
the microscale perfusion methodology (Figure 14).  However, the extent of the difference in 
growth is not significant when paired profiles up to the day of the transition of the shortest 
cultures are compared (micro and bench scale cultures to day ten; p-value = 0.10).   
The glucose concentration was maintained in bench and microscale perfusion cultures 
throughout Experiment 4.1.  This resulted in the utilisation of glucose as an energy source, and 
the metabolism of lactate was not deemed critical for energy production.  The residual lactate 
concentrations resulted in a slightly basic biochemical environment for both bench and micro 
scale cultures at the point of transition, respectively.  
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The cellular characteristics of the two scales of perfusion cultures during exponential growth 
were evaluated in the performance of respective subsequent fed batch production cultures.  
Whilst a monoclonal cell line, the act of culturing cell lines generates heterogeneous sub-
population of phenotypes with different functional characteristics (Davies et al., 2013).  The 
hypothesis tested was that the semi-continuous method of perfusion at microscale was 
selectively removing the fast growing phenotypic sub-population of the culture (Stephens & 
Lyberatos, 1987).  The slower growing phenotype would present as a homogeneous population 
and be realised in the measured performance of the resulting production cultures. 
The perfusion cultures were transitioned into production cultures at concentrations between 2.5 
and 15 x106 cells/ml.  These inoculation concentrations were combined with two seeding 
densities that provided examples of sub-optimal nutrient feeding (1x and 2x).  Sub-optimal 
feeding commonly results in a reduction in culture growth, and subsequently mAb 
concentration (Kuwae, Ohda, Tamashima, Miki, & Kobayashi, 2005).  Conversely, optimising 
nutrient supply has been shown to increase viable cell concentration up-to 1.9-fold (Chong et 
al., 2010).  The sub-optimal nutrient environments generated will provide contrasting 
performances that can be replicated across scales and to highlight the holistic method related 
differences in the cultures. 
At microscale the high throughput nature of the ambr® 15 system allowed additional seeding 
densities (5 and 15 x106 cells/ml) to be evaluated for each feed condition.  The peak viable cell 
densities at microscale correlated in magnitude to the culture seeding densities (from lowest to 
highest 2.5, 5, 10, and 15 x106 cells/ml).  A significant difference (p-value <0.05) was observed 
between each paired profile.  Microscale cultures were harvested due to a decline in viability 
on days ten and seven, for feed conditions 1x and 2x, respectively.   
The bench scale 1x condition entered exponential growth when inoculated at seeding densities 
2.5 and 10 x106cells/ml.  The cultures achieved peak viable cell density on days seven and five, 
for seeding densities 2.5 and 10 x106cells/ml, respectively.  In the 10 x106cells/ml seeding 
density, peak viable cell densities of (18.99±0.36) and (29.6±0.00) x106cells/ml, were observed 
for micro and bench scale cultures, respectively.  In the 2.5 x106 cells/ml seeding density, peak 
viable cell densities of (10.37±0.80) and (20.0±0.01) x106cells/ml were observed for micro and 
bench scale cultures, respectively. These peak cell densities at bench scale were significantly 
higher than those observed for microscale cultures.   
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Exponential growth was not observed in any microscale cultures operated with 2x feed 
conditions.  Within bench scale cultures the 10 x106cells/ml seeding density culture was 
observed to grow exponentially with 2x feed conditions following inoculation.  The peak viable 
cell density of (25.2±0.3) x106cells/ml was observed. 
The higher feed condition (2x) resulted in shorter culture durations when compared to the 1x 
cultures.  This feed criteria for 2x is inherently sub-optimal and in excess of what is required 
by the culture.  The microscale operation of the 2x condition was uniform in its duration, 
harvesting after seven days due to a decrease in viability below 60%.  This uniform 
performance and short culture duration are indicative of a singular phenotype contained within 
these cultures.  The maintenance of a stationary phase over a prolonged duration indicates 
subpopulations growing and offsetting the non-viable cells present in the culture.  Therefore, 
the short culture duration is an indication of low population variance in the phenotypes present.   
The performance of the two 2x conditions at bench scale was not comparable in growth.  The 
2.5 x106 cells/ml inoculated culture was observed to enter exponential growth.  When 
compared to the respective condition at microscale, this culture appeared to have an ability to 
utilise the high nutrient environment presented by the 2x condition and exhibited an extended 
culture duration. 
Differences were also observed in the lactate profiles between microscale and bench scale 
cultures.  An elevation in lactate concentration was observed on the first day post inoculation 
for all microscale cultures.  An approximate three-fold increase in lactate concentration was 
observed across all microscale cultures, during or following peak viable cell density.  This 
accumulation of lactate is documented in mammalian bioprocessing and occurs as 
mitochondrial metabolism alters during the transition from exponential growth to stationary 
phase (Zagari et al., 2013).  It is stated that whilst lactate production is prevalent during 
exponential growth, the oxidative metabolism of the cell prevents its accumulation, and thus in 
the stationary phase the level of oxidation is decreased and resulting accumulation occurs. 
Similar trends in lactate concentrations were observed in three of the four bench scale cultures.  
One bench scale culture (2.5 x106 cells/ml, 1x feed condition) did not display this increase in 
lactate concentration towards the end of exponential growth.  Literature investigating the 
expression of anti-apoptotic genes has highlighted the impact their absence has on lactate 
concentrations within a culture (Dorai et al., 2009) 
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When evaluating the impact of the 2x feed condition on cultures (micro and bench scale), it 
appears the increased nutrient availability has accelerated cellular processes into a stationary 
phase.  This is observed in the accumulation of lactate from day four onwards, and the elevation 
in cell specific lactate production both shortly after inoculation and again from day four 
onwards.  Published work states that an abundance of glutamine within the feed composition 
could promote the lactate production metabolism pathways (Zagari et al., 2013), indicating the 
potential source of sub-optimal performance.   
In conclusion, the sedimentation method applied to the ambr® 15 microscale system to achieve 
perfusion produces unique physiochemical conditions for cultures (Section 3.2 Method 
Development).  The production cultures derived from these unique microscale physiochemical 
conditions have decreased performance when compared to bench scale counterparts.  
Additionally, under sub-optimal production culture conditions, lower variation in performance 
is observed in microscale cultures compared to bench scale cultures.    
As previously discussed, during cell sedimentation in microscale perfusion, the culture is being 
exposed to locally extreme pH and DO saturation.  In addition, to operate the method there are 
discrete media exchange steps that will produce a fluctuating nutrient exposure.  This discrete 
media exchange will ultimately result in oscillating variation in the dilution rate applied to the 
culture.  Therefore, it is important to understand if the performance observed in Experiment 
4.1 is due to inherent sensitivity to the dilution rate/supply of nutrients to the cultures or if the 
method of perfusion is generating selective pressure on the culture impacting sub-population 
expansions.  
Experiment 4.2 focused on understanding the cell line’s response to a reduced dilution rate.  
This was conducted exclusively at bench scale utilising the ATF perfusion technology to 
achieve high accuracy in the dilution rate applied. 
4.3.3 Experiment 4.2 Culture Response to Reduced Dilution Rate 
Experiment 4.2 evaluated the impact of dilution rate on perfusion culture performance.  This 
was conducted in a similar fashion as Experiment 4.1, by conducting subsequent evaluations 
of production fed-batch vessels with cells derived from the perfusion cultures.  The 
consideration of the transition operation between perfusion and production (fed-batch) 
inoculation was simplified in comparison to that outlined, in Section 4.2.1 Transition of 
Cultures From Perfusion to Production.   
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Each perfusion vessel operated within Experiment 4.2 was an independent experimental 
condition and thus, was used to inoculate the respecting duplicate production vessels. This was 
performed without the requirement for the pooling of multiple cultures before inoculation. 
4.3.2.1 Perfusion Expansion 
Experiment 4.2 was initiated with the inoculation of three bench scale perfusion vessels, at the 
target seeding density of 0.8 x106 cells/mL.   
Previous perfusion evaluations of Cell line 1 indicated glucose concentrations decreasing 
below 1g/L on the fourth day (Figure 21 and Figure 29).  Therefore, in Experiment 4.2 
perfusion was initiated on the third day of culture for all vessels.  This action mitigated the risk 
of the culture experiencing a glucose limited environment. 
 
Figure 57 Viable cell density (x106 cells/mL) representing the process performance of the n-1 phase 
vessels in Experiment 4.2 
Values are plotted against process duration (days); symbols and ●, ▲ and  ■ represent dilution rates 1.0, 0.75, 
and 0.5 VVD, respectively.  Single vessels were operated at each dilution rate. Perfusion initiation is indicated 
with an intersecting blue line. 
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The cultures displayed comparable growth over the initial three day batch period, with average 
cell density increasing in number and variability between days two and three, (3.1±0.2) and 
(5.8±0.1) x106cells/mL, respectively (Figure 57). 
Following the initiation of perfusion (indicated in Figure 57 with an intersecting blue line) a 
separation was observed in the growth profiles of Cell line 1.  The perfusion operation resulted 
in a variation in the growth profile based on the dilution rate.  Dilution rates 1.0 and 0.5 VVD 
reached criteria for the transition on day eight, with values of 53.5 and 55.0 x106cells/mL, 
respectively.  The 0.75 VVD dilution rate experienced a lag in growth between days four and 
six when compared to 1.0 and 0.5 VVD dilution rates.  The criteria for the transition were not 
met until day nine for the 0.75 VVD dilution rate, 49.7 x106cells/mL. The 0.75 VVD condition 
was an example of a mid-point dilution rate, between the other high and low conditions in 1.0 
and 0.5 VVD, respectively.   
No variation was observed in the viability of the cultures as, throughout the n-1 perfusion step, 
viabilities did not drop below 97% in any condition. 
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Figure 58 Glucose concentration (g/L) representing the process performance of the n-1 phase vessels in 
Experiment 4.2  
Values are plotted against process duration (days); symbols and ●, ▲ and  ■ represent dilution rates 1.0, 0.75, 
and 0.5 VVD, respectively.  Single vessels were operated at each dilution rate. Perfusion initiation is indicated 
with an intersecting blue line. 
 
Observed over the first three days of culture, is a gradual depletion of glucose concentration as 
the cells consumed the residual glucose concentration over the batch phase (Figure 58).  The 
average glucose concentration in all cultures on day three before perfusion initiation was 
(1.5±0.3) g/L.   
Following the initiation of perfusion, the culture concentration of glucose was increased to a 
peak, experienced on day five.  The dilution rate could be implied from the resulting glucose 
concentration with 1.0 VVD, 0.75 VVD and 0.5 VVD measured at 8.95, 8.10, and 5.03, g/L, 
respectively.  The glucose concentration gradually decreased as cultures progressed towards 
the transition to production cultures. 
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Figure 59 Lactate concentration (g/L) representing the process performance of the n-1 phase vessels in 
Experiment 4.2  
Values are plotted against process duration (days); symbols and ●, ▲ and  ■ represent dilution rates 1.0, 0.75, 
and 0.5 VVD, respectively.  Single vessels were operated at each dilution rate. Perfusion initiation is indicated 
with an intersecting blue line. 
 
Lactate levels were low across all cultures at inoculation, <0.5g/L across all cultures.  Cell line 
1 lactate concentration was maintained at a low level over the first two days, with values 
measured 0.31, 0.42, and 0.41 g/L for dilution rates 1.0, 0.75, and 0.5, respectively.  On day 
three, and the last day of batch growth before perfusion initiation, lactate concentrations 
increased stepwise to >1g/L where they were maintained until day eight when they reduced 
back to <1g/L. 
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Figure 60 pH representing the process performance of the n-1 phase vessels in Experiment 4.2  
Values are plotted against process duration (days); symbols and ●, ▲ and  ■ represent dilution rates 1.0, 0.75, 
and 0.5 VVD, respectively.  Single vessels were operated at each dilution rate. Perfusion initiation is indicated 
with an intersecting blue line. 
 
The pH is observed to remain close to setpoint (pH 7.2±0.1) over the initial three days of batch 
growth.  Following the initiation of perfusion, pH was seen to decrease, in line with the lactate 
accumulation detailed in Figure 59. 
The decrease in pH was not consistent across Cell line 1 cultures, and the transient 
accumulation, consumption, and dilution of lactate within the vessel caused fluctuations in the 
pH through to the point of transition into production cultures.  Transition to production culture 
for Cell line 1 occurred with pH within the 7.2±0.1 setpoint, in all dilution rates. 
4.3.2.2 Production Phase 
The perfusion culture dilution rates (1.0, 0.75, and 0.5 VVD) applied to Cell line 1 cultures 
were evaluated in production cultures.  These production cultures were operated at the 1x feed 
condition and 10 x106cells/mL seeding density.  These conditions represented the best 
performance in bench scale with relation to cell growth and titre from Experiment 4.1. 
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Figure 61 Viable cell density (cells/mL) representing the process performance of the production phase 
vessels in Experiment 4.2 
Viable cell density measurements are plotted against process duration (days); symbols and ●, ▲ and  ■ 
represent dilution rates 1.0, 0.75, and 0.5 VVD, respectively (n=2). 
 
The growth of cultures within production vessels presented comparability in the different 
dilution rates employed in the perfusion cultures (Figure 61).  Inoculation of production phase 
cultures was successfully conducted to the target seeding density. All cultures appeared to 
progress concurrently towards a peak viable cell density, reaching it on consecutive days.  Peak 
viable cell densities were (38.4±3.4, day seven), (41.1±5.2, day five) and (49.9±4.7, day six) 
x106cells/mL for 0.5, 0.75 and 1.0 VVD dilution rate cultures, respectively. 
Following these peaks, viable cell density decreased to the point of culture harvest that was 
met on day 10, for 1.0 VVD cultures and day 11 for 0.5 and 0.75 VVD cultures, respectively.  
As conducted for Experiment 4.1, the culture harvest criteria were set to be when viability 
reached <60%.   Viable cell density at harvest was (20.3±0.0), (23.3±0.4) and (27.9±1.1) 
x106cells/mL for 0.5, 0.75 and 1.0 VVD dilution rate cultures, respectively. 
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Figure 62 Viability (%) representing the process performance of the production phase vessels in 
Experiment 4.2 
Viability (%) measurements are plotted against process duration (days); symbols and ●, ▲ and  ■ represent 
dilution rates 1.0, 0.75, and 0.5 VVD, respectively (n=2). 
 
High culture viability (>97%) was maintained from inoculation through the first five days of 
culture (Figure 62).  This high viability was coupled with the culture expansion to peak viable 
cell density, presented in Figure 57, and as the cultures surpassed peak viable cell 
concentration, viability began to decline.   
The decline in viability was first observed on day six.  Viability decreased from >97% to 
(95.9±0.0), (93.1±3.0) and (93.9±1.1) % for 0.5, 0.75 and 1.0 VVD dilution rate cultures, 
respectively.  Starting from day seven, the viability for 1.0 VVD cultures varied when 
compared to 0.5 and 0.75 cultures, with observed viability of (76.5±4.4) compared to 
(91.3±3.0) and (92.7±2.4), respectively.  This increased rate of decline was slowed and culture 
duration was only shortened by one day (day 10 post inoculation), in comparison to the other 
dilution rates (day 11 post inoculation).  
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Figure 63 Glucose concentration (g/L) representing the process performance of the production phase 
vessels in Experiment 4.2 
Glucose concentration (g/L) measurements are plotted against process duration (days); symbols and ●, ▲ and  
■ represent dilution rates 1.0, 0.75 and 0.5 VVD, respectively (n=2). 
 
In contrast to the cultures conducted throughout Experiment 4.1, glucose concentrations spent 
a substantial period of time below 2g/L in Experiment 4.2a (Figure 63).  This control below 
2g/L occurred from day four onwards, coinciding with the highest culture cellular content, 
around the peak viable cell concentration (Figure 61).   
The fed batch target concentration to feed glucose back into the cultures appeared to be 
insufficient to maintain a daily concentration above 2g/L.  This ineffective control resulted in 
a high chance of cultures experiencing a temporary glucose limited environment.  This low 
glucose environment was observed concurrently across all cultures.  Therefore, the 
comparative analysis of the performance of different cultures’ respective responses is valid 
when analysed in this isolated experiment.  
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Figure 64 Lactate concentration (g/L) representing the process performance of the production phase 
vessels in Experiment 4.2 
Lactate concentration (g/L) measurements are plotted against process duration (days); symbols and ●, ▲ and  
■ represent dilution rates 1.0, 0.75 and 0.5 VVD, respectively (n=2). 
 
The lactate concentration of cultures was observed to rise in all cultures to an initial peak on 
day two (Figure 64).  The overall profile observed for culture lactate concentration aligns with 
that experienced in Experiment 4.1b (Figure 53). The lactate concentration on day two was 
(2.2±0.04), (2.0±0.1) and (1.9±0.1) g/L and decreased to concentrations on day five of 
(0.4±0.4), (0.2±0.0) and (0.2±0.1) g/L for dilution rates 0.5, 0.75 and 1.0 VVD, respectively. 
The lactate concentration peaked as culture viability decreased over the final days of culture.  
This peak was in excess of that displayed on day two.  Cultures operated in the 1.0 VVD 
dilution rate condition appeared to initiate this increase in lactate concentration on day seven, 
where 0.75 and 0.5 VVD cultures presented at days eight and nine, respectively. 
Lactate concentration at harvest was (5.6±0.0), (7.7±1.1), and (8.2±4.4) g/L for cultures 
operated at dilution rates 0.5, 0.75, and 1.0 VVD, respectively.  The pH of cultures was 
controlled within the ±0.1 deadband around setpoint 7.2. 
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Figure 65 Dissolved oxygen (%) representing the process performance of the production phase vessels 
in Experiment 4.2 
Dissolved oxygen (%) measurements are plotted against process duration (days); symbols and ●, ▲ and  ■ 
represent dilution rates 1.0, 0.75, and 0.5 VVD, respectively (n=2). 
 
Over the first four days, dissolved oxygen saturations were maintained to setpoint (50%) with 
the combination of culture agitation and sparged oxygen on demand (Figure 65).   
On day five, dissolved oxygen saturation was observed to decline to (35.0±5.8) % for cultures 
operated from the 0.75 VVD dilution rate.  This decline was then observed on day six in the 
0.5 and 1.0 VVD dilution rate cultures, with values reported (42.1±0.8) and (46.4±1.6) %, 
respectively. 
A combination of factors contributed to these declines.  The culture total demand for oxygen 
is inherently linked to the exponential expansion of the culture.  This was increasing during 
days five and six as cells grew exponentially towards max viable cell density (Figure 61).  This 
high oxygen demand was coupled with the addition of antifoam, decreasing the surface oxygen 
transfer and requiring additional input of the process control to maintain the saturation setpoint.  
The process control strategy for oxygen saturation requires operator input to incrementally 
increase the agitation rate of the culture as maximum sparging rates are experiences.  A delay 
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in this operator interaction was experienced during days five and six, however once culture 
agitation rate was increased, the control strategy re-established dissolved oxygen saturation to 
the setpoint.  This was maintained for the remainder of the culture duration. 
 
Figure 66 Cell specific glucose consumption rate (g/cell/day) representing the process performance of 
the production phase vessels in Experiment 4.2 
Cell specific glucose consumption rate (g/cell/day) measurements are plotted against process duration (days); 
symbols  and ●, ▲ and  ■ represent dilution rates 1.0, 0.75 and 0.5 VVD, respectively (n=2). 
 
Variation is observed in the cell specific glucose consumption rates during the first two days, 
and through the seventh to ninth days of cultures (Figure 66). The specific glucose consumption 
rates were comparable through the exponential growth to the maximum viable cell density 
(days three to six).   
Average cell specific glucose concentrations observed on day four matched that at the end of 
the culture (day ten) with values (4.4±0.8) and (3.9±0.6) x10-11g/cell/day, respectively. 
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Figure 67 Titre (g/L) representing the process performance of the production phase vessels in 
Experiment 4.2 
Titre (g/L) measurements are plotted against process duration (days); symbols  and ●, ▲ and  ■ represent 
dilution rates 1.0, 0.75 and 0.5 VVD, respectively (n=2). 
 
All cultures were observed to increase titre over process duration up to a peak at day eight, 
with (1019±143), (1102±64) and (977±15) mg/L, for dilution rates 0.5, 0.75 and 1.0 VVD, 
respectively (Figure 67). 
The cultures operated from the 0.5 VVD perfusion vessel displayed a lag in the production of 
mAb over the first two days.  The profile across the full culture duration was significantly lower 
when paired with the 0.75 VVD perfusion derived cultures (P<0.05).  Additionally, the 0.75 
VVD cultures displayed an increase in titre on day five, where titre measurements thereafter 
were observed to slowly increase to their maximum on day eight.  This deviation from the 
profile presented by 1.0 VVD culture is significantly different when averaged paired 
measurements are compared (p<0.05).  Interestingly, the titre values for the highest dilution 
culture (1.0 VVD) fell between the other two dilution rate cultures and displayed no significant 
difference with the lowest dilution culture (0.5 VVD, p-value=0.36), indicating comparability 
between cultures.   
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Figure 68 Cell specific productivity (g/cell/day) representing the process performance of the production 
phase vessels in Experiment 4.2 
Cell specific productivity (g/cell/day) measurements are plotted against process duration (days); symbols and 
●, ▲ and  ■ represent dilution rates 1.0, 0.75, and 0.5 VVD, respectively (n=2). 
 
Specific productivity measurements for all cultures were observed to increase linearly 
throughout the process duration (Figure 68).  During the exponential growth and at maximum 
viable cell density, day four and eight respectively, the cultures presented higher specific 
productivity in the 0.75 VVD dilution rate cultures compared with equivalent 0.5 and 1.0 VVD 
cultures.  Specific productivity for 1.0 VVD cultures was consistently lowest throughout the 
second half of the culture. The observed specific productivity measurements at harvest were 
(3.0±0.1), compared with (4.5±0.0) and (3.9±1.8) x10-11 g/cell/day, for 0.5 and 0.75 VVD 
cultures, respectively.   
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Table 7 Percentage monomer post Protein A purification of production cultures at harvest, inoculated 
with cells from perfusion cultures of respective dilution rates (Experiment 4.2) 
 
Dilution Rate (VVD) Monomer (%) 
1.0 (96.1±2.6) 
0.5 97.9 (n=1) 
0.75 (95.6±2.4) 
 
Finally, the product quality of the mAb expressed from Cell line 1 was not observed to be 
impacted by the dilution rate.  Monomer percentage observed post Protein A purification was 
greater than 96% for all dilution rate cultures (Table 7). 
4.4 Discussion 
Within Experiment 4.1, differences were observed in the performance of microscale production 
cultures that had previously been cultured in the microscale perfusion methodology when 
compared to bench scale, ATF perfusion derived cultures.  In a dynamic cell culture 
environment such as perfusion, it is challenging to isolate individual elements contributing to 
the observed performance differences.  
One of the nuances of the microscale perfusion sedimentation methodology is an oscillating 
supply of nutrients to the culture.   If this element was a contributing factor, an inherent 
sensitivity of the cell line performance to dilution rates may be observed when studied in 
isolation.  Therefore, Experiment 4.2 focused on understanding the cell line’s response to 
reduced dilution rate.  This was conducted exclusively at bench scale utilising the ATF 
perfusion technology to achieve high accuracy in the dilution rate applied. 
All perfusion cultures (dilution rates 0.5, 0.75, and 1.0 VVD, respectively) established 
exponential growth during the initial batch phase.  This continued through the operation of the 
perfusion cultures, before inoculation of production cultures.   
The dilution rates are observed in the glucose concentrations present in the cultures 
immediately after perfusion was initiated. The higher dilution rates supply larger quantities of 
glucose, in addition to the other key metabolites.  The lactate concentrations for all cultures 
were observed below 2g/L for the duration of the perfusion step, indicating exponential growth 
was maintained throughout the culture duration. 
The highest and lowest dilution rates (1.0 VVD and 0.5 VVD, respectively) both reach the 
criteria for the transition by the eighth day post inoculation.  The 0.75 VVD perfusion condition 
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lagged behind the other conditions and took an additional day to reach criteria for transition, 
day nine.  No indication for the reasons behind this lag in culture growth was observed in any 
of the measured parameters.  The alignment of the higher (1.0VVD) and lower (0.5VVD) 
dilution rate culture performances suggest that it is not related to the dilution rate applied.  
Perfusion cultures all experienced very high culture viability percentages throughout their 
operation (>98%).   
The production phase vessels were successfully inoculated with the respective perfusion 
cultures.  Culture growth performance was comparable to that achieved in the respective bench 
scale cultures in Experiment 4.1.  The cultures grew exponentially to day seven, followed by a 
stationary phase, and harvest on day 11.  Peak viable cell densities were not significantly 
different (p-value > 0.05 ), (38.4±3.4, day seven), (41.1±5.2, day five) and (49.9±4.7, day six) 
x106cells/mL for 0.5, 0.75 and 1.0 VVD dilution rate cultures, respectively. 
All cultures were observed to increase titre over process duration up to a peak at day eight, 
with (1019±143), (1102±64) and (977±15) mg/L, for dilution rates 0.5, 0.75 and 1.0 VVD, 
respectively (Figure 67). 
This comparability in growth and productivity across dilution rates indicates no sensitivity to 
dilution rate was observed for Cell line 1.  Potential causes for micro scale performance 
differences, compared with bench scale, may be attributed to a sensitivity to the unique 
physiochemical characteristics present during the sedimentation process, specifically pH, DO, 
and a loss of culture agitation.   
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Chapter 5 The Evaluation of Fed-Batch Culture Performance in 
Response to Targeted Parameter Deviation Before and After 
Controlled Inoculation   
5.1 Introduction 
Transfected, monoclonal CHO cell lines exhibit cell line specific traits and sensitivities that are 
evaluated during bioprocess development.  This is conducted by evaluating critical process 
parameters (CPPs) and operation ranges through the Quality by Design (QbD) manufacturing 
principles (Looby et al., 2011).  The QbD approach leads to a wealth of information generated 
on the process robustness and the relative impact on Critical Quality Attributes (CQAs) (A. S. 
Rathore, 2009; Anurag S. Rathore & Winkle, 2009). 
In this risk averse environment, the QbD approach will narrow the operational window; starting 
from a wide knowledge base gained through iterative investigation, to a smaller investigative 
space.  The approach concludes with a tightly defined operational window specific to the 
product (Read et al., 2010).  This approach safeguards the manufacturing process steps by 
defining product specific CPP operational ranges.  Operation of the process within defined 
ranges ensures CQAs are achieved (Nagashima, Watari, Shinoda, Okamoto, & Takuma, 2013).   
Fed batch bioprocessing exposes the cultures to a progressive evolution of cell cycles.  Cultures 
are assumed to grow exhaustively and transition into stationary and death phases (Selvarasu et 
al., 2012).  The CPP operational range is evaluated from inoculation to harvest.  Therefore, this 
is defined by the phase of operation that exhibits the highest sensitivity to variation or assumes 
a constant response to variation throughout the culture progression.  By simplifying the process 
in this manner it enables a single operational window to be defined for each CPP, aligning with 
QbD principles. 
Continuous culture operation differs from fed-batch in the sense that it exists primarily in one 
phase of operation (exponential growth) and culture success is defined by performance within 
this one phase, rather than across the progression of fed batch operation (Clincke et al., 2013). 
Therefore, the culture’s longevity is enhanced by the application of control strategies specific 
to the exponential phase, rather than considering the culture characteristics present during 
inoculation and stationary/decline phases, respectively. 
Observed through experimental evaluations in Chapters 3 and 4 is strict adherence to pH 
setpoint during inoculation (Figure 20, Figure 32, Figure 54 & Figure 60).  The fluctuations 
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discussed in gravity cell settling and perfusion occur once the cultures had established 
exponential growth, past an initial phase of batch growth (three to four days). 
The experiments and discussion presented within this chapter aim to understand the cell line 
sensitivities present within the progressive phases of operation of fed batch culture.  This will 
inform the creation of CPP control strategies for continuous cultures that emphasises the 
importance of appropriate control of the exponential growth phase of operation. 
Additionally, due to the extended duration of continuous culture, cell line sensitivities that may 
present through extended operation are investigated.  These may exist from the high culture 
age generated or through exposure to high nutrient environments (Frye et al., 2016).  The cell 
line responses are investigated both in isolation and included in the evaluation of phase 
sensitivity for a comprehensive understanding of sensitivity. 
5.2 Materials, Methods and Experimental Designs 
This chapter contains two independent experiments, 5.1 and 5.2.  These experiments were 
both conducted as fed-batch operated ambr®15 systems, in the 24 and 48 vessel system 
variants for 5.1 and 5.2, respectively. The materials and methods are presented in Chapter 2, 
with exceptions specifically noted.   
5.2.1 Generation of Cell Banks 
Three distinct cell banks were generated by the controlled expansion of cells revived from 
DCB1.  These three cell banks are defined as DCB2, DCB3, and DCB4.  The expansion of 
DCB1 and the creation of these cell banks are presented in Section 5.3.1 Preliminary Data, 
Cell Bank Generation. 
5.2.2 Experiment 5.1 
Experiment 5.1 contains two distinct experimental designs, Experiment 5.1a, and 5.1b.  These 
were conducted simultaneously on culture stations (CSs) one and two of an ambr®15 system 
(24 vessel variant), respectively.   
In Experiment 5.1a, each condition inoculated in triplicate.  The conditions were defined by 
the use of inoculum derived from the 4 independent cell banks of Cell Line 1 (Section 5.2.1 
Generation of Cell Banks). 
DCB1 represents the controlled expansion of inoculum from a frozen vial, with minimal 
generation number accumulation as would be designed in the process description of 
commercial fed batch bioprocess.  DCB2 is an extension of this inoculum expansion over a 
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period of >100 generations, providing an upper limit or “manufacturing window” for the 
operation of a commercial bioprocess.  The suitability of this ‘manufacturing window’ is 
determined by the cultures maintenance of Key Performance Indicators (KPIs) (Alvin & Ye, 
2014).  
DCB3 and DCB4 represent the preparation of an inoculum utilising continuous methods, both 
in the exposure to an enriched medium environment (DCB3) and the extension of the 
generation numbers beyond the ‘manufacturing window’ (>120 generations, DCB4).  All 
cultures within CS1 are operated at the experimental set points for Cell line 1, as detailed in 
Chapter 2. 
Experiment 5.1b was inoculated with cells from a vial expanded from DCB1.  The focus of the 
experiment was to observe the differences in the cell line's response to changes pH, occurring 
during inoculation or exponential growth.  Presented in the operation of Cell line 1 through 
Chapters 3 and 4 is an insensitivity to pH variation (>0.4 units) that conflicts expected 
sensitivity of >0.1 units deviation from setpoint (Brunner, Fricke, et al., 2017).   
Four pH conditions were evaluated in triplicate. Three of these conditions were operated from 
inoculation through to harvest.  They are referred to as ‘Basic’, ‘neutral’, and ‘Acidic’, defined 
by a target pH of (7.2±0.1), (7.0±0.1) and (6.8±0.1), respectively. The fourth condition was 
inoculated at pH (7.2±0.1), and the pH setpoint was reduced to (6.8±0.1) as the culture 
progressed through exponential growth.  This fourth condition is referred to as ‘drift’.  A 
detailed outline of pH setpoint and cell bank used for inoculation is provided below, Table 8.   
Table 8 Experimental conditions for vessels in Experiment 5.1 
The conditions were conducted in triplicate vessels (V), and the cell bank and pH control setpoints are outlined. 
  
  Experiment 5.1a Experiment 5.1b 
 V1, 2 &3 V4, 5 &6 V7, 8 &9 V10, 11&12 V1, 2 &3 V4, 5 &6 V7, 8 &9 V10, 11 &12 
Inoculum 
Cell Bank 
DCB1 DCB2 DCB3 DCB4 DCB1 DCB1 DCB1 DCB1 
pH setpoint, 
at inoculation 
(7.2±0.1) (7.2±0.1) (7.2±0.1) (7.2±0.1) (7.2±0.1) (7.0±0.1) (6.8±0.1) (7.2±0.1)  
pH setpoint, 
at exponential 
growth 
(7.2±0.1) (7.2±0.1) (7.2±0.1) (7.2±0.1) (7.2±0.1) (7.0±0.1) (6.8±0.1) (6.8±0.1) 
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5.2.3 Experiment 5.2  
During the inoculation of Experiment 5.2, the optimal pH, dissolved oxygen, and temperature 
setpoints for Cell line 1 (detailed in Chapter 2) were applied to all vessels within an ambr 
48® system.  Following successful inoculation and transition into exponential growth, the 
experimental conditions were applied (Table 9).  As an extension to the investigation of pH in 
Experiment 5.1b, Experiment 5.2 explores unexpected variation occurring during the 
exponential growth phase in order to understand potential impacts on culture longevity in a 
continuous setting.  Understanding of the impacts and potential sources of variation will 
allow control strategies to be adapted to safeguard bioprocess operation. 
Additional context of how these elements of variation may occur in a controlled system is 
provided (Table 9) as they are classified as ‘equipment failure’ (EF) or ‘operator error’ (OE). 
Table 9 Experiment 5.2 Conditions and the Classification of the Source of Variation 
Equipment Failure (EF) and Operator Error (OE) are defined for each condition, respectively.  The conditions 
were replicated in four culture stations of an ambr®15 48-variant system 
 
Vessel # Process variation Classification 
1 Control condition N/A 
2 pH drift upwards  EF 
3 pH drift downwards EF 
4 Dissolved Oxygen 30% EF 
5 Double antifoam addition OE 
6 Dissolved Oxygen 40% EF 
7 Triple antifoam addition OE 
8 DCB3 Inoculated OE 
9 DCB3 Inoculated OE 
10 Dissolved Oxygen 60% EF 
11 Control condition N/A 
12 Dissolved Oxygen 70% EF 
5.2.3.2 Equipment Failure (EF) 
5.2.3.2.1 pH 
In vessels 2 and 3, a fluctuating pH profile was generated to simulate the failure of a pH probe.  
Probes were simulated to drift either upwards or downwards from the operational setpoint over 
a period of 24 hours.  This drift was corrected back to setpoint at the end of each 24 hours, as 
would occur during routine daily maintenance. 
This simulation was conducted by instructing the top deadband to cycle through an increase or 
decrease of 0.1 units every 24 hours.  These steps were repeated for the duration of the 
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experiment from day 2 onwards.  After successful inoculation at setpoint (7.2±0.1), this 
condition acted on the culture's exponential growth phase and continued into stationary, and 
death phases. 
5.2.3.2.2 Dissolved Oxygen (DO) 
In vessels 4, 6, 10, and 12 on each of the four culture stations, dissolved oxygen (DO) setpoint 
to control at 30, 40, 60, and 70%, respectively.  This was performed to simulate an incorrectly 
calibrated DO probe.  Culture oxygen consumption from the saturated environment at 
inoculation will gradually decrease levels to the defined setpoints.  Therefore, the impact of 
this condition was not represented by cultures until 24-48 hours post inoculation, when the 
saturation levels stabilise at setpoint. 
5.2.3.2.3 Temperature 
The impact of hypothermic temperature shifts has been extensively studied for mammalian 
bioprocessing during or after exponential growth (Bastide et al., 2017; Birch & Racher, 2006; 
Gomez et al., 2012; Kaufmann et al., 1999).  Therefore, within Experiment 5.2 on each of the 
conditions outlined in Table 9, hyperthermic stress was investigated during late exponential 
growth.  
The hyperthermic temperature condition was achieved through the removal of the active 
cooling system of the ambr® system on day 12.  The measured culture temperature displayed 
an increase to >38°c for all cultures, maintained over 24 hours. 
5.2.3.3 Operator Error 
5.2.3.3.1 Antifoam 
The control level addition of antifoam (20µl per vessel) was provided to each condition every 
48 hours, starting from day two onwards.  Vessels five and seven on each culture station 
received additional antifoam additions, 20µl (double) and 40µl (triple), respectively. This was 
performed to simulate miscalculation and over-addition of antifoam into the reactor.  
5.2.3.3.2 Exposure to Continuous Culturing Environment 
Vessels 8 and 9 utilised an inoculum of cells from DCB3.  As detailed above (5.2.1 Generation 
of Cell Banks), this cell bank was generated through exposure to a continuous culture 
environment, prior to cryopreservation.  This condition provides an example of the 
performance of an exponential phase from a culture operated through a continuous method. 
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This variation occurring before inoculation may occur either by error or by design.  In error, 
the selection of the wrong medium components or raw material impurities may lead to exposure 
of the cells to enriched medium prior to inoculation.  By design, the utilisation of continuous 
bioprocessing methods in the inoculum expansion (as detailed in Chapter 4), will expose the 
cells to enriched medium environment prior to their production vessel inoculation.  
5.2.3.4 Data Analysis 
During Experiment 5.1, conditions are conducted in triplicate, and data is reported as means 
and standard deviations (SDs), provided in the format mean ± SD.  Paired or unpaired two 
tailed t-tests were used, where appropriate, to determine significance between conditions. 
In Experiment 5.2, the growth performance of the two control vessels per CS (vessels 1 and 
11) was analysed with respect to each other.   No variation was seen in control vessels across 
culture stations in the same position within their respective culture station. In addition, a 
significant difference (p-value < 0.05) was seen in the profiles of viable cell densities of control 
vessels within the same CS (vessels 1 and 11), throughout the experiment.  Variation within 
each culture station is highlighted as no variation is seen between biological replicates in vessel 
positions nearby (vessel 8 and 9) on each culture station.   
Vessels of the same condition across cultures stations are reported as replicates (n=3) and 
reported as means and standard deviations (SDs), provided in the format mean ± SD.  
Comparisons of significance against control are made between conditions and respective 
control vessel given the position; in either the first half (vessels 1 to 6; control from vessel 1) 
or the second half (vessels 7 to 12; control from vessel 11) of the CSs.  Assessment of 
significance is made by one-way ANOVA, significance reported where P < 0.05.   
The fourth culture station was omitted from the analysis as a programming error caused 
experimental variation in the temperature control when compared to the other three replicate 
culture stations. 
5.3 Results 
5.3.1 Preliminary Data, Cell Bank Generation 
In DCB2 (high generation cell bank), cells were revived and passaged in basal medium twice 
to three times weekly, over a period of 102 days.  Over this time the generation numbers were 
tracked and upon exceeding 100 generations a cell bank was laid.  This cell bank consisted of 
10 vials cryopreserved at 1 x107 cells/vial, in basal medium containing 10% DMSO. 
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The sawtooth plot of this expansion is presented in Figure 69, providing a visual representation 
of the viable cell density achieved at each passage.  The vertical lines of the sawtooth link each 
viable cell density to the seeding density of the following passage.   
 
Figure 69 Saw-Tooth plot of the expansion of DCB1 in the generation of DCB2 
Viable Cell Density (cell/mL x105) (right axis, solid red line), Viability (%) (left axis, dashed black line) and 
Cumulative Generation Number (left axis, solid black line) are plotted against Duration (days) 
 
The viability of the cultures presented in Figure 69 was consistently maintained above 95% 
viability for the duration of the expansion.  The average viable cell density reached at 
subculture was (33±13) cell/mL x105.  The reproducible viability and cell density achieved in 
repeated subculture as cell generation numbers increased highlights the ability of the cultures 
to reproducibly enter exponential growth following inoculation.   
For DCB3 (Enriched medium exposure cell bank), cells were revived and passaged in basal 
medium prior to inoculation into a 3L STR vessel (1.5L working volume).  This vessel was 
equipped to remove the culture (cells plus spent medium) through a dip-tube, installed onto the 
head-plate of the vessel.  Any removed culture was replaced with fresh medium to maintain 
the 1.5L working volume.  Cells were grown in batch over the first four days of culture, without 
any medium removal/replacement.  On day five of culture, the dilution rate of the vessel was 
initiated and was maintained between 0.36 and 0.45 VVD, until DCB3 was cryopreserved. 
During inoculation, the volume in the vessel was comprised of basal medium.  Basal medium 
was used for media exchange over the initial 20 days of culture dilution and the culture 
averaged a cell density of (6.4±1.4) cell/mL x106 was observed.  Whilst variation is present in 
the viable cell density measurements, a steady state is determined to be established during this 
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20 day period.  The enriched medium formulation was connected on day 26 of culture.  Due to 
unforeseen challenges with media availability, the culture was required to return to basal media 
exposure whilst replacement enriched media was prepared.  The culture existed in enriched 
media for 10 days followed by seven days in basal media before returning to enriched media 
exposure. 
On day 42 of culture, the enriched medium was connected to the exchange for a second time 
and the culture was operated with this medium formulation for a 20 day period as per the initial 
basal media exposure.  The cells were cryopreserved on day 62.  The respective viable cell 
concentration and viability obtained from the culture is presented in Figure 70, below. 
 
Figure 70 The expansion of DCB1 within a continuous bioprocessing environment, with exposure to 
enriched medium, in the generation of DCB3 
Viable Cell Density (cell/mL x106) (right axis, solid red line) and Viability (%) (left axis, dashed black line) 
are plotted against Duration (days) 
 
Following the 62 day culture, cells were removed aseptically and cryopreserved to generate the 
cell bank.  This cell bank (DCB3) consisted of 10 vials cryopreserved at 1x107 cells/vial, in 
basal medium containing 10% DMSO. 
As presented in Figure 70, high viability was observed throughout the expansion.  The culture 
responded to the enriched medium with an increase in viable cell density.  This increase 
occurred during both instances of the enriched medium introduction.  The culture reached a 
peak during the second enriched medium treatment at 23.0 cell/mL x106, on day 56.   
A further cell bank with a very high generation number, DCB4, was generated by reviving a 
vial from DCB3 into basal medium. 
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Following the revival, cells were passaged in basal medium twice to three times weekly, over 
a period of 102 days.  Over this time the generation numbers were tracked and surpassed 120 
generations, in addition to those accumulated in the generation of DCB3, at the generation of 
DCB4.  This cell bank consisted of 10 vials cryopreserved at 1x107 cells/vial, in basal medium 
containing 10% DMSO. 
 
Figure 71 Saw-Tooth plot of the expansion of DCB3 in the generation of DCB4 
Viable Cell Density (cell/mL x105) (right axis, solid red line), Viability (%) (left axis, dashed black line) and 
Cumulative Generation Number (left axis, solid black line) are plotted against Duration (days) 
 
The viability of the cultures presented in Figure 71 was consistently maintained above 95% 
for the duration of the expansion.  The average viable cell density reached at subculture was 
higher than that experienced for DCB2, (52.8±15.6) cell/mL x105.  The increased viable cell 
density at subculture contributed additional generation numbers to be accumulated over the 
same time period as DCB2. 
5.3.1 Experiment 5.1a - Cell Line Sensitivity to Cell Age and Enriched Media Exposure 
The inoculum cultures of the four cell banks were all successfully inoculated in triplicate, into 
CS1 of the ambr® system (as detailed in Table 8).  The viable cell density (VCD) 
measurements observed for cultures in Experiment 5.1a is presented in Figure 72, below 
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Figure 72 Viable cell density (VCD) of cultures within Experiment 5.1a plotted over duration (days) 
Viable cell density, cells/mL x106, is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 (), 
respectively. 
 
On the first two days after inoculation comparable growth was observed, with no significant 
variation (P-value > 0.05) in the VCD between conditions.  The average VCD measurements 
for all cultures was (1.5±0.2) and (2.6±0.6) x106 cells/mL for the first and second days, 
respectively.  The addition of the first nutrient feed on the second day, as per the fed-batch 
protocol (detailed in Section 2.2 Cell line, Medium and Bioreactor systems), supported the 
exponential growth of the cultures. 
On the third day of the process, significant differences were observed between the cultures and 
this continued throughout exponential growth.  Those cultures inoculated with cells from 
DCB4 displayed the fastest growth rate, reaching a peak viable cell density of (3.1±0.1) x107 
cells/mL of the exponential growth phase by day five.  The VCD measurements for DCB4 
were significantly higher (P-value <0.05) than for DCB1, DCB2, and DCB3 on days three to 
five, respectively. 
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Following the exponential growth of DCB4, the VCD plateaus and the cultures entered a 
stationary phase on day six.  This stationary phase was maintained until day 10, and the viable 
cell density on day 10 was not significantly different from that observed on day five (p-value 
= 0.50).  A rise in VCD was observed for DCB4 on the final days (day 11 to 14) of the culture, 
resulting in a universal VCD peak of (3.8±0.3) x107 cells/mL, recorded on the day of harvest 
(day 14).  
Cultures inoculated from DCB2 and DCB3 displayed comparable VCD measurements 
throughout exponential growth, P values = 0.53, 0.31, and 0.26 for days three, four, and five, 
respectively.   Both conditions transitioned into a stationary phase after day six of the process.  
The DCB2 inoculated cultures reached a significantly higher peak VCD during exponential 
growth than those from DCB3, (3.0±0.1), and (2.6±0.1) x107 cells/mL, respectively.  
Significant differences between the two cultures were also observed on the following day (day 
seven), (3.1±0.2) and (2.7±0.1) x107cells/mL, for DCB2 and DCB3, respectively.  The VCD 
measured during the remaining culture duration followed the trend observed for DCB4, 
whereby an increase was observed during the second half of the process resulting in a peak that 
exceeds that for the exponential growth phase.  On the day of harvest (day 14) the VCD 
measurements were, (3.6±0.2) and (3.9±0.2) x106cells/mL for DCB2 and DCB3, respectively.   
The DCB1 cultures were observed to enter exponential growth following day two.  The VCD 
through exponential growth and measured peak viable cell density (1.6±0.1) x107 cells/mL, 
observed on day nine) was significantly lower than those measured for DCB2, DCB3, and 
DCB4, respectively.  These cultures enter a stationary and death phase following the 
exponential growth and measured VCD at harvest was (1.30±0.03) x106cells/mL. 
The viability for the cultures in Experiment 5.1a is presented in Figure 73, below. 
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Figure 73 Percentage viability of cultures within Experiment 5.1a plotted over duration (days) 
Viability (%) is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 (), respectively. 
 
All cultures in Experiment 5.1a were observed to have high viability (>95%) at inoculation.  
This high viability was maintained as the cultures progressed through exponential growth, until 
day six.  On day seven a decrease in viability was observed in DCB4, to (90.8±0.8) %, whilst 
other cultures remained high (>95%).  On day 9, the viability had decreased in all cultures to 
< 95%.  
As the cultures progressed through stationary and death phases, the viability decreased in all 
cultures.  Viability measurements at harvest (day 14) were significantly lower (P<0.05) in all 
cultures, compared to the respective culture viability measured at the end of exponential 
growth.  The fluctuating rates of decline in viability resulted in harvest viability of (72.0±1.1), 
(78.0±1.4). (76.2±0.7) and (83.2±2.0) %, for DCB1, DCB2, DCB3 and DCB4, respectively. 
As detailed in Section 2.3 At-line and Offline Sample Analysis, glucose was actively 
maintained within fed-batch cultures through daily measurement and addition.  A maintenance 
range of 2 to 6g/L was targeted.   The glucose concentrations (g/L) are reported in Figure 74, 
and display the maintenance of glucose throughout the experiment. 
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Figure 74 Glucose Concentration of cultures within Experiment 5.1a plotted over duration (days) 
Glucose concentration (g/L) is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 (), respectively. 
 
Glucose measurements on the first day of culture <5g/L triggered glucose addition in all 
cultures, and subsequent peak concentrations >6g/L for all vessels were observed on day two 
of culture.  Following this peak, concentrations through exponential growth, up to day six, were 
controlled within the targeted 2 to 6g/L range for all cultures.  On day seven, DCB2, DCB3, 
and DCB4 all measured glucose concentrations <2g/L.  These cultures have previously been 
identified as showing high VCD (Figure 72).  These cultures required improvements in the 
glucose control strategy to maintain glucose concentration where high viable cell concentration 
is combined with high cell specific glucose consumption rate. Whilst < 2g/L was a deviation 
from the target range, the glucose concentration did not enter a limited state (Glucose 
concentration = 0 g/L).   
The glucose feedback control loop was initiated at each timepoint where concentration 
measurements were conducted.  The resulting measurement on day eight, following day seven 
being below the target range, was within the target range.  There is a further decrease in 
measured glucose to, and below, 2g/L in the subsequent samples on days 9, 11, 12, and 13, 
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respectively.  This fluctuation at the lower target highlights challenges of maintaining glucose 
concentrations within a high VCD environment. 
Conversely, the DCB1 cultures displayed concentrations within the target range throughout the 
exponential, stationary, and death phases, through to harvest on day 14.   
The contribution of VCD to variation in controlled glucose concentration requires that the cell 
specific glucose consumption rate be consistent across all vessels and phases of the process.  
The cell specific glucose consumption rate for Experiment 5.1a is presented below, in Figure 
75.  
 
Figure 75 Cell specific glucose consumption of cultures within Experiment 5.1a plotted over duration 
(days) 
Specific glucose consumption rate (g/cell/day) is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 
(), respectively. 
 
The calculated cell specific glucose consumption rate (g/cell/day) peaked on day one, with 
values of (1.4±0.2), (1.2±0.1), (1.6±0.2) and (1.8±0.0) x10-9 g/cell/day, for DCB1, DCB2, 
DCB3 and DCB4, respectively.  The cell specific rates in all vessels were observed to decrease 
from day one to day four.  On day four, the average cell specific consumption rate for all vessels 
was (2.7±0.4) x10-10 g/cell/day.  Similarly, the average for all vessels during stationary phase 
(day nine) and at harvest (day 14) was (2.4±0.2) and (2.1±0.4) x10-10 g/cell/day, respectively. 
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The rate of cell specific glucose consumption for DCB1 cultures was significantly higher than 
each of the other cultures on days eight, nine, and ten, respectively. 
Measured lactate concentrations within cultures represent the glucose consumption and back 
metabolism, respectively.  The measure lactate concentrations are presented in Figure 76, 
below. 
 
Figure 76 Lactate concentration of cultures within Experiment 5.1a plotted over duration (days) 
Lactate concentration (g/L) is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 (), respectively. 
 
The lactate concentration for DCB1 cultures increased from (0.4±0.0) g/L on day one, to a peak 
of (1.7±0.1) g/L on day eight of culture.  Following this peak, a decline in the lactate 
concentration was observed and decreased to (0.3±0.0) g/L at harvest (day 14).  The peak 
concentration and the concentration at harvest were both significantly lower (P<0.05) than that 
observed for DCB2, DCB3, and DCB4, respectively. 
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The concentration of the DCB2, DCB3 and DCB4 cultures on day one of culture was (0.5±0.0), 
(0.6±0.0) and (0.7±0.0) g/L, respectively.  On day three of culture, the concentration had 
increased to (2.0±0.0), (2.0±0.1), and (2.7±0.1) g/L for DCB2, DCB3, and DCB4, respectively.   
Paired average profiles for DCB2 and DCB3 displayed no significant difference from 
inoculation to day nine of the experiment (P-value = 0.19).  A peak in lactate concentration 
was observed on day five for DCB2 and DCB3, (2.4±0.1) and (2.3±0.1) g/L, respectively.  
DCB2 and DCB3 exhibited fluctuations in their lactate concentrations between days nine and 
13, in the range of 0 and 2 g/L.  The concentration was observed to increase at harvest and was 
measured as (1.5±0.1) and (0.9±0.3) g/L, respectively.   
The DCB4 cultures peaked in lactate concentration, (2.7±0.2) g/L on day four, which was 
significantly higher than the peak lactate concentrations for DCB1, DCB2, and DCB3, 
respectively (P<0.05).  DCB4 cultures had decreased to (0.3±0.1) and increased again to 
(2.6±0.2) g/L on days 6 and 9, respectively.  At harvest, DCB4 was observed to have the highest 
lactate concentration amongst all cultures, (2.2±0.6) g/L.  
The acidic and basic environments generated by the increase and decrease in lactate 
concentration were observed to impact the online pH readings (Figure 77, below). 
Page 157 of 204 
 
 
Figure 77 pH of cultures within Experiment 5.1a plotted over duration (days) 
Culture pH is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 (), respectively. 
 
At inoculation and through the first four days of culture, all vessels were maintained at the 
upper deadband of the setpoint (7.2±0.1).  On day five of culture, the pH of DCB2, DCB3, and 
DCB4 declined towards the bottom of the deadband, correlating with the increase in lactate 
concentration (Figure 76).  The cultures remained at the bottom deadband (>7.1) through days 
six and seven, before an increase was observed on day eight.  The pH at harvest for DCB2, 
DCB3, and DCB4 was (7.19±0.02), (7.17±0.01), and (7.18±0.01), respectively. 
The pH of DCB1 was controlled within the top deadband until day six, and a decrease in pH 
was observed that resulted in control within the lower deadband on day eight.  From day eight 
onwards, the pH was observed to increase for the remainder of the process.  The pH at harvest 
for DCB1 was (7.25±0.01), significantly higher than that for DCB2, DCB3, and DCB4, 
respectively. 
The production of the mAb product was analysed from samples taken on day six, and every 
other day thereafter until harvest.  The measured mAb produced (Titre, mg/L) is presented in 
Figure 78, below. 
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Figure 78 Titre (mg/L) of cultures within Experiment 5.1a plotted over duration (days) 
Titre (mg/L) is plotted for DCB1 (), DCB2 (), DCB3 () and DCB4 (), respectively. 
 
The titre of DCB1, DCB2, DCB3, and DCB4 on day six was (199±2), (294±5), (383±14) and 
(249±2) mg/L, respectively.  The titre of all cultures displayed a linear increase up until harvest, 
where measurements were (1152±19), (1277±97), (1433±95) and (1079±23) mg/L, 
respectively.  The highest recorded titre on each day was from DCB3, and the value was 
significantly higher when compared to the second highest value on each day (from DCB2).  
The lowest value at harvest from DCB4 was significantly lower than that reported for DCB1 
(p<0.05), (1079±23), and (1152±13) mg/L, respectively. 
Ultimately, the higher viable cell density of those cultures derived from DCB1 did not result 
in an increase in titre.  Therefore, the cell banks DCB2, DCB3, and DCB4 were observed to 
display a decrease in cell specific productivity, compared to DCB1. 
Replicate cultures were pooled together and harvested by centrifugation.  The clarified 
supernatant was purified by Protein A HPLC and the mAb product was analysed for 
aggregation by Size Exclusion Chromatography (SEC).  The measured percentage monomer 
and aggregate for each culture are presented in Table 10, below. 
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Table 10 Product quality (percentage monomer and aggregates) present for Experiment 5.1a cultures, 
at harvest, post product capture purification. 
 
Cell Bank Monomer (%) Aggregate (%) 
DCB1 96.28 3.72 
DCB2 97.90 2.10 
DCB3 97.16 2.84 
DCB4 97.64 2.36 
 
The percentage monomer measured presented low levels of aggregation across culture derived 
from each cell bank.  All cell banks display monomer percentage >96%, and the difference 
between the lowest and highest is 1.62 %, between DCB1 and DCB2, respectively.   
5.3.2 Experiment 5.1b – Culture pH Sensitivity, Magnitude Verses Timing 
Experiment 5.1b was successfully inoculated with cells from the DCB1 inoculum cultures.  The 
conditions were conducted in triplicate as outlined in Table 8, above.  The VCD measurements 
from cultures in Experiment 5.1b are presented in Figure 79, below. 
 
Figure 79 Viable cell density (VCD) of cultures within Experiment 5.1b plotted over duration (days) 
Viable cell density, cells/mL x106, is plotted for pH conditions ‘Basic’ (), ‘Neutral’ (), ‘Acidic’ () and 
‘Drift’ (), respectively. 
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The measured viable cell density of cultures increased over the first two days, reaching an 
average of (1.2±0.3) x106 cells/mL.  On day three, the cultures continued their exponential 
growth.  The viable cell density of the ‘Acidic’ pH condition was observed to be significantly 
lower than that for the highest ‘Basic’ condition, (1.3±0.3) and (3.1±0.4) x106 cells/mL, 
respectively.  Poor growth of the ‘Acidic’ condition cultures was observed throughout the 
duration of the experiment. The measured VCD for the ‘Acidic’ condition was significantly 
lower than the next lowest ‘Neutral’ condition on days six and each day until day 14.  The 
overall poor growth of ‘Acidic’ condition results is represented by the absence of clearly 
defined exponential and stationary periods of culture progression, and the viable cell density at 
day 14 is (5.6±0.2) cells/mL x106. 
Exponential growth was observed until day seven in the ‘Basic’, ‘Neutral’, and ‘Drift’ cultures 
and observed VCDs were of (1.1±0.1), (0.9±0.1), and (1.0±0.0) x107 cells/mL, respectively.  
No significant difference is observed between conditions on day seven (p-values= 0.12, 0.75, 
and 0.56, for ‘Basic’ to ‘Neutral’, ‘Basic’ to ‘Drift’ and ‘Neutral’ to ‘Drift’, respectively).  
Following day seven, cultures in conditions ‘Basic’, ‘Neutral’, and ‘Drift’ continued to increase 
their respective VCD through the stationary phase.  This continued growth resulted in VCD at 
harvest (day 14) of (1.2±0.1), (1.1±0.1) and (1.4±0.3) x107 cells/mL, for ‘Basic’, ‘Neutral’ and 
‘Drift’, respectively.  No significant difference in VCD was observed on day 14 between 
‘Basic’ and ‘Neutral’, ‘Basic’ and ‘Drift’ and ‘Neutral’ and ‘Drift’ cultures (p-value = 0.22, 
0.53 and 0.31, respectively). 
The observed changes in viability over the experiment duration are presented in Figure 80, 
below. High viability (>90%) was maintained by all cultures over the first three days of the 
experiment.   
Page 161 of 204 
 
 
Figure 80 Viability of cultures within Experiment 5.1b plotted over duration (days) 
Viability (%) is plotted for pH conditions ‘Basic’ (), ‘Neutral’ (), ‘Acidic’ () and ‘Drift’ (), 
respectively. 
 
On day four the viability of the ‘Acidic’ condition dropped to (89.8±1.0) %, and the average 
of the other three conditions remained at (93.9±0.9) %.  This represented a significant decrease 
(P-value < 0.05) in viability that was reproduced on each subsequent day until day 12.  On day 
13 the rate of decline slowed in the ‘Acidic’ condition and on the final day of culture it 
represented the highest viability of all cultures.  The viability of the ‘Acidic’ condition at 
harvest was (73.8±1.1) %.   
The remaining three conditions maintained high viability until day seven, where percentage 
viability of (93.4±1.8), (94.3±0.9), and (94.1±0.5), for conditions ‘Basic’, ‘Neutral’ and ‘Drift’ 
was observed, respectively. 
Following day seven, the viabilities of conditions were observed to decline simultaneously 
until harvest, reaching viabilities of (70.6±2.0), (68.0±2.8) and (68.8±2.4), for conditions 
‘Basic’, ‘Neutral’ and ‘Drift’, respectively. 
Glucose measurements from the cultures displayed control within the 2 to 6g/L target range 
throughout the experiment, presented below in Figure 81. 
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Figure 81 Glucose concentration (g/L) of cultures within Experiment 5.1b plotted over duration (days) 
Glucose concentration is plotted for pH conditions ‘Basic’ (), ‘Neutral’ (), ‘Acidic’ () and ‘Drift’ (), 
respectively. 
 
On day two, as observed in Experiment 5.1a, glucose concentrations exceeded the 6g/L upper 
target.  The highest measured glucose concentration was in the ‘Acidic’ condition, (7.9±0.1) 
g/L.  The lowest observed glucose concentration throughout the experiment was from the 
‘Drift’ condition on day nine, (2.3±0.8) g/L.  
The availability and consumption of glucose by the cultures throughout the experiment have 
resulted in lactate concentration profiles that vary for each condition based on the production 
and consumption rates of lactate.  The measured lactate concentrations (g/L) are presented in 
Figure 82, below. 
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Figure 82 Lactate concentration (g/L) of cultures within Experiment 5.1b plotted over duration (days) 
Lactate concentration is plotted for pH conditions ‘Basic’ (), ‘Neutral’ (), ‘Acidic’ () and ‘Drift’ (), 
respectively. 
 
The observed lactate concentration on day one is consistently low in all cultures, with the 
average concentration at (0.3±0.1) g/L.  Following this starting point, the cultures respond to 
their respective pH conditions, and variation was observed in profiles. 
Lactate concentrations were observed to increase initially in the conditions that exhibited a 
high pH at inoculation, (1.1±0.0) and (0.8±0.3) on day four for pH ‘Basic’ and ‘Drift’ 
conditions, respectively.  The concentration continued to increase and resulted in peak lactate 
concentrations of (1.8±0.3) and (1.2±0.2) g/L on days eight and six for pH ‘Basic’ and ‘Drift’ 
conditions, respectively.   
The ‘Neutral’ condition increased to a peak concentration of (0.9±0.2) g/L on day eight.  
Following this peak, three culture conditions (‘Basic’, ‘Neutral’ and ‘Drift’) all exhibited a 
decrease in lactate concentration.  The ‘Basic’ condition decreased to (0.4±0.1) g/L, on day 14.  
The conditions ‘Neutral’ and ‘Drift’ decreased to (0.3±0.2) and (0.2±0.1) g/L, respectively on 
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day 12, before increasing on the final two days.  The concentrations for the ‘Neutral’ and ‘Drift’ 
conditions on day 14 were (0.9±0.5) and (0.7±0.2) g/L, respectively. 
Significant differences (P-value < 0.05) were observed in the lactate concentration trend of the 
‘Acidic’ condition throughout the experiment when compared to the other three conditions.  
During the first eight days, the lactate concentration of the ‘Acidic’ condition remains 
significantly lower than all other cultures.  The concentrations of (0.3±0.0) and (0.2±0.0) g/L 
were observed on days one and eight, respectively. 
During the second half of the experiment, the measured lactate concentration in the ‘Acidic’ 
condition increased to a peak at harvest.  Measured lactate concentration on day 8 and day 14 
increased from (0.2±0.0) to (2.9±0.1) g/L, respectively. 
The pH profiles for each condition are presented in Figure 83 and display the movement of the 
pH within the deadband.  This is presented here to highlight the timing of the ‘Drift’ condition 
initiation.  Additionally, the natural movement of pH within the deadband is displayed as 
cultures progress from inoculation through to harvest. 
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Figure 83 pH of cultures within Experiment 5.1b plotted over duration (days) 
Measured pH is plotted for pH conditions ‘Basic’ (), ‘Neutral’ (), ‘Acidic’ () and ‘Drift’ (), 
respectively. 
 
During the first six days of culture, the pH of the conditions tracks along the top of the 
deadband, controlled by CO2 sparging.  The pH for conditions ‘Neutral’ and ‘Acidic’ were 
controlled at the upper deadband for the duration of the experiment, pH 7.10 and 6.90, 
respectively. On day seven, the pH of the ‘Basic’ and ‘Drift’ conditions both begin to move 
away from the upper deadband and a decrease in pH was observed.  In the ‘Basic’ pH condition, 
the pH reached the bottom deadband, pH 7.10 on day 10.  On day eight, the pH slowly increased 
in the direction of the upper deadband, pH 7.30.  This pH change correlated with the 
accumulation of lactate (up to day eight), and removal of lactate prior to harvest (Figure 82, 
above).   
In the pH ‘Drift’ condition, the pH moved from the ‘Basic’ condition to the setpoints for the 
pH ‘Acidic’ condition.  A basic pH was reached for the ‘Drift’ condition of (6.95±0.05), on 
day 10.  Following day 10, the pH increases to the 7.20 setpoint and is recorded at (7.06±0.01) 
on day 14. 
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The measured impact on mAb titre resulting from these conditions is presented in Figure 84, 
below. 
 
Figure 84 Titre (mg/L) of cultures within Experiment 5.1b plotted over duration (days) 
Titre is plotted for pH conditions ‘Basic’ (), ‘Neutral’ (), ‘Acidic’ () and ‘Drift’ (), respectively. 
 
The ‘Basic’ condition displayed the highest titre measurements on each day, respectively at 
harvest a final titre of (1080±40) mg/L was observed.  The titre of the pH ‘Drift’ increased at 
the same rates as the ‘Basic’ condition.  The titre at harvest for the ‘Drift’ condition was lower, 
(999±58) mg/L, but not significantly different from that observed for the ‘Basic’ condition.  
The third ranked condition was the ‘Neutral’ cultures that reached (868±156) mg/L, by day 14.  
The titre measurements for the ‘Neutral’ condition represent significantly lower values (p-value 
< 0.05) than those for the ‘Basic’ cultures on days six, eight, 10, and 12, respectively.  No 
significant difference is observed at harvest between the ‘Basic’ and ‘Neutral’ cultures (P-value 
= 0.08).  No significant difference was observed between titre measurements in the ‘Neutral’ 
and ‘Drift’ conditions respectively, P values = 0.99, 0.35, 0.12, 0.12, and 0.24 for days six, 
eight, 10, 12 and 14, respectively. 
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Titre measurements taken from samples within the ‘Acidic’ condition were significantly lower 
than respective timepoint samples from each of the other three conditions.  There was a 
significantly lower final concentration of mAb product observed at harvest, (261±9) mg/L for 
the ‘Acidic’ condition.  This ‘Acidic’ titre calculates as 24% of that achieved in the ‘Basic’ 
condition. 
Product quality measurements from harvest samples provided information on the cumulative 
impact of the pH condition on the final mAb product.  Percentage monomer data for cultures 
is presented in Table 11. 
 
Table 11 Product quality (percentage monomer and aggregates) present for Experiment 5.1b cultures, 
at harvest, post product capture purification. 
 
Condition Monomer (%) Aggregate (%) 
pH Setpoint ‘Basic’ 95.60 4.40 
pH Setpoint ‘Neutral’ 96.41 3.59 
pH Setpoint ‘Acidic’ 97.60 2.40 
pH Setpoint ‘Drift’ 95.19 4.81 
 
The percentage monomer of the mAb was measured by size exclusion chromatography 
following Protein A capture purification.  The observed aggregation of the mAb was 
consistently low (< 5%) in each pH setpoint condition.  The percentage monomer at harvest 
for ‘Basic’, ‘Neutral’, ‘Acidic’, and ‘Drift’ were 95.6, 96.4, 97.6, and 95.2, respectively. 
5.3.2 Experiment 5.2 – Culture Robustness During Exponential Expansion 
In Experiment 5.2, the conditions (as represented in Table 9) are replicated in each culture 
station of an ambr®, 48-variant system.  The successful operation of three (of a total of four) 
culture stations (CS) provides triplicate examples of each condition to compare against 
respective control vessels. 
Page 168 of 204 
 
 
Figure 85 Viable cell density (cells/mL x106) of cultures within Experiment 5.2, plotted over duration 
(days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 (▼), Vessel 12 – 70% DO () 
 
The viable cell density (VCD) measurements from Experiment 5.2 are presented in Figure 85, 
above.  After successful inoculation, all conditions displayed comparable VCDs up to day six.  
The average VCD on day six was (1.4±0.1) x 107 cells/mL.  No significant difference was 
observed in VCD (P-value > 0.05) across all conditions through this period when compared to 
their respective control.   
On day eight, the cultures in Experiment 5.2 reached the end of exponential growth and 
transitioned into a stationary phase.  The VCD observed for control vessels 1 and 11 on day 
eight was (2.4±0.1) and (1.9±0.1) x107 cells/mL, respectively.  On this day, a significant 
decrease compared to control (P < 0.05) was observed in conditions where dissolved oxygen 
(%) was maximally increased or decreased to 70% and 30% setpoints, respectively. 
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As the cultures progressed to days 10, 12, and 14, statistically significant increases were also 
observed in the viable cell density of conditions with additional antifoam, vessels 5 & 7, 
respectively (P < 0.05).  In addition, the peak VCD measurements were recorded on day 12 
from these two conditions, (3.5±0.3) and (3.2±0.6) x107 cells/mL for vessels 5 & 7, 
respectively. 
Furthermore, on day 12 there were significant differences in cell density observed between 
control and the pH up condition and 60% dissolved oxygen condition.  Notably, no significant 
difference was observed between the DCB3 cultures and control cultures on each day from 
inoculation through to harvest (P values > 0.05). 
Observed VCD of control vessels between days 10, 12, and 14, indicated no significant 
difference resulting from the temperature increases applied during day 12.  Control vessels 1 
& 11 displayed viable cell densities on day 12 of (2.0±0.2) & (1.7±0.1) and on day 14 of 
(2.1±0.3) & (1.6±0.2) x107 cells/mL, respectively. 
 
Figure 86 Viability (%) of cultures within Experiment 5.2, plotted over duration (days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 (▼), Vessel 12 – 70% DO () 
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The percentage viability of cultures in the experiment is presented in Figure 86 above.  The 
average percentage viability at inoculation was (98.0±1.5) %.  This high viability was 
maintained throughout the exponential growth phase and on day six, the average percentage 
viability for all cultures was (98.3±1.0) %.  As cultures transition into stationary phase on day 
eight, a decline in viability is observed in cultures with high (70% dissolved oxygen) and low 
(30% dissolved oxygen) dissolved oxygen percentage saturation setpoints, vessels 4 & 12 with 
(94.0±0.4) and (92.9±0.4), respectively.   
The control conditions (vessels 1 and 11) displayed a decrease in viability during the later 
stages of the culture.  A decrease in viability was observed between days 10 and 14, decreasing 
from (95.1±1.1) and (95.2±0.6) to (75.1±4.7) and (76.9±1.4) %, for vessels 1 and 11 
respectively.  
Cultures inoculated with DCB3 cells displayed a significant decrease in viability compared to 
control on days 10 and 12 with average viabilities of (88.0±0.9) and (78.1±2.6) %, respectively.  
Additionally, viability measurements were lower than control on days 12 and 14 of culture for 
conditions with additional antifoam additions (vessels 5 and 7), (83.6±4.5) & (83.0±4.7) and 
(60.8±8.2) & (59.7±6.3) for days 12 and 14, respectively.  These differences compared to 
control were significant (p < 0.05) in the triple antifoam condition (vessel 7). 
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Figure 87 Dissolved oxygen (%) of cultures within Experiment 5.2, plotted over duration (days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 (▼), Vessel 12 – 70% DO () 
 
The dissolved oxygen saturation (DO) percentages are presented in Figure 87.  Average DO 
for all cultures on day one was observed as (68.3±2.9) %.  The data in Figure 87, highlights the 
timing of the DO experimental conditions differentiating from the respective control cultures.  
The experimental conditions are produced sequentially between days 2 and 5, for the highest 
and lowest percentage saturation, respectively. 
The pH was tightly controlled within the (setpoint ± 0.1) deadband for the duration of the 
experiment.  The observed pH measurements are presented in Figure 88.   
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Figure 88 pH of cultures within Experiment 5.2, plotted over duration (days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 (▼), Vessel 12 – 70% DO () 
 
In response to the condition tested, the recorded pH in vessels 2 and 3 fluctuated between pH 
7.4 and 7.2, over the first 4 days of culture.  This occurred when the upper deadband setpoint 
was increased or decreased, as per the experimental design (Table 9).  After day 4, the acidic 
environment of the cultures resulted in the movement of recorded pH away from the alternating 
upper deadband, and thus this pH condition did not impact the culture. 
On day 5 the pH of the DCB3 derived cells decreased to (7.12±0.00) and  (7.13±0.01) for 
vessels 8 and 9, respectively.  On day 6 the pH of all other vessels transitioned from acidic to 
basic control, as they were maintained at the lower deadband of pH 7.1.  This low pH was 
maintained on day 7 for all cultures.   
On day 8 an increase was seen in double (Vessel 5) and triple (vessel 7) conditions, increasing 
to pH (7.17±0.01) and (7.21±0.04), respectively.  This increase was replicated in all other 
cultures on days 9, 10, and 11, respectively.  A decrease in average pH from (7.14±0.01) to 
(7.11±0.03) was observed in all vessels between days 12 and 14, respectively. 
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Figure 89 Lactate Concentration (g/L) of cultures within Experiment 5.2, plotted over duration (days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 (▼), Vessel 12 – 70% DO () 
 
The lactate concentration (g/L) observed in Experiment 5.2 is presented in Figure 89, above.  
An increase in lactate concentration was observed in the control vessels during the first five 
days of cultures, rising to (1.6±0.1) and (1.5±0.0) for vessels 1 and 11, respectively.  The 
highest concentrations observed until day five were from the DCB3 derived cultures, 
displaying (2.1±0.1) and (2.0±0.1) for vessels 8 and 9, respectively.  
The DCB3 vessels (8 & 9) also exhibited a significant increase compared to control, 
maintaining a concentration of approximately 2g/L each day from day five to 11, respectively.  
All other cultures displayed initial peaks on day five of between (1.4±0.1) and (1.7±0.1) g/L, 
for vessels 3 and 2, respectively.  Following this peak, the concentrations were observed to 
decrease, reaching <1g/L on days nine and 10, respectively.    
The lactate concentration on days 12 to 14 was observed to increase across all conditions.  The 
magnitude of the lactate concentration increases in vessels 5 and 7 was significantly higher 
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than control.  The lactate concentration at harvest ranged from between (3.1±1.4) and (1.2±0.5) 
g/L for vessels 5 and 11, respectively. 
 
Figure 90 Specific glucose consumption rate (g/cell/day) of cultures within Experiment 5.2, plotted over 
duration (days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 (▼), Vessel 12 – 70% DO () 
 
The cell specific glucose consumption rate (g/cell/day) is displayed in Figure 90, above.  The 
rate of glucose consumption rises during the first four days of culture, exceeding 3 x10-10 
g/cell/day for all cultures on day four, respectively.  The increasing cell specific glucose 
consumption rate was observed to plateau on days five and six, averaging (3.0±0.3) and 
(3.3±0.3) x10-10 g/cell/day, respectively.  On day seven, a decline in the rate of glucose 
consumption was observed, (1.4±0.8), and (0.5±0.6) x10-10 g/cell/day were calculated for the 
highest (Vessel 2) and lowest (Vessel 10) rates, respectively.  Average rates were maintained 
below 2.0 x10-10 g/cell/day for the remainder of the experiment. 
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Cultures inoculated from the DCB3 cell bank followed the trends outlined for glucose 
consumption rates (Figure 90).  However, they displayed a significant increase in their rate of 
glucose consumption compared to control on days three and four, respectively (P-value < 0.05).  
The peak glucose consumption rate for all cultures was observed in vessels 8 and 9, at (4.4±0.4) 
and (4.1±0.1) x10-10 g/cell/day on day four, respectively.   
 
Figure 91 Titre (mg/L) of cultures within Experiment 5.2, plotted over duration (days) 
Plotted conditions are, Vessel 1 - Control (●), Vessel 2 – pH up(■), Vessel 3 – pH down (▲), Vessel 4 – 
30%DO ( ), Vessel 5 – Double Antifoam (), Vessel 6 - 40% DO (○), Vessel 7 – Triple Antifoam (□), 
Vessel 8 – EM (∆), Vessel 9 - EM (◊), Vessel 10 – 60%DO (), Vessel 11 - Control (▼), Vessel 12 – 70% DO 
() 
 
The profile of measured mAb titre (mg/L) was observed to increase for all cultures as the 
experiment progressed, the data is presented in Figure 91, above.  The observed mAb titre 
increased rapidly between days seven and nine, respectively.  During this period the control 
vessels 1 and 11 were observed to increase from (215±18) and (189±9) mg/L to (495±45) and 
(496±46) mg/L, respectively.  On day 12, titre in control vessels had increased to (757±50) and 
(679±10) mg/L for vessels 1 and 11, respectively.  Cultures inoculated with DCB3 cells 
(vessels 8 and 9) displayed significantly higher titre measurements from control, on days 12, 
Page 176 of 204 
 
13, and 14, respectively.  All other vessels displayed no significant difference to control on 
each of these days, respectively.  The highest titre at harvest was observed in vessel 8, (910±89) 
mg/L. 
The harvest samples from each condition were Protein A purified and analysed by size 
exclusion chromatography.  The data generated by this analysis is present in Table 12, below. 
Table 12 Product quality (percentage monomer and aggregates) present for Experiment 5.2 cultures, at 
harvest, post product capture purification. 
 
Vessel - Condition Monomer (%) Aggregate (%) 
Vessel 1 - Control 95.7±1.0 4.2±0.9 
Vessel 2 – pH up 95.9±0.6 4.1±0.5 
Vessel 3 – pH down 96.0±0.3 4.0±0.3 
Vessel 4 – 30%DO 95.7±0.7 4.3±0.6 
Vessel 5 – Double Antifoam 96.6±0.1 3.5±0.1 
Vessel 6 - 40% DO 95.9±0.1 4.1±0.1 
Vessel 7 – Triple Antifoam 96.3±0.6 3.6±0.5 
Vessel 8 – DCB3 96.3±0.3 3.7±0.2 
Vessel 9 – DCB3 96.4±0.4 3.6±0.4 
Vessel 10 – 60%DO 95.8±0.5 4.2±0.5 
Vessel 11 - Control 95.6±0.8 4.4±0.8 
Vessel 12 – 70% DO 96.2±0.1 3.8±0.1 
 
The monomer percentage from the conditions was observed to remain consistently high (> 
95%) across all samples.  These values are consistent with the SEC analysis performed on 
DCB1 and DCB3 cultures in Experiment 5.1a, where no hyperthermic temperature exposure 
was conducted on the final days of culture.  This leads to a conclusion that the increase in 
temperature prior to harvest has no observable impact on the purity of the mAb.  In addition, 
the consistency of the monomer percentage observed within the conditions of Experiment 5.2, 
supports the robustness of the cell line to process variation occurring post inoculation. 
5.4 Discussion 
The evaluation of cell line sensitivity presented within this chapter began with the generation 
of cell banks exposed to conditions common with continuous culturing.  These were the high 
generation number of cells (DCB2) and exposure to an enriched nutrient environment (DCB3).  
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The cell banks DCB2 and DCB3 were generated from an expansion of DCB1.  The fourth cell 
bank (DCB4) combined the exposure to an enriched nutrient environment followed by an 
accumulation of cell age.   
Within Experiment 5.1a, the performance of the three conditioned cell banks (DCB2, DCB3, 
and DCB4) was evaluated in a fed-batch operation.  This evaluation displayed significantly 
higher growth (P-value > 0.05) when compared to DCB1.  The resulting peak VCDs for DCB2, 
DCB3, and DCB4 were each one-fold higher than those observed for DCB1, respectively.   
The high VCD presented in higher generation number cultures (DCB2, DCB3, and DCB4) is 
beneficial in the operation of continuous cultures.  In perfusion specifically, it provides a larger 
range for the cultures to be maintained within exponential growth, before reaching maximal 
cell density.  However, the correlation of increase in VCD with cell generation number did not 
translate into an improved titre.  The measured mAb produced at harvest was observed between 
(1079±23) and (1433±95) mg/L, for DCB4 and DCB3, the lowest and highest conditions, 
respectively. 
The observed titre for the DCB1 cultures was (1152±19) mg/L, and these cultures maintained 
a higher cell specific productivity than DCB2, DCB3, and DCB4, respectively.  The loss of 
cell specific productivity at higher generation numbers is a negative attribute specific to CHO 
cell lines (Ghorbaniaghdam, Chen, Henry, & Jolicoeur, 2014).  This loss in productivity is not 
uncommon for transfected CHO cell lines and it impacts commercial manufacturing activities 
both in fed-batch and continuous cultures alike (Shukla & Thömmes, 2010).  
The loss in cell specific productivity observed in DCB3 cultures was lower than for DCB2.  
The improved performance of DCB3 cultures appeared transiently, and further subculture of 
DCB3 cultures (the generation of DCB4), resulted in a reduction in titre.  The lowest titre 
values reported in this chapter are occurring in DCB4 cultures. The exposure of cells to a high 
nutrient environment, as is observed in the generation of DCB3, can result in an improved 
production phenotype (F. Wurm, 2013). 
These changes in specific productivity between DCB1 and the generated cell banks (DCB2, 3, 
and 4) display a genetic instability of the cell line.  The instability in production and growth is 
not observed to impact the product quality attribute (aggregation of mAb).  Analysis by SEC 
results in a high monomer percentage (> 96%) for all cultures. 
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In Chapters 3 and 4, observations were made of measured pH deviating by > 0.1 units from 
setpoint in perfusion vessels, without impacting CPPs (maximum VCD, cell specific 
production rates and product quality attributes, specifically).  The pH of all cultures within 
Chapters 3 and 4 were tightly controlled to pH setpoint ± 0.1 during inoculation.  The deviations 
of > 0.1 from setpoint occurred within microscale perfusion vessels after inoculation, during 
exponential growth, as sedimentation method was conducted.  These observations led to 
challenging the cell line’s sensitivity to pH deviations, at inoculation, and during exponential 
growth. 
Within Experiment 5.1b, the sensitivity of Cell line 1 (DCB1) to deviations in pH was tested.  
This was conducted through the operation of conditions ‘Basic’, ‘Neutral’, and ‘Acidic’, 
characterised by pH setpoints of (7.2±0.1), (7.0±0.1), and (6.8±0.1), respectively.  These 
cultures were inoculated at their respective setpoints and maintained through to harvest.  The 
operation of the ‘Drift’ condition provided insight to cell line sensitivity to pH deviations of 
>0.1, following inoculation at the ‘High’ setpoint (7.2±0.1).   
The growth characteristics of pH conditions that were kept consistent throughout the 
experiment (‘Basic’, ‘Neutral’, and ‘Acidic’) highlighted the cell line’s sensitivity to pH.  A 
correlation was observed between the magnitude of the pH setpoint change and the growth 
performance of the culture. 
During exponential growth, the ‘Basic‘ condition reached the highest cell density and was the 
most productive, generating a titre measurement at harvest of (1080±40) mg/L.  The growth 
and productivity of the ‘Neutral’ and ‘Acidic’ conditions were significantly lower than those 
observed for the ‘Basic’ condition.  
When compared to the fixed pH setpoints (‘Basic’, ‘Neutral’ and ‘Acidic’), the ‘Drift’ 
condition ranked second overall, behind the ‘Basic’ condition, for growth and productivity 
measurements.  During the first nine days, the pH correlated with the ‘Basic’ conditions.  
Following this, the pH was in the range of the ‘Acidic’ condition on day 10 of culture and in 
the ‘Neutral’ cultures from days 11 to 14, respectively. Whilst observations of performance are 
cell line specific, CHO cells have been well documented to possess an inherent sensitivity to 
pH (Brunner, Fricke, et al., 2017; F. Li et al., 2010) (Section 1.4.2 pH Control). 
For continuous systems (specifically perfusion operation), the culture spends the majority of 
its time in exponential growth, and thus understanding the particular sensitivity during this 
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phase of the operation can allow operational ranges to be set to appropriately, with an 
understanding of the risk associated with the control of the CPPs. 
Cell line sensitivity during exponential growth was also evaluated during Experiment 5.2.  This 
experiment design expanded the pH evaluation of Experiment 5.1b, and sought CPP variation 
during exponential growth, after a successful inoculation at setpoint.  The application of QbD 
principles will define sensitivity for CPPs at inoculation and deviation during operation would 
place the process at risk without explicitly understanding the situational impact that the 
deviation applies (Horvath, Mun, & Laird, 2010).   
All conditions were inoculated at designated setpoint ranges for Cell line 1 (Detailed in Chapter 
2).  The majority of conditions of Experiment 5.2 (see Section 5.2.3) was conducted with 
DCB1, with the exception for vessels 8 and 9 on each culture station.  These vessels (8 and 9, 
inoculated with DCB3) are important to consider for this experimental design as the sensitivity 
during the exponential expansion of continuous culture may be influenced by exposure of the 
culture to continuous operation (Cong, Chang, Deng, Xiao, & Su, 2001; Seth et al., 2013).   
Differences were observed during Experiment 5.2 in these DCB3 conditioned cultures when 
compared with control vessels (DCB1).  This difference was in the observed lactate 
concentrations of the cultures.  Prolonged production of lactate within a pH controlled culture 
is thought to limit productivity through suppressed growth (Glacken, Fleischaker, & Sinskey, 
1986; W. S. Hu, Dodge, Frame, & Himes, 1987).   
High lactate producing cultures (Vessels 8 and 9 significantly higher than control) display 
comparable growth to control.  Previous experience of the DCB3 cell bank (Section 5.3.1 ) 
indicates an expected improved growth characteristic compared to DCB1 is being suppressed 
by the lactate concentration within cultures. 
Whilst no significant difference was observed in the VCD measurements of DCB3 cultures, 
the cultures were able to utilise excess glucose.  This correlated with an observed increased 
mAb production.  The increased mAb production aligns with the previously investigated CHO 
response phenomena to increased lactate accumulation, in both improved efficiency of 
metabolic processes (Zagari et al., 2013), and transcription signalling adjustments (M. Zhou et 
al., 2011). 
In addition to the observation of DCB3 cultures in Experiment 5.2, the conditions aimed to 
evaluate the impact of deviations occurring during the exponential expansion of cultures.  
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Controlled conditions (pH, DO, antifoam addition) were simulated to experience probe failures 
and process operation errors.  The resulting deviations displayed no significant difference to 
control in performance criteria for the pH and DO conditions.  Increasing antifoam additions 
displayed a significant increase in peak viable cell density of cultures when compared to 
control.  This may have been a result of the setpoint antifoam addition being sub-optimal for 
the cell line and increasing this provided improved control and culture performance. 
The final condition for Experiment 5.2 was a temperature increase, conducted across all 
cultures on day 12.   The temperature of all cultures was increased to  38°C on day 12 of culture.  
Analysis of data across the conditions displayed that no comparative impact in conditions 
against control.  Whilst temperature deviations away from biological optimum are expected to 
limit growth and have a significant impact of process performance (Kaufmann et al., 1999), 
this variation occurs post peak viable cell density.  Additionally, the deviation occurs in close 
proximity to the end of the fed-batch operation. 
After exponential growth, culture process control is centred on delaying cell apoptosis, 
maintaining viability, and providing an environment for mAb secretion.  Viability remains > 
50% at the point of harvest, indicating that whilst declining the cellular membrane is intact for 
the majority of cells within the culture, and cellular waste products are not being released.  
Appropriate CHO cell survival at this mild temperature increase is supported by investigations 
into the heat shock response at incrementally increasing temperatures (Peksel et al., 2017) 
(Gerweck, Richards, & Michaels, 1982).  Any decline in viability resulting may trigger the 
harvest criteria and thus the evaluation of the impact of this condition must be focused on the 
product quality attributes of the product. 
A consistently high (>95%) monomer percentage was observed for all conditions.  These 
values are consistent with the SEC analysis performed on DCB1 and DCB3 cultures in 
Experiment 5.1a, where no hyperthermic temperature exposure was conducted on the final days 
of culture.  This leads to a conclusion that the increase in temperature before harvest has no 
observable impact on the purity of the mAb.  In addition, the consistency of the monomer 
percentage observed within the conditions of Experiment 5.2, supports the robustness of the 
cell line to process variation occurring post inoculation. 
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Chapter 6 Overall Conclusions and Future Work 
6.1 Overall Conclusions 
The work contained within this thesis investigates the topic of continuous bioprocess development 
through a high-throughput microscale system.  During the operation of continuous cultures at 
microscale, differences are observed in culture performance when compared to bench scale 
equivalent cultures.  These differences highlight the potential and limitations of the system as a 
bioprocess development tool and indicate novel operation and control strategies for mammalian 
cultures that apply to both fed-batch and continuous modes of operation. 
A key methodology utilised in continuous manufacturing is perfusion.  In Chapter 3, a cell 
sedimentation method is applied to an existing automated microscale bioreactor system to enable 
it to operate perfusion.  An early reference to the application of this methodology was contained in 
seminar presentations sponsored by the manufacturer of the system (Sartorius, 2016).  The detailed 
design and evaluation of the technique was published for the first time from the work contained 
within Chapter 3 (Sewell et al., 2019).   
The evaluation of the method indicates the microscale system's ability to operate in perfusion, 
achieving comparable maximal cell densities to bench scale operation.  Variation was observed in 
the initial growth rates of cultures in the two scales.  This manifested itself in a seven-day lag for 
the micro scale vessels to reach maximal density observed in bench scale.  As the systems used for 
micro and bench scale had previously been presented as equivalent across many criteria (Lewis, 
2010; Moses et al., 2012; Nienow et al., 2013; Rameez et al., 2014), differences in culture 
performance were accredited to the perfusion operations, namely the method of cell retention.   
Inherent to the cell retention method was the need to stop gas sparging and agitation of the micro 
scale cultures.  This allowed cells to settle and generate a ‘cell-free’ fraction for media exchange.  
The first potential cause for the lag in culture growth is identified in the pH and DO traces.  Steep 
declines were observed in the measured values during the sedimentation that, if maintained for an 
extended period would be incompatible with high culture viability.  This is confirmed by the decline 
in performance observed in the extension of the method from 30 minutes settling to 37 minutes.  It 
is important to note that the location of the sensors within the vessels is on the bottom, facing 
upwards into the culture.  During sedimentation, the local environment around these sensors will 
increase in cell density and present a biased measurement, not representative of the total culture.   
This local heterogeneous environment is a known challenge of larger scale bioreactors whereby 
mixing may be sub-optimal and it has been shown to impact growth and productivity of cultures as 
poor DO and pH control will impact cellular physiology (Brunner, Braun, et al., 2017; Lara, 
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Galindo, Ramírez, & Palomares, 2006).  The pH extremes at larger scales are the inverse of what 
is observed here, with pH spikes as opposed to drops, resulting in cellular stress (Jiang, Chen, & 
Xu, 2018; Ozturk, 1996).  Within the microscale cultures, sustained increased lactate production 
was observed in the microscale cultures compared to bench scale that could be indicative of limited 
oxygen concentration during sedimentation through the Warburg effect (Warburg et al., 1927). 
A compounding difference in the microscale cultures that could impact the growth profile was the 
efficiency of cell retention.  In the bench scale cultures, 100% retention efficiency is assumed due 
to the hollow fibre filtration membrane used (Karst, Serra, Villiger, Soos, & Morbidelli, 2016).  At 
micro scale, the efficiency was calculated to be between 95 and 99%, measured by counting cells 
present in the removed perfusate.  The measured physical characteristics of these cells that were 
removed highlighted lower density, smaller size, and higher viability than the retained culture.  The 
significantly smaller size (3 to 4µm difference in diameter), indicates that the calls are either very 
young, new cells or older cells in the stages of apoptosis resisting trypan blue ingress (Pan, Dalm, 
et al., 2017; Seewöster & Lehmann, 1997).    Therefore, to comment further on the characteristics 
of the cells removed further cellular analysis techniques would be required, such as flow cytometry 
(Moore et al., 1995; Pekle et al., 2019). 
Notwithstanding the differences to bench scale systems, the microscale perfusion method displayed 
functionality to support screening and ranking activities for cell lines in perfusion culture.  
Evaluating maximum growth potential, titre, and product quality attributes in a low resource, high 
throughput manner. Ultimately, the prevalence of the ambr® systems within industrial labs and the 
simple operation of the methodology will enable perfusion evaluations to be conducted without 
significant outlay in resource. Further development of the methodology is required to function as 
an efficient process development tool in defining operating ranges as the ambr® systems are used 
for fed-batch applications (Manahan et al., 2019).   
As perfusion culture retains cells, holding them in a pseudo steady state of growth, the method has 
been utilised for expansion applications (culture inoculation expansion and cell therapy 
applications)(Levine, Miskin, Wonnacott, & Keir, 2017).  Whilst Chapter 3 focused on the 
sedimentation method’s impact on culture growth, productivity, and product quality, 
In the absence of single-cell characterisation techniques, Chapter 4 highlights indicators of cellular 
health by progressing cells from micro and bench scale perfusion cultures, into fed-batch 
production.  The performance of the production scale vessels was viewed as a surrogate 
characterisation tool, highlighting scale dependant differences in the perfusion methods.  The 
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operating ranges of production vessels were varied to compound any differences, challenging the 
comparability of the scales further. 
Operation of the microscale perfusion vessels displayed consistent performance in their respective 
production cultures, achieving performance ranking that aligned with the respective inoculation 
concentration.  When the same perfusion, inoculation, and fed-batch parameters were tested on 
bench scale cultures, higher variation was observed, with a greater response to the increased 
nutrient feed concentrations applied.  Proposed in the discussion was a sensitivity to fluctuating 
dilution rates inherent to the sedimentation method, thought to be removing culture heterogeneity 
(Stephens & Lyberatos, 1987).  It is reasonable to also expect heterogenicity of the cultures to 
be impacted by the two differences highlighted above (frequent local pH &DO fluctuations and 
cell removal). The frequent media exchanges were tested in isolation to the other factors 
through a bench scale evaluation of dilution rate sensitivity and no significant difference in 
performance was observed. 
On balance, as a tool for inoculum expansion for subsequent production cultures, it is not 
appropriate to utilise the microscale perfusion method as there is uncertainty in the impact of 
cellular sedimentation on the culture.  However, the volumetric differences bench and 
microscale aligns well with the inoculum requirements if process development for n-1 
perfusion was to be conducted with bench scale vessels, inoculating microscale production 
cultures.  In the evaluation of microscale perfusion, the ambr® system displayed the ability to 
operate at very high cell densities and maintain control of critical process parameters. 
Sensitivity to physiochemical conditions, defined within this thesis as poor growth and 
productivity, is generally thought to be cell line specific and management of the environment is 
bespoke for each cell line (Y. M. Huang et al., 2010).  The performance of the cell line in perfusion 
culture through Chapters 3 and 4 highlighted a particular insensitivity to pH and DO concentrations 
that is misaligned with the understanding of pH and DO responses in fed batch cultures (F. Li et 
al., 2010).   
In a fed-batch setting, pH sensitivity was investigated and in Experiment 5.1a, the pH setpoint was 
varied, at inoculation, but also during exponential growth and stationary phase.  The testing 
indicated that cultures with pH tightly controlled at inoculation performed comparably regardless 
of the pH control applied through the remainder of the culture.  Transversely, if pH was not 
controlled well during inoculation, the culture did not display high performance.  The comparable 
performance of the culture with the ‘drift’ pH control could have been realised through the lower 
cellular stress experienced. 
Page 184 of 204 
 
Altering key parameters, such as pH, at defined points in culture progression has previously been 
identified as an optimisation method for fed batch cultures (Trummer et al., 2006).  This has 
application in continuous culture, however, the impact on culture longevity is an additional 
consideration over a terminally operated batch culture. For batch cultures, this is not widely 
performed as a dual setpoint process design is conflicting to current QbD directives and DoE 
techniques that use MVA of singular setpoints applied from inoculation through to harvest 
(Mandenius & Brundin, 2008; A. S. Rathore, 2009).   
To apply multiple, progressive setpoints for a culture requires a profound understanding of the 
responses to the physiochemical environment.  For continuous cultures, whereby there is a distinct 
bi-phase operation (inoculation and steady-state growth), this control strategy warrants further 
investigation as the culture will be maintained for the majority of its time away from inoculation.  
A phase-dependent pH control strategy could also provide benefits in commercial-scale fed-batch 
bioreactors whereby there are challenges with local extreme pH environments each time an 
adjustment is made (Brunner, Braun, et al., 2017). 
During the operation of perfusion in Chapters 3 and 4, an insensitivity to pH is observed in this cell 
line and this was discretely investigated (Experiment 5.1b), focusing on the cell line’s pH 
sensitivity during and after inoculation.  It was found that cultures where pH was tightly controlled 
(pH 7.2±0.1) during inoculation performed well regardless of the level of control after inoculation.  
Cultures that had a varied setpoint (pH 7.0 or 6.8) at inoculation displayed significantly lower 
growth and productivity, in comparison.  This finding aligns with pH control present in microscale 
perfusion, where the setpoint is tightly controlled at inoculation but can be seen to vary as cell 
sedimentation occurs, without a significant impact on culture performance. 
The point of culture inoculation was identified as a critical control step.  Further investigation 
within the chapter focused on expanding the understanding of culture phase-dependent sensitivity.  
Supporting Experiments 5.1a and 5.2, investigated pre inoculation and post inoculation control, 
respectively.  In a highly regulated industry, such as bioprocess manufacturing, novel control 
measures around these process steps are not typically investigated, and as such their potential 
overlooked (Fisher et al., 2019).   
The controlled expansion of a cell line from cell bank vial thaw to production vessel inoculation 
ensures consistent performance from batch to batch.  Experiment 5.1a focused on disrupting 
the expansion step by introducing environments that would be observed during continuous 
culture expansion (as seeding cultures or as independent production vessels), such as high 
generation cell lines or exposure to nutrient-rich media environments.  The cells displayed an 
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ability to adapt to pre-conditioning, aligning with an industry held perspective that culture 
heterogenicity is maintained beyond the point of clonality, due to the inherent stability of 
immortalised cell lines (Frye et al., 2016; Patel et al., 2018; Vcelar et al., 2018).  This 
preconditioning is supported by studies investigating metabolomic and proteomic changes, and 
enhanced protein expression characteristics of cell lines exposed to high glucose environments 
(Z. Liu et al., 2015; Takuma, Hirashima, & Piret, 2007).  Depending on the longevity of these 
effects, they have the potential to improve fitness and performance in production cultures if 
deployed at the correct stage in inoculum expansion (Cong et al., 2001; Seth et al., 2013).  
Whilst requirements to display phenotypic stability will dictate the maximum expansion period 
(manufacturing window), this may alleviate any loss in productivity observed at the end of that 
period.  Ultimately, these findings for phenotypic stability loss over long term subculturing are 
expected for CHO cultures, and be caused by loss of gene copy number and assumably a 
malfunctioning splicing mechanism of the bicistronic mRNA (Beckmann et al., 2012).   
Experiment 5.2 concluded the experimental work detailed within this thesis by testing a 
combination of pre and post inoculation control variations to determine the impact that they may 
pose on performance.  An experimental design maintained tight parameter control (pH, seeding 
density, temperature, dissolved oxygen, etc) during inoculation and varied process control before, 
in inoculation expansion (as detailed in Experiment 5.1), or process control post inoculation. No 
significant difference in performance was observed in conditions whereby the process parameters 
were subject to variation post inoculation.  These conditions ranged from pH and DO setpoint 
variation to increased antifoam additions.  This data, in combination with that presented in previous 
chapters, leads to speculation that the window of inoculation for any culture is where the highest 
sensitivity is located, and thus should be controlled with increased attention.  This assessment 
suggests that applying flexibility to parameter controls elsewhere in the process could present 
avenues for process improvement in optimisation and improved robustness. 
In conclusion, this thesis has detailed the design, execution, and evaluation of a novel scale down 
perfusion methodology developed in an industrially relevant and commercially available system.  
Through highlighting the method’s potential application, and ability to assist in screening in a 
perfusion setting, it is hoped that the benefits of continuous manufacturing can be realised to help 
meet future demand.  Novel control strategies have been proposed that apply to both perfusion and 
fed-batch bioprocesses.  These centre around culture phase sensitivity mapping and applying 
measured operational control limits appropriately, with the hope to reduce manufacturing risk in 
extremely high-value settings.  
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6.2 Future Work 
6.2.1 Refinement and Characterisation of Microscale Perfusion Methodology 
In the development, optimisation and characterisation of a microscale perfusion methodology, 
certain nuances of continuous operation have been observed.  Further refinement and 
characterisation remains unexplored that may lead to increased robustness and inform 
scalability of the microscale perfusion methodology. 
The methodology involves a period of time where the culture is uncontrolled.  Method 
improvements are sought through the reduction of the time taken to operate the 
sedimentation/media exchange step. 
The improvements to the exchange step could be made into two defined sections.  The first 
section of this step is the sedimentation of the cells within the vessels, and investigations within 
this thesis details a minimum settling time of 30 minutes.  To improve this settling time, some 
manipulation of the vessels must be made.  The operation of continuous cultures details the use 
of centrifugation and incline settling as two processing improvements over gravity cell settling 
in-situ to be explored. 
The media exchange section, post cell settling, is currently limited in the methodology due to 
the requirement of the system to utilise a 1ml pipette tip due to physical dimensional 
incompatibility of the 5 mL tip.  This limitation triples the liquid handling operations per vessel, 
from what would be achieved with a 5mL tip.   
Alternatively, the restriction to the 1 mL tip size could result in improvements.  By limiting 
liquid handling interactions per sedimentation, the process operation results with more frequent 
smaller exchanges to achieve the same dilution rate. 
A more frequent, lower volume sedimentation/media exchange protocol results in greater 
accuracy in the attainment of target dilution rate.  A challenge in operating in this manner 
would be attaining sufficient process control for a process when it is frequently uncontrolled.  
If this is not feasible, media and feed optimisation for the addition in this bolus manner should 
be considered, specifically to mitigate the Warburg effect observed in Experiment 3.1. 
The setup presented within Chapter 3 could utilise either the 48-vessel or the 24-vessel variants 
of the microscale system at 50% capacity with half of each culture station being utilised at a 
time. At a liquid exchange rate of 1 vessel volume per day, this setup allowed suitable 
maintenance downtime and a single operator intervention per day. This facilitates the 
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applicability of this setup in conducting multifactorial DoE to effectively evaluate perfusion 
process set points, medium optimisation or as a cell line screening tool.  Any improvement or 
adjustment to the methodology must take these capacity requirements into account such that 
the method is able to support process development. 
Ultimately, any application of a scale down system in an industrial setting and to be accepted 
by regulators would require extensive, multifactor characterisation of the system.  As future 
work, this characterisation would need to present a detailed understanding of the scale 
dependent parameter interactions with multiple cell lines such that any scale-up activities could 
be performed within the QbD paradigm.   
One aspect of this characterisation is the holistic impact that the sedimentation method is 
having on the culture. This assessment should include both cells within the culture that are 
exposed to the uncontrolled conditions, and the small percentage that are removed with each 
media exchange. 
Due to the continuous nature of the cultures, there is opportunity to take many samples to 
conduct such characterisation without terminating or unbalancing the culture.  Single cell 
analysis techniques, such as flow cytometry, provided they are conducted with suitable 
resolution allow the visualisation of culture heterogeneity for a number of factors.  These 
include the growth and gene expression (Strovas, Sauter, Guo, & Lidstrom, 2007), proteomic 
and translation (Newman et al., 2006), and cell fate analysis (Colman-Lerner et al., 2005). 
Combined with this single cell analysis, the detailed analysis of a product quality attribute that 
is heavily impacted by fluctuation in media nutrient levels(Y. Fan et al., 2015; Yang & Butler, 
2000), culture conditions (Jiang et al., 2018) or cellular stress (Goldrick et al., 2017) is a good 
measure of comparability across scales. 
Ultimately, to conclude the characterisation of the sedimentation perfusion methodology, 
operation with a variety of cell lines is required, with ranking of performance between micro 
and bench scale operations as a critical step in displaying suitability of the system for screening 
applications. 
6.2.2 Culture Phase Focused Bioprocess Development 
The design and observations from Experiment 5.1b represented an initial step in development 
of a novel control strategy for cultures, building on optimisations involving pH and temperature 
shifts in latter stages of fed-batch processes (Moore et al., 1997; Oguchi et al., 2006).  Current 
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QbD application to process optimisation challenges the culture from inoculation to harvest with 
a single setpoint with upper and lower limits for each parameter.  This method could not unveil 
the global optimum and will be restricted by the culture phase that displays the highest 
sensitivity to the parameter setpoints, assuming this sensitivity changes over time.  Conclusions 
from Experiment 5.1b indicate that Cell line 1 has a high sensitivity to pH changes at 
inoculation, and a comparatively lower sensitivity during exponential growth. 
To effectively and comprehensively evaluate culture sensitivity at inoculation and the 
subsequent process performance, an iterative strategy of process development is required.  
Firstly the optimal conditions for inoculation must be determined through screening of 
setpoints.  Termination of these cultures after two days, and evaluation of the cell density, 
oxygen uptake rate and glucose utilisation will provide sufficient information to determine 
optimal conditions for inoculation.   
A subsequent screening experiment is then required to evaluate conditions post inoculation.  
This will be initiated with the predetermined optimal conditions for inoculation and will 
continue to explore a design space for each parameter from day two onwards.  Finally, 
progression with optimal inoculation and exponential growth setpoints may allow the final 
stationary and death phases to be interrogated in increasing detail to ensure culture success 
when operated at larger scale. 
Such an investigation into culture phase focused sensitivities has examples of similar 
application, specifically in temperature and pH shifts during stationary operation to prolong 
culture longevity, increase productivity and manage the physiochemical environment 
(Kaufmann et al., 1999).   
However, this description of process optimisation is envisaged to generate wider operating 
ranges as the culture sensitivity to setpoint deviation decreases as a function of time.  Allowing 
wide operating ranges at commercial scales ultimately leads to robust, low risk manufacturing 
processes. 
6.2.1 Production Improvements Through Preconditioning 
Current inoculum expansion best practices are highly regulated and risk averse.  They involve 
taking cell banks from vial thaw to inoculation through sub-culturing regimes that are centred 
around minimal process variation to ensure reproduceable production culture performance 
(Birch & Racher, 2006).  However, it has been observed within this thesis that the action of 
preconditioning cultures a high nutrient environment generates some beneficial culture traits.  
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This is supported by literature investigating the metabolic and proteomic changes, and 
enhanced protein expression present when cultures are exposed to high glucose environments  
(Z. Liu et al., 2015; Takuma et al., 2007) 
During Experiment 5.2, the preconditioned culture metabolism was observed to consume 
greater glucose quantities when compared cultures sub cultured in basal media for the inoculum 
expansion. 
Future work could explore optimal conditions for priming cultures for production, prior to 
inoculation.  As highlighted above this is likely to include high nutrient environments, but 
could also include a balance of the redox potential of the culture to mitigate against undesirable 
Warburg effects through media and pH adjustments (Zhang et al., 2015). 
Whilst this would require extensive screening activities, including detailed analysis of the 
proteome and metabolome, findings are likely applicable to all CHO host systems.  For an 
organisation that has  multiple commercial processes deriving from the same host system, this 
outlay of resource could provide process improvements across the portfolio of products 
simultaneously. 
Certainly, any commercial adoption would require extensive characterisation and need to stand 
up to regulatory interrogation, for an high value industry such as biologics the risk reward 
equation is balanced. 
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Appendix 
 
Appendix Figure I Perfusate amino acid profiles for microscale and bench scale experiments (Chapter 
3) 
Figure shows the Arginine, Aspartic acid, Glutamate, Isoleucine, Glycine, Lysine, Leucine and Methionine 
profiles, denoted by (A-H), respectively, starting from the 6th day post inoculation measured every three days. 
Concentrations were scaled randomly in the interest of protecting the IP of the proprietary medium and are 
reported as “Scaled concentrations (mg/L)”.  Microscale reactors: (▲) Experiment 3.1, n=6 (30 minutes 
settling); (▼) Experiment 3.2a, n=4 (33.5 minutes settling); (■) Experiment 3.2b, n=6 (37 minutes settling); 
(♦) Bench scale reactors: Experiment 3.1, n=2. Data shows mean ± SD 
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